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Abstract 
 
Strong evidence suggests that the tumour microenvironment is inflammatory and that 
activation of the innate immune system plays a role in cancer progression, therefore 
targeting the multiple interactions of tumour cells with other cell types within the tumour 
microenvironment may lead to development of new cancer therapies. Sphingosine kinase 
(SPHK1) is a tumour-associated enzyme whose over-expression has been linked to patient 
mortality in many types of cancer. Here I investigate whether activation of the SPHK1 
pathway, with a known involvement in inflammatory responses, is a signal transduction 
component of the tumour-monocyte/macrophage cellular interaction and a key element in 
inflammation-related cancer progression. Using a co-culture model, this study shows that 
the presence of monocytes increases cancer cell proliferation, an effect abrogated by 
knockdown of SPHK1 in cancer cells. Both monocytes and cancer cells showed a transient 
increase in SPHK1 activity and mRNA expression levels together with an increase in MCP-1 
and IL-6 secretion. Silencing of SPHK1 in cancer cells abrogated SPHK1 activation in 
monocytes and pharmacological inhibition of SPHK1 in monocytes cells decreased monocyte 
induced-SPHK1 expression in cancer cells. Mechanistically, activation of AKT was observed in 
cancer cells upon co-culture with monocytes, an effect that was abrogated when cancer cells 
were pre-treated with siRNA for SPHK1. Moreover, the increase of phospho-AKT, ERK1/2 and 
NF-KB in monocytes by cancer cells was also reduced by RNAi-mediated knockdown of 
SPHK1 in cancer cells. My data show that STAT1 can bind to SPHK1 promoter or coding 
region and may be involved in SPHK1 transcriptional regulation in cancer cells upon 
monocyte stimulation, however its role still remains unclear as it acts as a transcriptional 
repressor of SPHK1. Monocytes induced cancer cell chemoprotection via a SPHK1-dependent 
mechanism, and reduced the inhibitory effect of docetaxel on cancer cell proliferation. 
Accordingly, increased AKT and ERK1/2 phosphorylation in monocytes were also affected by 
siRNA targeting of SPHK1 in docetaxel treated cancer cells. Altogether I show for the first 
time that selective inhibition of SPHK1 in tumour cells can affect their interaction with 
surrounding cells through the modulation of signal transduction pathways (ERK, PI3K, NF-kB) 
and cytokine exchange (IL-6, MCP-1 and potentially S1P, GM-CSF, GROα, IL-32 and ICAM-1). 
SPHK1-mediated increase in proliferation and chemoresistance of cancer cells conferred by 
monocytes renders this enzyme a promising target for future cancer therapies. 
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1 Introduction 
1.1 Prostate Cancer 
 
Prostate cancer (PCa) is the most common cause of cancer-related death and the most 
commonly diagnosed cancer in men in the UK [1](Figure 1.1). Current data suggest in the UK 
that more than 10,000 men die from prostate cancer every year and one in eight men will 
develop prostate cancer during their lifetime [2]. The vast majority of patients diagnosed 
with PCa are aged over 50 years, however new epidemiological data suggest that the 
incidence of advanced, highly aggressive prostate carcinomas is increasing in younger men 
[3, 4]. When PCa is locally confined the survival rate increases considerably to approximately 
100% up to 5 years in comparison with non-localised PCa. The high mortality of PCa arises 
from its metastatic potential; in men with metastatic PCa the 5 year survival rate decreases 
to 30% [5], with the main metastases occurring in bone in approximately 90% of all men 
diagnosed with the disease. Other tissue sites affected by the dissemination of metastatic 
PCa include lung (46%), liver (25%), pleura (21%) and adrenals (13%) [6].  
1.2 The prostate 
  
The prostate is an exocrine gland forming part of the male reproductive system. This 
male gland is involved in the production of prostatic fluid and ejaculation of this through the 
contraction of prostate smooth muscle cells. The prostatic fluid is a component of the 
seminal fluid that is released during ejaculation with an important role in the protection and 
motility of the sperm. It is an alkaline fluid and contains among other components, prostate-
specific antigen (PSA), kallikrein enzymes such as KLK2, citric acid, zinc and proteases [7].  
Prostate gland growth and development requires hormones such as testosterone, a 
male sex hormone produced in the testis from 6 weeks of gestation. This process is 
particularly important in utero and during puberty where the development of male 
reproductive systems including the prostate gland occurs. The prostate gland stops growing 
upon reaching full development and only grows when dysregulated, a common event during 
PCa.  
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Figure 1.1: The 20 most commonly diagnosed cancers excluding non-melanoma skin cancer, 
UK, 2009.  
Reproduced with permission from: 
http://www.cancerresearchuk.org/cancer-info/cancerstats/incidence/commoncancers/ 
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1.3 Prostate Cancer Development 
 
Prostate cancer can be classified as adenocarcinoma (more than 90%) or glandular 
carcinoma, and is attributed to a deregulation in the proliferation of epithelial cells in the 
prostate that leads to the development of a primary malignant tumour [8]. As well as genetic 
lesions resulting in the incidence of PCa, it has been hypothesised that PCa could also be 
derived from the lesions that follow prostate tissue injury [9][9]. Following injury, epithelial 
prostate cells may lead to the development of prostate intraepithelial neoplasia (PIN), which 
is suggested to be an early pre-malignant stage of PCa progression [10]. The steroid 
hormones, androgens and oestrogens, and growth factors such as epidermal growth factor 
(EGF), transforming growth factor (TGF), fibroblast growth factor (FGF), hepatocyte growth 
factor (HGF), vascular endothelial growth factor (VEGF) and insulin growth factor (IGF-1) are 
implicated in the transition of PIN to malignant PCa and therefore identified as contributory 
factors in PCa development [11]. As previously mentioned, genetic modifications also play a 
crucial role in the development of PCa, with the induction of oncogenes such as RAS, Bcl-2 or 
c-MYC, or the ablation of tumour suppressor genes such as p53, PTEN and MXI1 prime 
examples of the manner in which gene regulation can affect prostate cancer development 
(Hanahan and Weinberg 2000, Karan, Lin et al. 2003. Epigenetic DNA modifications such as 
hyper-methylation have been shown to increase with age and are found at a high incidence 
in prostate cancer tissue [12-14]; GSTP1 was found to be methylated in 90% of PCa and more 
than 70% of high-grade PIN [15]. These modifications could derive from a genetic 
predisposition or from microenvironmental pressures. Indeed, the microenvironment can 
act as an ideal “partner” for tumour development by behaving in a paracrine manner or by 
helping tumour cells to migrate from the primary site and form metastases [13].  Prostate 
cancer may remain latent for several years and in some cases can be successfully treated 
with current therapies such as radical prostatectomy or radiotherapy. However, PCa can 
relapse and may develop into life threatening metastatic disease, resistant to current 
therapies.  
Metastatic PCa is the main cause of disease morbidity and treatment options are 
limited. Metastasis is defined as the process of cancer cells escaping from the primary 
tumour and establishing new growth at a secondary tissue site [16], with metastasising cells 
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needing to overcome several physical and gradient barriers in order to establish 
micrometastases at this secondary site. After the initial neoplastic transformation of PCa 
cells, neoangiogenisis and lymphogenesis are necessary for tumour growth and proliferation. 
The loss of cell adhesion and detachment from other tumour cells facilitates local invasion 
through the extracellular matrix and intravasation into the vascular and lymphatic systems. 
The tumour cells will encounter and need to circumvent the immune cell response and 
traverse the turbulent physical environment of the circulatory system before they can 
extravasate and enter the secondary site where tumour establishment can occur [16]. It has 
been estimated that only 2% of cancer cells are able to form metastases [17] and only 1% 
will form vascularised macrometastases [18]. As previously stated, metastasis is currently 
the main cause of prostate cancer morbidity and to date there remains an unmet clinical 
need with regards to identifying a suitable treatment.  
   
1.4 Androgen dependency and independency 
 
Androgens are required for the normal homeostasis, maintenance and growth of the 
prostate gland. The most abundant male hormone is testosterone, which can be converted 
by 5α-reductase to 5α dihydrostestosterone, a ligand with high affinity for androgen 
receptor (AR) [19]. AR is a member of the nuclear receptor superfamily which, in normal 
prostate cells, plays a pivotal role in driving the differentiation of luminal epithelial cells and 
regulating the transcription of several genes (e.g PSA) involved in the normal development 
and function of the prostate gland [20]. The activation of AR signalling is correlated with the 
increased growth and survival of prostate tumour cells [21, 22]. This is mostly a reflection of 
the ability of AR to regulate several cell cycle genes (e.g Cyclin D1) leading to an increase in 
survival and growth [23, 24]. 
Since PCa is also initially androgen dependent for growth, targeting of AR signalling is 
the standard treatment for the majority of advanced localised or metastatic PCa [25]. This 
may be as a component of androgen depravation therapy (ADT), involving chemical 
castration with or without AR antagonist treatment, the current gold standard of which is 
bicalutamide. 
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 ADT shows an initial clinical response in approximately 80% of patients; however in 
the majority of cases patients will relapse and develop a highly aggressive PCa within two 
years [26, 27]. At this stage androgen ablation is no longer effective and PCa is commonly 
referred to as androgen-independent, hormone refractory or (more currently accepted) 
castrate-resistant PCa (CRPC). Indeed there is evidence that in CRPC, where the levels of 
circulating testosterone and DHT are reduced, AR still plays a role in PCa development. 
Immunohistological studies indicated AR protein expression was higher in CRPC patients in 
comparison with patients with benign PCa [28, 29]. In support, AR mRNA levels were also 
found to be significantly higher in CRPC tumours [30, 31].  
The activation of AR in PCa patients treated with ADT could result from many factors: 
AR gene amplification [32, 33], AR mutations (20-50%) [34, 35] or alternative splicing [36, 
37]; alterations of AR co-regulators or co-repressors [38, 39]; activation of signalling 
pathways that modulate AR function [40, 41]. Consequently, there is growing evidence that 
AR still remains an important regulator in CRPC and therefore future therapies directly 
targeting AR should be explored.  
 
1.5 Symptoms and risk factors  
 
1.5.1 Symptoms 
 
PCa symptoms are often not evident at early stages of the disease; most often PCa 
symptoms are similar to those observed with benign prostatic hyperplasia (BPH), which 
comprises the enlargement of the prostate gland during ageing. BPH affects approximately 
50% of men by the age of 50 years and 75% by the age of 80 years [42]. To date, there is no 
firm evidence that BPH increases the risk of PCa or that it is a precursor of PCa. The most 
common symptoms for PCa or BPH are related to urinary problems, such as urgency and 
inability to retain flow, difficulty passing urine and an increased frequency in urinary passing. 
Pain during urination or blood in the urine could also be symptoms but are rare. If PCa has 
spread from the primary site, symptoms such as pain in the bone, back or hips could be 
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associated with its metastatic site. Loss of appetite, weight loss, tiredness and erectile 
dysfunction are also symptoms of PCa, more associated with patients of advancing age.  
 
1.5.2 Risk factors 
1.5.2.1 Age 
 
Age is one of the major risk factors for PCa. A recent report from the American Cancer 
Society indicated that at the time of diagnosis more than 60% of PCa patients are older than 
65 years and that 97% occur in men aged 50 or older in the US [43]. In the UK, 75% of cases 
were diagnosed in men aged 65 years or over in 2010. Moreover, men aged between 55-59 
showed an incidence of 163 per 100,000 men, this rate triples in men aged 65-69 and is 
approximately five times higher in the 75-79 years age group [1]. 
  
1.5.2.2 Genetic predisposition 
 
 Genetic predisposition is another important risk factor for PCa, in which it is estimated 
that around 9% of malignancies are correlated with an inherited increase in the likelihood of 
disease onset [44]. It is thought that this predisposition could be due to an existence of 
mutations within or inhibition of multiple tumour suppression genes (e.g. PTEN/MMAC1, 
BRCA2) [45, 46]. A 2003 study by Zeegers et al. revealed that men are 2.5 times more likely 
to develop PCa if they have a first-degree family member with PCa, rising to approximately 
3.5 times more likely if a brother was afflicted with the disease [47]. Single nucleotide 
polymorphisms (SNPs) have also been associated with PCa, with SNPs in chromosomes 7, 8, 
10 and 19 reported to increase PCa risk [48, 49]. Using whole-genome mapping, 
chromosomal region 8q24 was associated with a highly increased risk for PCa [50].   
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1.5.2.3 Ethnicity and diet 
 
Over the last decade, the incidence of PCa in countries such as China and Japan has 
increased; according to some authors this was accompanied by an increase in the intake of 
red meat, animal fat and low fibre diets over the same period of time [51]. Moreover, 
second and third-generation Chinese emigrants in the US are showing a higher incidence of 
PCa in comparison with the same age population in their native countries [52]. 
Epidemiological studies indicate that mortality rates from PCa are twice as high in 
African American compared to Caucasian men; with the lowest rates of mortality observed 
in Hispanic and Asian populations [53, 54]. In the UK, a study between 2002 and 2006 
indicated that African and Caribbean men under 65 years had a three-fold higher incidence 
than Asian men and a six-fold higher incidence than Chinese men. Over 65 years of age, 
African and Caribbean males had a three times higher likelihood of disease onset than both 
Asian and Chinese men [55].   
Although dietary habits, such as a high fat and red meat rich diet [56], have been 
suggested to account for these differences more recent studies cannot confirm this 
correlation [57]. Nonetheless diet remains as a risk factor for PCa, more specifically a high 
intake of red meats and saturated fat is correlated with a higher risk of developing PCa [58, 
59]. Diets rich in fish, vegetables and produce such as tomatoes, tea or vitamin D have been 
reported to be inversely correlated with the risk of PCa, although there is still some debate 
as to how effective they are in repressing the development of the disease [60].  
 
1.6 Screening and Therapies 
 
Screening for PCa is crucial as it could allow the detection of the malignancy in an early 
stage of development, which increases the chance to effect a cure and/or prevent the 
incidence of metastasis. The combination of digital rectal examination (DRE) and measuring 
prostate-specific antigen (PSA) levels in serum are the most commonly used methods for 
initial PCa screening [61, 62]. DRE was the most commonly used method in the 1990’s, 
whereby the diagnosis is determined by the detection of palpable abnormalities in patients 
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[63]. PSA is a serine protease that is produced by prostatic epithelial cells and its 
physiological function is to lyse seminal vesicle proteins into smaller polypeptides resulting 
in liquefaction of the seminal coagulum [64]. Increased PSA levels have been shown to 
correlate with PCa; although PSA production is only increased insofar as more epithelial cells 
may be present, a disruption of the prostate by PCa or benign prostatic hyperplasia (BPH) 
can result in the leakage of this PSA into the bloodstream causing a surge in serum PSA levels 
[65-67]. Serum PSA levels can be influenced by several factors, including the presence of 
tumour cells, prostatitis or BPH, which involves continuous prostatic growth and is reported 
to be associated with increased PSA levels. In the indication of PCa, a biopsy is taken and 
graded following the Gleason score system, which aims to predict the aggressiveness of the 
disease and the likelihood that the tumour will be metastatic; the higher the score the more 
aggressive the tumour tends to be [68, 69]. According to the Gleason score and clinical stage 
there are different strategies for PCa treatment. If PCa is localised the most current 
therapies involve the removal of the entire prostate gland (radical prostatectomy) or 
radiation-based therapy [70]. These procedures could be combined with ADT if the 
recurrence risk is intermediate or high or cancer spreads outside the prostate. ADT can also 
include castration, AR antagonist and combined therapy as described before. There are also 
other possibilities such as watchful waiting, external-beam radiation therapy, brachytherapy 
and cryotherapy [71]. The chosen treatment will depend on patient characteristics, such as 
general health, body condition and age, as well as personal feelings regarding the available 
therapies [72]. Despite the initial treatment, PCa can recur and in most cases with a more 
aggressive and mestastatic phenotype.  
Chemotherapeutic intervention is used when the cancer spreads outside of the 
prostate gland and the tumour cells become unresponsive to androgen deprivation. 
Docetaxel (taxotere), belonging to the taxane class of drugs, is the current standard of care 
for CRPC, resulting in a survival benefit of up to three months over other chemotherapeutics 
such as mitoxantrone [10, 73, 74]. More recently Cabazitaxel, a tubulin-binding taxane drug, 
was shown to have beneficial effects in CRPC patients with resistance to docetaxel. Clinical 
trials indicate a 2.4 month increase in survival for men with docetaxel-pretreated metastatic 
CRPC receiving cabazitaxel (with prednisone) in comparison with mitoxantrone (with 
prednisone) [75]. Abiraterone, a potent inhibitor of key enzymes involved in the 
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testosterone synthesis pathway, is another second-line drug for metastatic prostate cancer 
that was recently approved by the FDA. A clinical trial study showed that treatment with 
abiraterone afforded a further 3.9 month increase in survival in docetaxel-treated men with 
CRPC compared with the placebo group [76]. Enzalutamide (MDV3100), an AR antagonist, 
was also recently approved for the treatment of CRPC post-chemotherapy; patients treated 
with this drug had an overall survival increase of 4.8 months over the placebo group [77]. An 
immunotherapy-based drug, sipuleucel-T, whose mechanism of action uses autologous 
peripheral-blood mononuclear cells (PBMCs) to activate an immune response, has shown a 
4.1 month improvement in median survival and an improvement in the rate of 3-year 
survival over control groups (31.7% for patients receiving sipuleucel-T, as compared with 
23.0% for those receiving placebo).  
Despite recent advances in CRPC drug therapies, it is clear that the overall survival rate 
is still low and new drugs are required to overcome this deathly pathology. Recently our 
group has shown that docexatel therapy together with the inhibition of sphingosine kinase 1 
(SPHK1) sensitises metastatic PCa cells to docetaxel, which suggests that SPHK1 regulation is 
a potential new target for PCa therapy [78]. 
 
1.7 Prostate Cancer Biomarkers 
 
Currently there are few markers for diagnosis of early stages of PCa, with PSA an 
indicator although not specific to PCa. In clinical practice PSA is the most commonly used 
biomarker for diagnosis and response to treatment of prostate cancer. PSA is detected in the 
blood (serum), however its limitations as a biomarker arise from the fact that PSA increase is 
not a PCa specific event. Non-cancer related pathologies, such as BPH and prostatitis, also 
increase serum PSA levels. A recent review indicated that less than 50% of men undergoing 
biopsy, following an increase in PSA levels, were diagnosed with PCa [79]. It is therefore 
important to identify and characterise new biomarkers for detection of PCa to augment or 
replace screening by PSA levels. Current research for new biomarkers includes analysis of 
amino acids, proteins or nucleic acids. Promising biomarkers include GSTP1 and RASSF1A, 
urine-based DNA markers that were shown to be hyper methylated in patients with PCa [80]. 
GSTP1 (glutathione-S-transferase P1) hypermethylation was detected in more than 90% of 
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prostate tumours (no detection was found in BPH), whereas RASSF1A was found to be 
hypermethylated in 60%–74% of prostate tumours (18.5% in BPH samples). 
Prostate cancer antigen 3 (PCA3, also known as DD3), a urine-based RNA marker that 
has recently been made commercially available, is another very promising biomarker for PCa 
diagnosis as its expression was not found in any other normal human tissues. PCA3 was 
highly over-expressed in more than 95% of primary and metastatic PCa [81]. It is believed to 
function as a non-coding RNA due to its multiple stop codons across the reading frames and 
a non-extended open reading frame. Despite its specificity in detection of PCa, its prognostic 
value for aggressiveness has been controversial. Some reports indicate no correlation 
between PCA3 score and more established prognostic parameters such as Gleason score, 
tumour size and stage [82, 83]. In contrast, earlier studies found a positive correlation 
between high PCA3 scores, Gleason score ≥7 and tumour volume [84, 85]. Due to its 
specificity and high expression in PCa tissues, PCA3 is currently the most specific gene 
product available in PCa diagnosis and could prove fundamental in selecting patients for 
active surveillance. The potential for PCA3 as a suitable predictor of PCa aggressiveness still 
remains unclear. 
α-methylacyl-CoA racemase protein (AMACR, also known as P504S) is another 
potential biomarker that has been found to be consistently upregulated in PCa. Studies 
revealed that 88% of PCa cases (CRPC and untreated metastases) had a high expression of 
AMACR [86]. Moreover, immunohistochemical data showed that AMACR expression in 
needle biopsies had a 97% sensitivity and a 100% specificity for PCa detection [87]. AMACR is 
currently used as a biomarker for PCa biopsies and is regarded as an improvement over 
the serum PSA test [88], however efforts are ongoing to develop a body fluid-based assay 
for AMACR, with its detection in urine specimen being the most promising test to date 
[89]. 
A broader approach for PCa diagnosis could comprise the use of a multiplex panel of 
possible prostate cancer biomarkers. One study tested simultaneous analysis of several 
genes such as PCA3, TMPRSS2-ERG, Annexin A3, Sarcosine, and urine PSA, with the assay 
proving to have a higher accuracy when compared with the individual markers alone [90]. 
Another similar assay, including AMACR, ERG, GOLPH2, PCA3, SPINK1, TFF3, and TMPRSS2-
ERG, using sedimented urine, outperformed PCA3 or serum PSA for the early detection of 
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prostate cancer [91]. In the future the diagnosis of PCa could be determined by these 
multiplex analyses, however further optimisations and validations are needed.  
Recently our group has shown that Sphingosine-1-phosphate (S1P) was inversely 
correlated with the incidence of PCa. Circulating S1P levels were an early marker of PCa 
progression to hormonal unresponsiveness and correlated with prostate-specific antigen 
levels and lymph node metastasis. Interestingly, the decrease in circulating S1P in PCa 
patients was accompanied by a decrease in SPHK1 activity in comparison with healthy 
patients, suggesting a potential role of S1P and SPHK1 activity in erythrocytes as possible 
biomarkers for early diagnosis of PCa [92].  
1.8 Sphingolipids 
 
Sphingolipids belong to the lipids family and are characterised by a long chain base or 
sphingoid (long-chain aliphatic amines, containing two or three hydroxyl groups) that are 
bonded to fatty acids via amide bonds. They are mainly located in the plasma membrane 
where they can act as an anchoring site for extracellular proteins, or have a structural 
function by conferring stability and chemical resistance to the outer layer of the lipid bilayer 
[93]. Two key sphingolipids, S1P and ceramide, have attracted researchers attention due to 
their pleiotropic effects on cellular processes such as growth, apoptosis, survival, 
angiogenesis and immune cell trafficking, with implications in human diseases such as 
cancer, inflammation, and immune and metabolic disorders [94-96].  
 
1.8.1 Biosynthesis of S1P 
 
In sphingolipid metabolism ceramide is the central metabolite of sphingolipids 
biosynthesis as it is the only precursor for sphingosine metabolism (Figure 1.2). Ceramide 
can be produced de novo by the condensation of serine and palmitate, often of dietary 
origin, or by the hydrolysis of sphingomyelin, glucosylceramide or galactosylceramide [97]. 
Ceramidases catalyse the conversion of ceramide into sphingosine, which is then 
phosphorylated by SPHK1 or SPHK2 into sphingosine-1-phosphate. S1P is the only exit point 
of the sphingosine pathway, it can either be dephosphorylated by S1P phosphatases (SPP1 
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or SPP2) into sphingosine or converted into the non-sphingolipid ethanolamide phosphate 
by S1P lyase [96]. Ceramide and sphingosine are important mediators of stress responses 
and are inducers of apoptosis and cell cycle arrest [93, 98, 99]. On the contrary, S1P has a 
pro-survival role, where it can abrogate apoptosis and induce cell proliferation, growth and 
survival [96, 98]. The opposite roles of ceramide/sphingosine versus S1P lead to the concept 
of the “sphingolipid rheostat” whereby the dynamic balances between these metabolites 
can determine cell fate [98].  
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Figure 1.2: Sphingolipid metabolism. The structure of the key sphingolipids and their 
metabolic cycle are shown, the enzymes involved at each step are shown in red. Ceramide can 
be synthesised by the hydrolysis of Sphingomyelin by sphyngomyelinase, or by the degradation 
of Glycosphingolipids. Alternatively, ceramide can be produced by palmitate and serine 
condensation and further converted into dihydrosphingosine and dihydroceramide, which in 
turn can also be synthesised from dihydrosphingomyelin. Ceramide is then converted into 
sphingosine at a ratio of 30/1 by ceramidase. Sphingosine can be phosphorylated into 
Sphingosine-1-phosphate (S1P) by sphingosine kinases at a ratio of 100/1. S1P phosphate 
converts S1P to sphingosine whereas S1P lyase converts S1P into a non-sphingolipid 
phosphoethanolamide and hexadecenal. The degradation of S1P is the only exit from the 
Sphingolipid pathway. The balance between S1P (pro-survival) and ceramide/sphingosine 
(apoptotic inducers) levels is known to influence cell fate and led to the concept of the 
“Sphingolipid Rheostat”. 
  

1.8.2 S1P secretion and transport 
 
S1P in the plasma is associated with high-density lipoproteins (HLP) and albumin, and 
concentration varies between 0.2 to 1μM, whereas in serum it ranges from 0.4 to 1.1μM 
[100]. S1P levels in the blood and other bodily fluids are higher than in tissues, which 
suggests that there is a secretion mechanism for S1P [101], with the platelets, red blood cells 
and epithelial cells being the major sources of plasma S1P [102, 103].  
S1P is constitutively expressed and its regulation is affected by the balance between 
SPHKs and S1P lyases [96]. S1P can act as an intracellular second messenger where it is 
involved in calcium mobilisation, preventing apoptosis and inducing cell growth [104, 105], 
however its mechanisms of action have not been fully elucidated. The presence of a polar 
head group prevents S1P migration across the plasma membrane without a dependency on 
transmembrane transporters. In this context, ATP-binding cassette (ABC) transporter family 
members (ABCC1 and ABCG2) and sphingolipid transporter spinster homolog 2 (SPNS2) have 
been described to be involved in S1P export, as indicated in figure 1.3. ABCC1 was shown to 
be important for S1P secretion in mast cells, the inhibition of ABCC1 by small interference 
RNA or by specific inhibitors markedly decreased S1P export from these cells [106]. A similar 
finding was reported in rat uterine leiomyoma cells (ELT3) when S1P secretion was abolished 
by ABCC1-siRNA, interestingly no effect was observed when ABCA1 or ABCB1 transporters 
were inhibited [107]. The importance of the ABCA1 transporter in S1P secretion has been 
characterised in astrocytes [108] and platelets [109] and in endothelial cells both ABCC1 and 
ABCA1 were shown to be of equal importance [110]. In MCF-7 breast cancer cells, estradiol-
induced S1P export via ABCC1 and ABCG2 transporters has been reported [111]. Some 
studies in zebrafish myocardial precursors and CHO cells indicate that the export of S1P from 
cells requires SPNS2 [112, 113]. A schematic representation of S1P secretion and transport is 
shown in figure 1.3. 
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Figure 1.3: S1P receptor signalling. Sphingosine Kinase 1 (SPHK1) catalyses the phosphorylation 
of sphingosine into sphingosine-1-phosphate. This reaction occurs in the plasma membrane 
where sphingosine is located. Upon production, S1P can be secreted into the extracellular space 
where it can act in an autocrine or paracrine manner. S1P secretion can be mediated by an ATP-
binding cassette (ABC) transporter family (ABCC1 or ABCG2) or by sphingolipid transporter 
spinster homolog 2 (SPNS2). S1P can bind to a family of 5 G-Protein coupled receptors named 
S1P1-5 that, in turn, interact with different G proteins (Gi, Gq and G12/13). These proteins are 
involved in the activation of several important signalling molecules (cAMP, RAC, PI3K, ERK1/2, 
PLC and Rho) which in turn regulate several important cellular processes. 

1.8.3 S1P receptors signalling 
 
Extracellular S1P binds specifically to a family of G-protein coupled receptors (GPCRs) 
named S1P1-5, encoded by endothelial differentiation genes (EDG). Through these it can 
mediate both autocrine and paracrine actions [114]. S1P1-5, as the receptors are now known, 
are historically referred to as their EDG family names of EDG1, 5, 3, 6 and EDG8 respectively. 
Upon activation, S1P receptors (S1PRs) are known to couple to different G proteins which in 
turn are involved in several downstream signalling pathways. S1P1 receptor was shown to 
bind exclusively to Gi whereas S1P2 and S1P3 coupled with Gi, Gq and G13 [115]. S1P4 can 
couple to Gi, and G12/13 [116], while S1P5 couples with Gi and G12 [117]. A schematic 
representation of the binding patterns can be seen in figure 1.3.  
S1P receptors are ubiquitously expressed on all cells, however their relative 
expression levels vary by cell type. S1P1, S1P2 and S1P3 are widely expressed in most 
mammalian tissues, S1P4 is mainly present in hematopoietic and lymphoid tissue whereas 
S1P5 is highly present in brain tissue [118]. S1P activation of S1P1 stimulates motility 
through activation of the GTPases Rac1 and Cdc42 in fibrosarcoma cells [119], whereas in 
ovarian cancer cells S1P1 and S1P2 are involved in cell invasion and calcium mobilisation 
[120].  
S1P1 is also crucial for immune-cell trafficking, more specifically the migration of 
hematopoietic cells and lymphocytes into blood, lymph and tissues [121, 122]. S1P1 
knockout mice were found to die prenatally as a consequence of incomplete vascular 
maturation which caused vascular leakage, indicating a role of S1P1 in angiogenesis and 
vascular maturation [123]. In CHO cells, S1P-induced activation of S1P1 receptors lead to 
ERK1/2 activation in a Ras-dependent manner, simultaneously there was an inhibition of 
cyclic AMP accumulation [124]. 
S1P, via S1P2 receptor, inhibits cell motility in glioblastoma and astrocytoma cells 
[125], whilst S1P2 deletion in MEF cells increased their migration towards serum or PDGF. 
The authors also found that this effect was dependent upon SPHK1 activity and S1P1 [126]. 
In glioma cells S1P2 is involved in increasing invasiveness via cytoskeletal rearrangements 
[127]. S1P2, but not S1P1 or S1P3, decreased doxorubicin-induced apoptosis in 
cardiomyocytes via ERK1/2 and STAT3 [128]. In vivo studies in S1P2-deficient mice showed 
no anatomical or physiological defects during birth, however spontaneously lethal seizures 
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occurred within the first seven weeks of life. The authors proposed that S1P2 was involved in 
the development and mediation of neuronal excitability [129]. 
S1P3 is highly expressed in heart, lung, kidney and spleen, however its absence (as 
investigated in S1P3-/- mice) does not induce any phenotype modifications. S1P3 signalling 
via ROCK and Rho is important for the regulation of vascular permeability and chemotactic 
migration of cancer cells towards growth factors [127, 130]. The role of S1P3 in endothelial 
barrier function is critically important for immune responses [131] and more recently S1P3 
was suggested as a biomarker for acute lung injury as a result of its increased levels in 
circulation during inflammatory lung states [132]. 
S1P4 is involved in cytoskeletal rearrangement, calcium mobilisation and cell motility 
[116]. Furthermore, in S1P4-/-mice, megakaryocytes showed atypical and reduced formation 
of proplatelets indicating S1P4 involvement in megakaryocyte terminal differentiation. S1P4 
involvement in T-cell cytokine production has been proposed; the receptor was shown to 
mediate immunosuppressive effects of S1P through the inhibition and enhancement of the 
secretion of cytokines [133]. In MDA-231 cells S1P4 was crucial for ERK1/2 activation via 
HER2 (human epidermal growth factor receptor 2) upon S1P stimulation, with the authors 
proposing S1P4 as a possible target for breast cancer therapy [134]. A more recent study 
showed that high levels of S1P4 expression were associated with shorter disease-free 
periods for breast cancer patients [135]. 
In prostate cancer cells S1P5 is required for an S1P-induced effect in increased 
autophagy activity in starvation conditions [136]. In MEK cells S1P5 was shown to localise 
with SPHK1 and SPHK2 in centrosomes, indicating a possible role of S1P5 in cell division 
[137]. In brain endothelial cells S1P5 is required for modulation of endothelial inflammatory 
processes by maintaining an immunoquiescent state in the brain [138]. Furthermore, natural 
killer (NK) cell trafficking and mobilisation to inflamed organs was affected in S1P5 deficient 
mice [139]. 
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1.8.4 S1P signalling as a therapeutic target 
 
It is clear that S1P receptors play a pivotal role in modulating S1P responses upon 
binding interactions. The immunosuppressant drug FTY720 (Fingolimod), a sphingosine 
analogue, has been described to decrease autoimmune disease severity in animal models 
[140, 141]. Interestingly, FTY720 actions appear to be mediated through S1P receptors, in 
particular S1P1 where it induces receptor internalisation and degradation. S1P-induced 
migration of lymphocytes was blocked by FTY720 in an S1P1-dependent manner; another 
study showed S1P1 activation by FTY720 reduced lymphocyte transmigration by increasing 
endothelial barrier function [121, 142]. Indeed, FTY720 immunosuppressive properties 
against T cell migration could contribute to tumour tolerance and development by 
inhibiting lymphocyte recruitment from lymph nodes into efferent lymphatics and blood 
[143]. 
FTY720 was also shown to have anticancer properties; FTY720 treatment induced 
prostate cancer apoptosis, reduced tumour growth and increased radiotherapeutic 
sensitivity. Interestingly, the FTY720 inhibition of SPHK1 was crucial for its pro-apoptotic 
actions [144]. This potent inhibitory effect has been reported in other types of cancer such 
as breast [145], lung [146] and pancreatic [147]. FTY720 phosphorylation is an important 
step for its activation, however the mechanism underlying this process is still in debate. 
SPHK1 and SPHK2 are natural candidates, with a SPHK2 knockout mouse model displaying 
impaired FTY720 effects in reducing the number of lymphocytes in the blood [148]. In 
contrast, a similar study using a knockout SPHK1 mouse model did not reduce FTY720 effects 
on lymphocyte numbers in the blood, indicating that SPHK1 may not be involved in FTY720 
phosphorylation. The molecular mechanisms of FTY720-induced cancer growth arrest and 
apoptosis include activation of caspases [149], mitochondrial damage [150] and inhibition of 
cyclin D1 , Akt and ERK1/2 [151]. FTY720 has been approved by the FDA for the treatment of 
multiple sclerosis [152] however due to its anti-cancer effect it is reasonable to assume that 
an additional indication as a possible therapy for cancer may be considered. 
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1.8.5 S1P internalisation 
 
Upon activation, S1P receptors can either be transported to lysosomes for 
degradation or can be recycled back to the plasma membrane (re-sensitisation). The 
lysosome pathway is considered a way to down-regulate receptor expression and 
consequently to abrogate its intracellular signalling [153]. At the moment the causes 
underpinning this difference in receptor fate remain unclear, with some reports indicating 
that ubiquitination status could play a major role. Studies on S1P1 receptor showed that S1P 
and FTY720-P induce different receptor conformations, most likely due to the fact that S1P 
induces mono-ubiquitination whereas FTY720-P induces poly-ubiquitination and consequent 
degradation [154]. Internalisation of S1P receptors is important not only due to their 
capacity to activate nuclear signalling pathways but also due to the capacity to directly 
interact with important signalling molecules. In this context S1P1 has been shown to be 
phosphorylated by Akt and GPCR kinases (GRKs) on serine and threonine residues [155, 156]. 
Furthermore, in endothelial cells S1P induced a rapid S1P1 internalisation and translocation 
from the plasma membrane to the nucleus where it was involved in the transcription of 
Cyr61 and CTGF, two growth factors involved in the regulation of vasculature [157]. In mast 
cells activation of SPHK1 leads to an increase in intracellular S1P which in turn promotes 
S1P1 and S1P2 internalisation; the mechanism underlying the internalisation of these 
receptors still remains unclear [158]. Contrary to S1P1, the S1P3 internalisation event seems 
to be independent of phosphorylation [159]; interestingly S1P3 internalisation appears to be 
quicker than for S1P1 receptors. S1P and FTY720 are both known to induce a concentration-
dependent effect on S1P3-receptor internalisation [159, 160]. In contrast with the other S1P 
receptors, S1P5 is constitutively active and is mainly located in intracellular compartments, 
believed to be as a consequence of constitutive internalisation. Nonetheless the remaining 
plasma membrane fraction is regulated and internalised by S1P and FTY720 ligand binding. 
S1P5 translocation to the centrosomes indicates a possible role in cell division [137]. 
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1.8.6 S1P signalling independently of S1P receptors 
 
Recent reports indicate a nuclear epigenetic regulation by S1P binding to histone 
deacetylases (HDAC1 and HDAC2) [161]. In support, in vivo work performed in S1P lyase-
deficient mice showed elevated intracellular levels of S1P and enhanced Ca2+ storage, whilst 
nuclear accumulation of S1P caused a reduction in HDAC activity. This was accompanied by 
an increase in acetylation of histone 3-Lys9 and the HDAC-regulated gene p21 cyclin-
dependent kinase inhibitor, leading to a dysregulation of Ca2+ homoeostasis [162]. 
Moreover, S1P was shown to form complexes with TNF receptor-associated factor 2 (TRAF2), 
resulting in the activation of NF-KB signalling [105].  
The multifaceted roles of S1P in cell survival, proliferation, migration, angiogenesis 
and immune system regulation including the pro-inflammatory response, identify S1P as a 
key target in the treatment of cancer and inflammatory disease, upon which potential new 
therapies could be focused [163]. Consequently S1P regulators such as SPHKs could also be 
targeted in the same clinical setting. 
 
1.9 Sphingosine Kinase 
 
Cellular S1P formation is mediated by the action of sphingosine kinases (SPHKs). Two 
kinases have been identified, SPHK1 and SPHK2, the genes for which are located on different 
chromosomes; SPHK1 is present at 17q25.2 whereas SPHK2 is found at 19q13.2. In terms of 
size, SPHK1 encodes a protein of 43KDa whilst a 65KDa protein is encoded by SPHK2. There 
is high homology between the sequences of the two enzymes, with N-terminal sequences 
displaying 47% similarity whereas C-terminal regions share 43% identical amino acid 
sequence. There are five highly conserved regions evolutionarily present within all known 
sphingosine kinases (C1-C5). Their catalytic domain is located within C1 and C3 whereas the 
ATP-binding site for S1P phosphorylation of sphingosine is situated within the C2 domain. To 
date, three isoforms of human SPHK1 and two isoforms of human SPHK2 have been 
identified, a schematic representation of which can be seen in figure 1.4. 
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 There are three splice isoforms of SPHK1 (SPHK1a, b and c) that differ only in their N-
terminal region. There are an additional 14 amino acids in SPHK1b (RefSeq NM_021972) and 
a further 86 in SPHK1c (RefSeq NM_182965) in comparison with SPHK1a (RefSeq 
NM_001142601). The longer sequence of SPHK2 is mainly due to its additional regions at the 
N-terminus and between the conserved C4 and C5 regions (Fig.1.4). To date there are two 
SPHK2 isoforms reported and these appear to arise from alternative start codons, SPHK2a 
(GenbankTM accession number AF245447) and SPHK2b (RefSeq NM_020126). SPHK2b has 
an additional 36 amino acids in the N-terminus region and appears to be a more dominant 
form in cell lines and tissues [164]. This region contains nuclear localisation and export 
signals that are not present in SPHK1 [165]. 
 
1.9.1 Localisation of SPHK1 and SPHK2 
 
Celullar localisation of SPHKs appears to be important for their function. SPHK1 is 
mainly cytosolic whereas upon activation it translocates to the plasma membrane where it 
produces S1P. Importantly, this translocation event is only observed for the wild-type form 
of SPHK1; phosphorylation-deficient forms are unable to translocate and subsequently 
unable to induce an oncogenic cascade. However, both forms of SPHK1 retain intrinsic 
activity; the basal levels of phosphorylation-deficient forms are indicative of an ability to 
maintain a housekeeping role independent of its signalling role. The phosphorylation and 
subsequent translocation of SPHK1 to the plasma membrane are therefore critical factors 
involved in the oncogenic effect of this protein [166]. Supporting its subcellular localisation 
in the plasma membrane, phosphatidic acid [167] and filamin [168] have been implicated in 
SPHK1 function. Calcium and integrin-binding protein 1 (CIB1) interacts with SPHK1 in a 
calcium-dependent manner and functions as a Ca(2+)-myristoyl switch that enables SPHK1 
translocation to the plasma membrane. Inhibition of CIB1 by siRNA or by dominant-negative 
CIB1 blocked SPHK1 translocation upon PMA stimulation [169]. It is to be noted that the 
authors suggest that CBI1 binding to SPHK1 is not dependent on Ser225, instead they believe 
that CIB1/SPHK1 binding to the plasma membrane is calcium dependent and that S225 
phosphorylation is important in retaining SPHK1 in the plasma membrane by enabling the 
binding to acidic phospholipids such as phosphatidylserine. 
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The localisation of SPHK1 within the plasma membrane plays an important role in the 
regulation of its signalling function; the location of SPHK1 in lipid rafts, highly organised 
membrane microdomains implicated in signalling molecule assembly and membrane protein 
trafficking, induces pro-survival and proliferative effects [170]. In contrast, another study 
indicated that an SPHK1-derivative tagged with a myristoylation sequence (50-fold increase 
in SPHK1 activity in crude membrane) had a strong inhibitory effect on cell proliferation but 
an increased protection from apoptosis induced by serum withdrawal. SPHK1 containing a 
false myristoylation sequence and consequently less present in the lipid rafts did not protect 
cells from apoptosis, suggesting a different role for SPHK1 according to its location [169].  
SPHK2 is mainly located in the nucleus and cytoplasm; however, studies have 
reported changes in SPHK2 location under different conditions and cell type. In HEK293 cells 
it is present in the plasma membrane, mitochondria, endoplasmic reticulum (ER) and cytosol 
[163], whilst in HeLa and MCF-7 cells it is predominantly found in the nucleus [165]. Upon 
serum deprivation SPHK2 was found to be highly present in the ER where it is believed to be 
involved in ceramide-mediated pro-apoptotic signalling by metabolising S1P [171]. 
Protein kinase D (PKD) activation induces a post-translational regulation of SPHK2 leading to 
its export from the nucleus in HeLa cells. It has been shown that PKD phosphorylates serine 
residues in the nuclear export signal of SPHK2 both in vivo and in vitro [172]. SPHK2b was 
found to be secreted from apoptotic cells in a caspase-1 dependent event involving cleavage 
at its N-terminus [173]. Similarly, the catalytically active form of SPHK1 is shed in vesicles 
from tumour cells. The presence of sphingosine within the membrane of the shed vesicles 
provides an appropriate substrate for the SPHK1, leading to the concept that the vesicles 
could be a site for S1P production in the extracellular medium and also within other cells if 
endocytosis occurs [174]. A schematic representation of SPHK1 and SPHK2 localisation is 
shown in figure 1.5. 
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Figure 1.5: Cellular location of sphingosine kinase 1 and 2. SPHK1 is mainly located in the 
cytoplasm; upon activation SPHK1 translocates to the plasma membrane to catalyse the 
phosphorylation of sphingosine into S1P. SPHK1 activation can be mediated by ERK1/2 
phosphorylation or through receptor signalling upon binding of growth factors (e.g EGF, TGF-β) 
or other cytokines (e.g TNF-α). Transport to the membrane can be mediated by calcium and 
integrin-binding protein 1 (CIB1) in a calcium-dependent manner. Catalytically active SPHK1 
could also be shed into vesicles and secreted from the cell. SPHK2 is predominantly present in 
the nucleus where it can be phosphorylated by protein kinase D (PKD) and exported from the 
nucleus, or it can produce S1P. In the nucleus S1P acts as a repressor of histone deacetylases 
(HDAC). In the cytoplasm SPHK2 can be directly phosphorylated by ERK1/2 and translocated to 
the plasma membrane, where it produces S1P. In the endoplasmic reticulum (ER) SPHK2 is 
involved in apoptotic signalling through S1P, which in turn, is degraded by S1P phosphatases 
(S1Pase) to sphingosine and ceramide. SPHK2 was also found to be present in the mitochondria, 
where it produces S1P. 

1.9.2 Sphingosine kinase activation and regulation 
 
Sphingosine kinases have intrinsic catalytic activity, this allows the generation of 
basal levels of S1P to occur independently of any post-translational modifications in both 
kinases [175]. In SPHK1 this intrinsic activity can be further increased via stimulation by 
several soluble molecules such as  platelet-derived growth factor (PDGF), fetal calf serum 
(FCS) [176], nerve growth factor (NGF) [177], endothelial growth factor (EGF) [178], vascular 
endothelial growth factor (VEGF) [179], agonists of GPCRs, vitamin D [180], transforming 
growth factor-beta (TGF-β) or pro-inflammatory cytokines such tumour necrosis factor-alpha 
(TNF-α) [181].  
ERK1/2 (extracellular signal-regulated kinases 1 and 2) is an important regulator of 
SPHK1 activity as it has the ability to further increase SPHK1 activity. Pitson et al. showed 
that in HEK293 cells ERK1/2 phosphorylates SPHK1 on Ser225 leading to an increase in 
SPHK1 activity and translocation to the plasma membrane [182]. SPHK1 binding specificity to 
membrane acid phospholipids is increased by conformational changes induced by its 
phosphorylation at Ser225, suggesting that these conformational changes expose the lipid 
binding domain [183]. Phorbol 12-myristate 13-acetate (PMA) induces SPHK1 up-regulation 
via the activation of activator protein-2 (AP-2) binding motifs; an effect that is abrogated by 
ERK1/2 and protein kinase C (PKC) inhibition. These findings suggest that ERK1/2 and PKC 
mediated transcriptional factors that bind AP-2 motifs regulate SPHK1 transcription [184, 
185]. SPHK1 activation is reported to regulate Ca2+ signalling, which in turn regulates SPHK1 
translocation and subcellular distribution, however Ca2+/calmodulin is not critical for SPHK1 
activity [186]. Other signalling molecules such as PI3K/AKT2 and mTOR have also been 
shown to be involved in SPHK1 regulation in imatinib-
resistant chronic myeloid leukemia cells [187]. K-RAS, an upstream regulator of the MAPK 
pathway, increased S1P production via an SPHK1 dependent manner; it also increased SPHK1 
plasma membrane localisation leading to a decrease in cytoplasmic levels [187]. Cytokines 
have also been shown to play a role in the activation of SPHK1; TNF-α activates SPHK1 via a 
TNF-associated factor 2 (TRAF2)-dependent mechanism, leading to activation of the Akt 
signalling pathway in glioblastoma cells [188]. The aforementioned multiple signalling 
molecules that are associated with SPHK1 regulation and activation are important mediators 
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in oncogenic events; this clearly underpins SPHK1 as a focal point in such events and the far 
reaching implications of targeting SPHK1 in potential cancer therapies. 
 
1.9.3 The role of SPHK2 
 
The role of SPHK2 in a pro- or anti-apoptotic manner is still debatable; early reports 
indicate its main mechanisms of action to be via inhibition of DNA synthesis, suppression of 
cell growth and proliferation through the activation of cell cycle inhibitors [161]. Moreover 
SPHK2 has BH3 (Bcl-2 homology 3)-binding domain activity that can inhibit the anti-apoptotic 
protein BCL2L1 and induce apoptosis [189], however contrasting publications implicate 
SPHK2 in a pro-survival role. SPHK2 knockdown increases sensitivity of glioblastoma, breast, 
colon and lung tumour cells to chemotherapy [190, 191]. In support, xenograft tumours 
(MCF-7 cells) showed a reduction in growth when SPHK2 was subject to knockdown [192], 
whilst similar findings were reported in breast adenocarcinoma, hepatocellular carcinoma 
and renal xenograft tumours following SPHK2 inhibition [193-195]. In vitro, SPHK2 chemical 
inhibition induced autophagic cell death in kidney, prostate and breast tumour cell lines and 
also a decrease in cell proliferation [195]. Overall, it is clear that the role of SPHK2 varies in 
different settings, with further studies needed to elucidate and clarify its potential as a pro- 
or anti-tumorigenic factor. 
SPHK2 has also been shown to play a role in the proliferation of synovial fibroblasts in 
rheumatoid arthritis [196]. In addition it was also shown that SPHK2 is both ubiquitously and 
highly expressed in limb buds, branchial arches and eyes, indicating a possible role for SPHK2 
in their development [197]. The genetic ablation of SPHK2 or SPHK1 in a mouse model did 
not result in abnormalities, however when both SPHKs were simultaneously deleted it 
proved to be embryonically lethal due to severe bleeding [198]. The author also showed 
abnormalities in angiogenesis and neurogenesis suggesting a role for SPHKs in these critical 
physiological processes.  
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1.9.4 The role of SPHK1 
 
SPHK1 is a multi-faceted molecule with wide-ranging implications in the promotion of 
cellular survival, proliferation and transformation, stimulation of angiogenesis and apoptosis. 
As a consequence, its role in tumour progression and chemoresistance has been studied, 
with significant findings outlined below. 
 
1.9.4.1 The role of SPHK1 in cancer  
 
SPHK1 is over-expressed in several solid tumours and is associated with a poor 
prognosis in patients with glioblastoma [199] and breast cancer [200]. High levels of SPHK1 
were detected in more than 60% of colorectal cancer tumours [201] and in colon cancer 
SPHK1 expression was higher in carcinomas than in benign lesions [202]. Importantly, SPHK1 
expression was crucial for tumour growth and aggressiveness in azoxymethane-induced 
colon carcinomas [202], whilst in breast cancer SPHK1 expression is estimated to be 4-fold 
higher than in normal breast tissue [203]. In both ER positive and ER negative tumours, 
SPHK1 expression was correlated with a poor outcome and increase in metastatic incidence 
during a five year period [200]. In prostate cancer SPHK1 activity was correlated with PSA 
levels, tumour volume, gleason score and disease recurrence in patients who underwent 
radical prostatectomy [204]. Moreover, SPHK1 is reported to have a ten-fold higher basal 
activity in androgen independent metastatic PC-3 than in androgen-dependent, non-
metastatic LNCaP cells; interestingly androgen deprivation increases SPHK1 levels in LNCaP 
cells in a PI3K/AKT dependent manner. The authors propose that SPHK1 could act as a 
compensatory mechanism to androgen deprivation that could ultimately lead to androgen-
independence [205].  
The mechanism underlying SPHK1 over-expression in PCa still remains unclear, however a 
recent study showed for the first time that SPHK1 is regulated by prostate tumour inducer-1 
(PTI-1) which can induce neoplastic cell transformation. PTI-1 is a truncated isoform of 
eEF1A1 (elongation factor 1A) that was previously shown to activate and interact with SPHK1 
[206]; indeed these actions appear crucial for PTI-1 induced neoplastic transformation. 
SPHK1 inhibitors or the over-expression of dominant-negative SPHK1 abrogate the 
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carcinogenic effect of PTI-1, indicating SPHK1 may be a crucial partner in prostate cancer 
oncogenesis [207].  
 
SPHK1 has also been shown to induce cancer cell migration. In the MCF-7 breast 
cancer cell line estradiol-induced migration was accompanied by an increase in SPHK1 
activity and inhibited by the use of siRNA-SPHK1 [208]. In gastric cancer cells SPHK1 
expression and protein levels were increased after LPA (Lysophosphatidic acid) stimulation, 
this was concomitant with an increase in migration. Inhibition of SPHK1 or EGF receptor 
attenuated LPA-stimulated migration and invasion of MNK1 cells [130]. In ML-
1 thyroid carcinoma cells SPHK1 over-expression increased migration, with the authors 
identifying the autocrine S1P-induced ERK1/2 and PKC activation loop as crucial for this 
migration [209]. Expression of PAI-1 and uPAR, two known regulators of cell migration and 
adhesion, have also been linked with SPHK1 expression by increasing adhesion and invasion 
of U373 glioblastoma cells [210].  
 
Angiogenesis is a critical and vital process in tumour growth, with SPHK1/S1P 
signalling reported to be involved. S1P can induce VEGF expression and promote endothelial 
cell growth [211]. Tumour cells can secrete S1P into peripheral blood or lymph flow to 
attract different cells, such as vascular endothelial cells, into the tumour site [212]. In murine 
models S1P1 expression is strongly induced in tumour vessels whereas its ablation by siRNA 
abrogates angiogenesis and decreases tumour growth [213]. VEGF-induced blood vessel 
formation and endothelial cell migration was inhibited by S1P antibody in several cancer cell 
lines. Proangiogenic cytokines such as IL-8 and IL-6 were also reduced by the presence of an 
anti-S1P antibody [214] 
 
1.9.4.2 The role of SPHK1 in chemoresistance 
 
SPHK1 over-expression increases resistance to chemotherapeutic agents such as 
doxorubicin in MCF-7 breast cancer cells; conversely, SPHK1 inhibition sensitises these cells 
to the drug [215]. The synergistic effect of SPHK1 inhibition with other chemotherapy agents 
such as camptothecin [216] and radiotherapy have also been reported [144]. SPHK1 over-
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expression inhibited apoptosis in MCF-7 breast cancer cells and HL-60 acute myeloid cells 
upon doxorubicin and etoposide treatment [217, 218], whilst the SPHK1 inhibitor N,N-
dimethylsphingosine (DMS) proved very effective in overcoming radio and chemo-resistance 
in acute myeloid leukaemia cells [219]. An increase in sensitivity to cisplatin, carboplatin and 
doxorubicin was observed in HEK293 and A549 lung cancer cells expressing human S1P lyase 
[220], whilst high levels of SPHK1, S1P1 and S1P3 were associated with the development of 
tamoxifen resistance in ER positive breast cancer patients [221] 
Previous work by Pchejestki et al. showed that over-expression of SPHK1 in LNCaP 
and PC-3 cells increased their resistance to docetaxel treatment and that by inhibiting SPHK1 
using siRNA this protective effect was abrograted [78, 222]. This mechanism was also 
confirmed in an in vivo setting; increases in tumour volume and docetaxel resistance were 
observed following SPHK1 over-expression in PCa cells when compared to empty vector 
controls [222]. 
 
1.10 Tumour microenvironment  
 
1.10.1 Cancer and Inflammation 
 
There is strong evidence to suggest that the tumour microenvironment is inflammatory 
and that activation of the innate immune system plays a role in the progression of cancer. 
The identification of this phenomenon has led to the development of new strategies that 
target the multiple interactions of tumour cells with other cell types within the tumour 
microenvironment [223-225].  
The inflammatory tumour microenvironment contains an abundance of cytokines (e.g. 
CSF-1 (Colony stimulating factor-1), GM-CSF-1 (Granulocyte-macrophage colony stimulating 
factor), IL-8, IL-6 and TNF-α), chemokines (e.g. CCL1, CCL2, CCL3 and CCL7) and growth 
factors (e.g. TGF-β, EGF, VEGF) that are secreted by tumour cells and stromal cells (e.g. 
macrophages, fibroblasts and endothelial cells) creating a favourable microenvironment for 
tumour survival, growth and progression [226-228]. Likewise, inflammatory diseases such as 
Crohn’s and ulcerative colitis, viral infections such as Hepatitis B and C, or bacterial 
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infections have been associated with an increased risk of developing cancer [226, 229, 230]. 
Harmey et al. have used in vitro and in vivo models to demonstrate that lipoplysaccharide 
(LPS), a cell wall component of Gram-negative bacteria, promotes metastatic growth, 
angiogenesis and an increase in vascular permeability [231].  
 
1.10.2 Monocyte/Macrophage differentiation: Th1 and Th2 involvement in cancer 
 
Myeloid progenitor cells in the bone marrow are the precursors of monocytes which 
in turn, after entering the blood stream, have the ability to migrate into different tissues. 
This migration is modulated by chemotactic stimuli such as chemokines or growth factors, 
and once in the site (or still in circulation) monocytes can be differentiated to macrophages 
by different growth factors including GM-CSF or M-CSF [232](Figure 1.6). As part of their 
natural functions monocytes and macrophages are among the first cells of the immune 
response to arrive at sites of infection or wound healing. Recent studies reveal that direct 
communication between macrophages and tumour cells is critical to invasion and egress of 
tumour cells into blood vessels [233]. Tumour cells also have the ability to recruit myeloid 
cells by secreting a variety of different growth factors including GM-CSF, CSF-1 and 
macrophage stimulating protein (MSP) or chemokines such as monocyte chemotactic 
protein-1 (MCP-1), macrophage migration inhibitory factor (MIF) or macrophage 
inflammatory protein-1 alpha (MIP-1α) [233]. Blood circulating and tissue resident 
monocytes are attracted to tumour sites, where according to the stimulus, they can be 
differentiated into two main macrophage phenotypes, classically activated macrophages 
(M1) or alternatively activated macrophages (M2) [234] as shown in figure 1.6. LPS or IFN-γ 
are known inducers of M1 activation which is characterised by a high capacity to present 
antigen, high levels of IL-12, IL-23, nitric oxide (NO) and reactive oxygen intermediates (ROI), 
along with an activation of Th1 immune responses, including the activation of T-cells and 
other cell types such as NK cells [235, 236]. Th1 responses are known to have an anti-cancer 
activity, it is thought M1 type macrophages are capable of inducing lysis in cancer cells due 
either by the secretion of high amounts of superoxide anions, oxygen radicals, and nitrogen 
radicals; or by expressing high levels of MHC class I to facilitate complement-mediated 
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phagocytosis. Their ability to interact with T-Cells though MHC class I and present the 
antigen to CD8+ T-cell leads to a cytotoxic effect of these cells towards cancer cells [237].    
 Alternatively activated macrophages, M2, and Th2 immune responses are induced 
by IL-4, IL-10, IL-13, inhibition of Th1 responses by production of immunosuppressive 
mediators such as TGF-β or PGE2, an increase in the production of IL-6 and VEGF, and the 
production of chemokines (e.g. CCL17 or CCL22) capable of recruiting Th2 cells [227, 238].  
Tumour associated macrophages (TAMs) are phenotypically similar to M2 
macrophages and it has been shown that a high amount of TAMs are associated with a poor 
clinical prognosis [239]. TAMs are linked to tumour progression, intravasation and the 
initiation of the metastatic process [238-240]. Interestingly, Chen et al. showed that high 
mobility group box 1 protein (HMGB1) is secreted from necrotic cells and acts as a strong 
chemotactic factor for macrophages [241]. Conversely, apoptotic tumour cells (ATCs) can 
release anti-inflammatory cytokines such as IL-10 and TGF-β to promote an M2 phenotype. 
The macrophage phenotype is also affected by phagocytosis of ATCs resulting in an 
inhibition of the pro-inflammatory cytokines IL-8, TNF-α and GM-CSF, leading to an increase 
in TGF-β and PGE2 [242]. Mantovani et al. also showed that conditioned media from ATCs 
can induce a TAM phenotype in macrophages [243]. 
 
 
 
 
 
 
 
 
 
49
Figure 1.6: Monocyte and macrophage diversity. Both monocytes and macrophages derive 
from hematopoietic stem cells (HPSCs). HPSCs are produced in the bone marrow where they 
can be differentiated into pro-monocytes through various multipotent progenitor stages 
involving granulocyte/macrophage colony-forming unit (GM-CFU) to monocyte colony-forming 
unit (M-CFU). The presence of colony-stimulating factor 1 (CSF-1) induces M-CFU 
differentiation into monoblasts and subsequently into pro-monocytes. At this point cells enter 
the blood stream and monocytes are produced in two main groups; the classical monocytes 
which comprise approximately 90-95% of total monocytes in an adult, and non-classical 
monocytes (5-10%). These two sets of monocytes express different surface markers and 
receptor expression profiles which may determine not only their function but also their 
migration patterns. Monocyte migration into the tissues leads to their differentiation into 
either M1 or M2 macrophages depending on the microenvironment signalling profile. Once 
activated, macrophages secrete an array of cytokines and growth factors commonly accepted 
as pro-inflammatory (M1) and anti-inflammatory (M2) responses. The interaction with T-cells is 
different for each subset of macrophages; TH1 (M1 macrophage) and TH2 (M2 macrophage) 
resulting in different T-Cell responses.  
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1.10.3 The effect of the tumour microenvironment on cancer development 
 
Inflammatory cells such as monocytes and macrophages have been suggested to play 
a role in the early stages of cancer development where they appear to be present in areas of 
hyperplasia and atypia [233, 244]. Importantly, Lin et al. reported that mice lacking CSF-1, a 
strong chemoattractant for monocytes and macrophages, display attenuated tumour 
progression and metastasis when compared to wild-type mice; an effect not related to 
changes in primary tumour growth [245]. Conversely, human leukemic monocyte lymphoma 
cell line (U937) co-inoculated with PC-3 in male athymic nude mice increased tumour growth 
and vascular density when compared to PC-3 tumours alone. Pre-treatment of U937 with IL-
4 to promote an M2 phenotype induced a bigger increase in tumour size and was 
accompanied by the secretion of CCL2 (MCP-1) [246]. In support, breast cancer cells showed 
higher invasion and motility into a basement membrane (Matrigel) when in co-culture with 
U937 cells [247]. Another monocytic cell line, THP-1, enhanced the growth of colon cancer 
cells in an IL-1β dependent mechanism [248]; interestingly the authors showed that Vitamin 
D interrupted the cross-talk between tumour cells and monocytes and that it was crucial for 
a reduction in tumour cell proliferation.  PMA-treated THP-1 cells (M2 phenotype) enhanced 
angiogenesis and invasion in human basal cell carcinoma through the activation of COX-2 
[249], whereas in ovarian cancer the increase in angiogenesis was also accompanied by an 
increase in IL-8 mRNA expression levels [250]. Direct culture of blood derived monocytes 
with MDA-231 breast cancer cells resulted in increased expression of factors such as MMP9, 
PAI-1 and uPAR that are involved in cancer cell invasiveness. In this case the authors did not 
perform analysis on the proliferation or invasion of the cancer cells [251].   
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1.10.4 SPHK1/S1P regulation in immune cells 
 
Monocytes and macrophages are part of the first line of defence against invading 
organisms such as bacteria. SPHK1 and S1P have been reported to be involved in 
antimicrobial activity in macrophages. Indeed, ingestion of non-viable M.tuberculosis 
triggers a rapid increase in SPHK1 activity in human macrophages after its ingestion; 
interestingly viable M. tuberculosis inhibited SPHK1 activity and its translocation to the 
nascent phagosomes [252]. Moreover, the addition of exogenous S1P activated 
phospholipase D which is involved in the acidification of mycobacteria-containing 
phagosome [253]. This study also showed that in mycobacteria-infected mice the addition of 
S1P reduced pulmonary tissue damage and mycobacterial growth. 
As previously described for tumour cells, the SPHK1/S1P signalling pathway can also 
play a role in the protection of macrophages against apoptosis. S1P secreted from apoptotic 
cells protected macrophages from TNFα/cycloheximide-induced cell death. This effect was 
correlated with an increase in  PI3K, ERK1/2 and calcium signalling which were shown to be 
activated by S1P [254]. Furthermore, in apoptotic bone marrow-derived macrophages S1P 
stimulation inhibited acid sphingomyelinase activity via PI3K signalling. Interestingly there 
was no ceramide accumulation but instead an increase in Bcl-XL expression [255]. Another 
study indicated that COX-2 activation by LPS was mediated by SPHK1/S1P; more interestingly 
S1P can mediate induction of arachidonic acid, an upstream regulator of COX-2 [256, 257].  A 
schematic representation of SPHK1 and S1P role in macrophages is shown in figure 1.7. 
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Figure 1.7: Divergent role of S1P and SPHK1 signalling in macrophages. S1P binding to S1P 
receptors induces anti-inflammatory responses and inhibits the production of pro-
inflammatory cytokines whilst elevating the production of pro-angiogenic mediators. COX-2 
expression is increased by S1P, leading to the production and secretion of PGE2 
(prostaglandin), which in turn is able to induce cAMP (cyclin adenosine monophosphate) via 
EPR2 receptor (E prostanoid receptor). S1P can also induce cAMP production independently 
of PGE2 signalling. Extracellular S1P induces phagosome maturation after pathogen uptake. 
M.Tuberculosis (if non-viable) can induce the rapid recruitment of SPHK1 to the phagosome 
where it contributes to phagosome maturation. Ingestion of viable M.Tubeculosis inhibits 
SPHK1 recruitment to the phagosomes. S1P can also activate PI3K/AKT and ERK1/2 that 
mediate cell survival and inhibit apoptosis. SPHK1 activation by inflammatory mediators also 
contributes towards pro-survival signalling.  

1.10.5 SPHK1/S1P role in immune cell trafficking  
 
S1P is a potent regulator of immune trafficking not only due to its direct binding to 
membrane receptors and consequent activation of migratory pathways but also due to its 
differential concentrations in different tissues and in circulation [114, 258]. S1P secreted 
from apoptotic cells is a potent chemotactic agent for monocytes and macrophages [259]. A 
more recent in vivo study showed that S1P antibody reduced the level of macrophage influx 
into ischemic areas [260]. Similarly, the inhibitor FTY720 also decreased macrophage 
infiltration into peripheral nerves and into the central nervous system in experimental 
autoimmune neuritis [261] and encephalomyelitis models [262]. It is known that FTY720 
blocks S1P signalling by binding to the S1P receptors (S1P1 receptor) causing its 
internalisation and degradation [263]. KRP-203, an FTY720 analogue and S1P1 receptor 
antagonist, reduced macrophage infiltration in the myocardium of rats [264].  
SPHK1 involvement in the regulation of vascular cell adhesion molecules in 
endothelia is an important link to the recruitment of different types of leucocytes such as 
macrophages during inflammation [265]. In monocytes, SPHK1 activation triggers calcium 
release and regulates NADPH oxidase activity, both of which were shown to be mediated via 
the high-affinity IgG receptor (FcγRI) [266] which is a key regulator of immune responses, 
indicating SPHK1 as a critical molecule in immune cell  intracellular signalling regulation.  
In lymphocyte trafficking, S1P and S1P1 receptor are important regulators of T-cell 
egress from the thymus into the blood stream and their subsequent maturation and 
transition to a secondary lymphoid organ. In B cells the S1P/S1P1 axis regulates their 
position in the spleen as well as mediating the control of mature B cell emigration from the 
lymphoid tissue or in the case of immature B cells, the egress to the bone marrow vascular 
compartment and peripheral blood [267]. 
During mast cell degranulation, S1P was found to be one of the released factors 
along with histamine, cytokines and chemokines. Indeed, S1P action in mast cells can 
increase their migration towards antigen or induce its degranulation, indicating S1P as a 
mediator in the recruitment of these cells to the inflammatory sites and in inducing their 
degranulation as part of their immune response [158]. 
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1.10.6 Bidirectional regulation of SPHK1 and cytokines in macrophages  
 
A key event in inflammation-related tumorigenesis is cytokine release by TAMs, 
which has been associated with an up-regulation of several intracellular pathways, most 
notably TNF-α, PI3K/Akt, MAPK and NF-ĸB [188, 227, 268, 269]. In primary human 
monocytes SPHK1 is activated by TNF-α leading to the activation of Ca2+ intracellular 
signalling, activation of NF-kB and cytokine production (IL-1β and IL-6). Furthermore, SPHK1 
inhibition by siRNA abrogates the TNF-α induced effect [268] whilst similarly in RAW 
macrophages, TNF-α induced PGE2 production, which was inhibited by SPHK1 siRNA [256]. 
In microglia, resident macrophages of the central nervous system, LPS has been 
shown to induce TNF-α, IL-1β and iNOs through SPHK1 transcriptional activation, whereas its 
inhibition reduces cytokine secretion and iNOs levels. Moreover, the addition of exogenous 
S1P can restore these LPS-induced effects [270]. On the contrary another study showed that 
S1P induced an inflammatory response in macrophages. This study indicated that S1P 
inhibits LPS-induced secretion of pro-inflammatory cytokines such as TNF-α, MCP-1 and IL-12 
in peritoneal macrophages isolated from S1P2 receptor-deficient mice. This effect was 
mediated through S1P1 receptor, as the addition of S1P1 receptor-specific agonist SEW2871 
mimics the S1P inhibitory effect on LPS-induced cytokines. In addition, S1P increased 
Arginase I activity and decreased iNOS, indicating an alternative anti-inflammatory 
macrophage phenotype [271]. Unfortunately the authors did not measure SPHK1 and 
therefore it is not possible to establish a correlation with the previous study in order to 
understand if SPHK1 was playing a central role in the macrophage phenotype switch. 
Interestingly, Spiegel et al. have shown that apoptosis of Jurkat and U937 cells can induce 
the release of S1P via the up-regulation of SPHK1. This effect was independent of SPHK1 
Inhibition, which led to the hypothesis that S1P release is a consequence of stress rather 
than SPHK1 inhibition.  
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1.11  Interleukin-6 
 
Interleukin-6 (IL-6) is a potent cytokine that is omnipresent in inflammatory 
responses and most cancers [272]. IL-6 signals through a cell-surface type I cytokine receptor 
complex involving IL-6 receptor (IL-6R) and gp130, the signal-transducing component. IL-6 
belongs to the cytokine family encompassing OSM (oncostatin M), LIF (leukaemia inhibitory 
factor), IL-11, CT-1 (cardiotrophin-1), CNTF (ciliar neurotrophic factor) and cardiotrophin-like 
cytokine (CLC) [273]. IL-6 intracellular signalling is mediated through Janus Activated Kinases 
1 and 2 (JAK1 and JAK2) which in turn induces the activation of signal transducers and 
activators of transcription (STAT) proteins (mostly STAT3) [274], RAS/MEK/ERK [275] and 
PI3K/Akt signalling pathways [276] (Figure 1.8). These IL-6 activated signalling pathways are 
involved in tumour proliferation, migration [277], survival and chemoresistance [272] 
increasing the appeal of IL-6 as a potential therapeutic target.  
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Figure 1.8: IL-6 signalling link with the SPHK1/S1P pathway. a) IL-6 receptor (IL-6r) requires the 
presence of signal transducer activator G130 to activate the IL-6 signalling pathway. Upon 
receptor activation JAKs are phosphorylated and can induce STAT1 and STAT3 phosphorylation, 
which in turn can result in the formation of heterodimers (STAT1/STAT3) or homodimers (STAT3 
/STAT3 (most common) or STAT1/STAT1). STATs can then translocate to the nucleus and act as a 
transcription factor for several genes, including IL-6 itself. Alternatively, IL-6/IL-6r/gp130 signalling 
can lead to the activation of PI3K/AKT /NF-kB  and/or RAS/MEK/ERK1/2 signalling pathways which 
results in the transcriptional regulation of several genes involved in pro-survival actions. b) 
Schematic showing how SPHK1/S1P signalling connects with NF-k/IL-6/STAT3. SPHK1 production 
of S1P induces NF-kB activation via S1P1 receptor, which in turn acts as a transcription factor for 
IL-6 and TNF-α. IL-6, in turn, can activate STAT3 as well as S1P/S1P1 signalling to generate a 
positive feed-back loop resulting in a persistent activation of STAT3. 
a) 
b) 
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1.11.1 IL-6 and cancer 
 
IL-6 expression has been described in several human cancers; in colorectal cancer IL-6 
expression and serum levels have been correlated with advanced stages and poor survival 
[278], whilst in gastric cancer elevated IL-6 expression correlates with invasive and 
metastatic potential. Of particular interest to my study, gastric cancer initiation is linked with 
chronic gastritis in which high levels of inflammatory mediators and inflammatory cells are 
present to promote cancer progression [279, 280]. In pancreatic cancer [281], cervical cancer 
[282], melanoma [283], ovarian cancer [284] and glioblastoma [285] IL-6 levels were also 
indicative of tumour progression and poor survival. Interestingly in ovarian cancer IL-6 was 
also responsible for the induction of other inflammatory mediators and angiogenesis factors 
including TNF-α, IL-1β, CCL2 and VEGF which can act in an autocrine and paracrine manner 
within the tumour microenvironment [286] 
In prostate cancer high levels of IL-6 were found to be a tumour cell survival factor 
and mediator of chemoresistance in prostate tumours [287-289]. IL-6 has also been shown 
to induce androgen receptor activation and increase cell proliferation and tumour growth, 
whereas the use of the androgen receptor antagonist bicalutamide abrogated IL-6-induced 
growth [290]. IL-6 involvement in myeloid recruitment to the tumour site was shown in an 
androgen-independent prostate cancer xenograft model. This study correlated STAT3 and IL-
6 levels with high infiltration of myeloid cells; in contrast IL-6 ablation reduced the 
recruitment of these cells and decreased tumour growth and angiogenesis [291].   
 
1.11.2 IL-6 signalling and the SPHK1/S1P pathway 
 
The SPHK1/S1P pathway and IL-6 signalling are known to be involved in various 
cellular processes with pro-survival effects. Evidence of their cross-regulation has been 
reported in several studies with particular relevance to cancer and in inflammatory diseases, 
with most studies to date indicating SPHK1 as a regulator of IL-6 expression [292-294]. In 
patients with severe acute pancreatitis, SPHK1 activity and S1P3 expression in peripheral 
neutrophils and lymphocytes were higher than in healthy patients, in addition the IL-6 serum 
levels positively correlated with SPHK1 intracellular expression. In this case no direct 
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regulation of SPHK1 on IL-6 or vice-versa was investigated [295]. TNF-α induced IL-6 in 
fibroblast-like synoviocytes (key contributors to rheumatoid arthritis) was blocked by SPHK1 
inhibition, which also resulted in a decrease in STAT3, ERK1/2 and PGE2 [296]. In THP-1 and 
RAW264.7 macrophages SPHK1 was crucial for IL-6 expression upon LPS treatment [297].  
In STAT3 positive tumours S1P1 receptor expression was elevated in comparison with 
STAT3 negative tumours. In addition, the over-expression of S1P1 receptor (S1P1R) induced 
STAT3 activation, IL-6 up-regulation and increased tumour growth and metastasis, whereas 
the absence of S1P1 receptor in either tumours or immune cells had an opposite effect. 
STAT3 was shown to be involved in S1P1 receptor activation, indicating a positive feed-back 
loop for persistent STAT3 activation in either tumour cells or immune cells [298]. This work 
was followed by another study indicating S1P1 receptor and STAT3 as a link between chronic 
intestinal inﬂammation and development of colitis-associated cancer (CAC). In this work it is 
suggested that SPHK1 is crucial for S1P production, which in turn activates STAT3, creating a 
positive feed-back loop (figure 1.8b). It was also shown that intracellular S1P increases IL-6 
and TNF-α expression through NF-kB. As a result, IL-6 has the capacity to activate STAT3 
whereas TNF-α can induce SPHK1 activation which again creates a positive feed-back loop 
with persistent activation of STAT3 leading to chronic inﬂammation and CAC development 
[299]. It is believed that cancer cells recruit immune cells to produce S1P and other 
cytokines, such as IL-6, to activate STAT3, sustain inflammation and induce tumour 
development [300, 301]. Interestingly this STAT3-S1P1 axis has been implicated in the 
colonisation of future metastatic sites for prostate cancer cells; indeed a disruption in either 
STAT3 or S1P1 in myeloid cells decreased their ability to intravasate to distant sites and 
inhibited not only their own proliferation but also that of  stromal cells [302]. A very recent 
study in BeWo cells indicated S1P2, and not S1P1, as a critical component of S1P induced IL-6 
activation in a RhoGTPases-dependent pathway.  
 
1.12  Monocyte chemotactic protein-1 (MCP-1) 
 
CCL2, also known as monocyte chemotactic protein-1 (MCP-1) is a chemokine that 
has a strong chemoattractant effect on immune cells. It belongs to a family with three other 
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members (MCP-2 or CCL8, MCP-3 or CCL7 and MCP-4 or CCL4) sharing a sequence homology 
of 61% (MCP-2 and MCP-4) and 71% (MCP-3) with these [303]. Endothelial, epithelial, 
fibroblast and smooth muscle cells, monocytes and macrophages are amongst the cells that 
express MCP-1; this expression may be constitutive or induced by growth factors or 
cytokines. Its action is mediated by specific binding to the CCR2 G-Protein coupled receptor, 
that conversely to CCL2 is restricted to few cell types including monocytes, B cells, T cells and 
some tumour cells [304]. MCP-1 is involved in the migration and infiltration of 
monocyte/macrophages, T-lymphocytes and natural killer cells to sites of tissue injury and 
inflammation and in many cases to tumour sites [304]. Indeed the involvement of MCP-1 has 
been described in several human diseases such as rheumatoid arthritis, atherosclerosis 
[305], inflammatory bowel disease [306], asthma [307], diabetes (insulin resistance) [308] 
and in the development of many types of cancer [309].  
 
1.12.1 MCP-1 and cancer 
 
MCP-1 is highly expressed in several human tumours such as melanoma [310], glioma 
[311], ovarian carcinoma [312], breast cancer [313] and prostate cancer [314, 315], with 
MCP-1 expression levels in the tumour positively correlating with the recruitment of 
monocytes and macrophages into the tumour tissues. In addition, a study using melanoma 
cell lines with differential levels of MCP-1 expression indicated a strong positive association 
between MCP-1 expression and the recruitment of monocytes and macrophages as well as 
tumour size and vascularisation [316]. Studies in which MCP-1/CCR2 signalling was blocked 
by anti-MCP-1 antibodies or by the use of siRNA showed a delayed tumour progression and 
metastasis seeding, as well as a reduced recruitment of monocytes and macrophages [313, 
317]. One mechanism of action of MCP-1 in monocyte recruitment and accumulation in the 
tumour site is through its ability to induce the up-regulation of MAC-1, which is the receptor 
for intracellular adhesion molecule-1 (ICAM-1) in endothelial cells [318]; this molecule can 
also be secreted in its soluble form as siCAM-1 acting as an autocrine or paracrine molecule 
in the tumour microenvironment and promoting tumour growth [319]. 
As previously stated, MCP-1/CCR2 expression correlates with poor clinical prognosis 
in prostate cancer patients [320, 321]. A Mizutani study showed that mouse monocyte 
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migration was higher towards conditioned media from PC-3 cells over-expressing MCP-1 (PC-
3/MCP-1) than towards parental PC-3 cells. In vivo, tumours grew significantly quicker and 
formed bone metastases in transplanted PC-3/MCP-1 xenografts, an effect that was 
accompanied by an increase in macrophage accumulation in the tumour site [315]. In 
support, MCP-1 importance in prostate cancer growth was found to be through a direct 
regulation of macrophage infiltration into the tumour microenvironment. MCP-1 induces 
phenotypic changes in mouse macrophages (TAMs) whereas a neutralising MCP-1 antibody 
decreased macrophage infiltration to the tumour site as well as the lowering the amount of 
TAMs. This effect results in the retardation of tumour, decrease in microvascular density and 
decrease in Akt phosphorylation in tumour cells [322]. Another study showed that 
exogenous MCP-1 induced migration and proliferation in PC-3 and VCaP (prostate cancer cell 
line) in an Akt dependent manner [323]. 
 
1.12.2 MCP-1/SPHK1 interactions 
 
SPHK1/S1P are known to play an important role in inflammation and regulation of 
immune cell trafficking, effects that can also be attributed to MCP-1/CCR2, suggesting that 
these two important mediators could have a synergistic action not only in inflammatory 
responses but in cancer development and the tumour microenvironment. So far most 
studies identify SPHK1 as an important mediator of MCP-1. In mast cells SPHK1 was critical 
for MCP-1 secretion whereas S1P stimulated the production and secretion of MCP-1 (TNF-α 
and IL-6 to a lesser extent) in a SPHK1-dependent mechanism [324]. In human aortic 
endothelial cells SPHK1 knockdown by siRNA was found to abrogate TNF-α-induced MCP-1 
expression and secretion, whereas exposure to S1P increased MCP-1 protein secretion and 
mRNA expression in a p38 MAPK-dependent manner [325]. Similarly, in A549 lung carcinoma 
cells, MCP-1-induced expression by TNF-α and IL-1β was mediated by SPHK1 [326]. In a 
SPHK1 deficient mouse model, MCP-1 production was inhibited in dermal microvascular 
endothelial cells despite treatment with thrombin, a known inducer of MCP-1 [293]. In this 
study a dominant negative SPHK1 mutant and SPHK1 inhibitor (DMS and SKi-II) also inhibited 
the MCP-1, as well as IL-6, IL-8, and PGE(2), response to thrombin. 
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1.13 PI3K/AKT pathway 
1.13.1 AKT activation 
 
AKT (also known as PKB) is a down-stream target of the phosphoinositide 3-kinase 
(PI3K) signalling pathway. To date there are three described isoforms, namely AKT1, AKT2 
and AKT3, although the elucidation of their roles, in terms of similarity between the isoforms 
or whether each maintains a responsibility for a specific function, remains a topic of debate 
[327]. These isoforms share 80% homology; all contain a hydrophobic motif at the C-
terminus and a similar ATP binding region which in AKT3 contains a switch from Ala232 to 
Val228 in comparison with AKT1 and AKT2. AKT is initially inactive and located in the 
cytoplasm, its translocation to the inner membrane occurs by the activation of the growth 
factor receptor-associated PI3K. This activation is mediated through the receptor tyrosine 
kinases (RTKs) that can either induce direct binding to PI3K or act by activating scaffolding 
adaptors such as IRS1. Once activated, PI3K induces the phosphorylation of 
phosphatidylinositol-4,5-bisphosphate (PIP2) into phosphatidylinositol-3,4,5-trisphosphate 
(PIP3), which serves as an anchor for the assembly of signalling proteins such as AKT, PDK1 
and PTEN. The binding of PI3K occurs through the pleckstrin-homology (PH) domains. PIP3 
can be reversed to PIP2 by PIP3 phosphatase PTEN (Figure 1.9). Once in the membrane, AKT 
is phosphorylated at two sites in two independent phosphorylation events; AKT1 at Thr308 
and Ser473, AKT2 at Thr309 and Ser474, and AKT3 at Thr305 and Ser472. PDK1, when 
recruited to the plasma membrane, acts as key molecule in the phosphorylation of the 
tyrosine residue (T-loop). This first event is crucial for AKT activation, whereas the second 
phosphorylation in the C-terminus enhances AKT activity by inducing conformational 
changes in the T-loop. mTOR complex 2 (mTORC2) is activated by the RTKs and has the 
ability to phosphorylate AKT in the Ser473 motif. Once activated, AKT migrates to the cytosol 
where it acts as a key mediator and activator of several pro-survival pathways (Figure.1.9) 
[328].  
 
 
62
1.13.2 The role of AKT in cancer 
 
PI3K/AKT is often dysregulated in many types of cancer and has become a pivotal 
target for cancer therapy due to its ability to regulate several cellular processes such as 
proliferation, survival, angiogenesis, chemotaxis and apoptosis [328]. Increase in AKT kinase 
activity is observed in several human cancers; in thyroid carcinoma 83% of tumours were 
shown to have increased levels of AKT1 [329], 25-55% of breast cancer tumours showed an 
increase [330, 331], as well as 57% of glioma [332], 40-70% of non-small cell lung carcinoma 
[333, 334], 78% of gastric carcinoma [335], 60-70% of pancreatic carcinoma [336, 337], 40-
70% of ovarian [338, 339] and 45-55% of prostate carcinoma showed an increased activation 
of AKT kinase [331, 340]. In prostate cancer biopsies, AKT expression correlated with high 
gleason score (8-10) and 92% of cases correlated with a strong staining for AKT, in 
comparison with prostatic intraepithelial neoplasia and other grades of PCa where AKT was 
only highly expressed in 10% of the cases [340].  
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Figure 1.9: Schematic representation of AKT activation pathway. Activation of Receptor 
Tyrosine Kinases (RTKs) provokes activation of class I phosphatidylinositol 3-kinase (PI3K) 
through direct binding or through tyrosine phosphorylation of IRS1, that in turn activates PI3K. 
As a consequence, PI3K phosphorylates PIP2 into PIP3 allowing AKT binding through the PH 
domain. PTEN acts as a negative regulator of PIP3 production as it converts PIP3 into PIP2. PIP3 
activation also allows PDK1 to bind and induce AKT phosphorylation at Thr308 (AKT1). A second 
AKT phosphorylation on Ser473 results from the mTORC2 activation induced by RTKs, which can 
be dephosphorylated by PHLPP. AKT activates mTOR complex 1 (mTORC1) through PRAS40 
phosphorylation that disrupts the binding between mTORC1 and PRAS40, and relieves the 
inhibitory effect of PRAS40 in mTORC1. Activated mTORC1 phosphorylates the hydrophobic 
motif on the S6 kinases that, together with mTORC1, can act as a negative regulator of PI3K 
through the inhibition of IRS1 phosphorylation. AKT phosphorylation results in its translocation 
to the cytosol where it represses or activates important signalling molecules involved in several 
cellular processes such as survival (Caspase 9, FOXO,BAD,GSK3,MDM2), angiogenesis 
(eNOS,TSC2), metabolism (GSK3,FOXO), glucose uptake (AS160), growth (TSC2) and proliferation 
(TSC2,p27, GSK3,MDM2, FOXO). 
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In PCa genetic alterations of the PI3K/AKT pathway are observed in approximately 
40% of primary and 70% of metastatic PCa [341]. In this context PTEN, a negative regulator 
of PIK3/AKT signalling, is the most commonly mutated tumour-suppressor gene in PCa [342]. 
PTEN loss of function is normally attributed to DNA methylation, deletions, point mutations 
or defects in protein stability [343]. Immunohistological data in PCa tumours indicated that a 
higher PTEN expression was associated with a higher relapse-free survival (85.7%) than in 
low PTEN-expressing tumours (16.6%) at 30 months post-surgery. Furthermore, after 36 
months 100% of low PTEN-expressing tumours had a biochemical relapse compared with 
only 28.5% of PTEN high expressors [344]. Beside the loss of PTEN function, AKT constitutive 
activity in prostate cancer cells is mainly due to EGFR and PDGFR activation [345, 346]. 
Interestingly the ligands for these two receptors are EGF and PDGF, both of which have been 
reported to activate SPHK1 (Section 1.9.2).    
AKT activation is also important for epithelial-mesenchymal transition (EMT) [347], 
induction of metastasis, and cell invasion by activating the secretion matrix 
metalloproteinases (MMP-9) in ovarian cancer cells [348]. 
 
1.13.3 AKT and SPHK1 cross-talk 
 
Involvement of both AKT and SPHK1 in anti-apoptotic and pro-survival responses in 
different disease states is well documented. A cross-regulation between these two potent 
mediators has been reported; in non-small cell lung cancer (NSCLC) SPHK1 inhibition by SKi-I 
inhibitor resulted in a reduction in AKT levels and increased the sensitivity to doxorubicin 
and docetaxel-induced apoptosis. On the contrary, SPHK1 over-expression increased AKT 
phosphorylation levels and the inhibition of AKT abrogated the SPHK1 anti-apoptotic effect 
on NSCLC [349]. Another study suggested that SPHK1 can act through the AKT/FOXO3 
pathway to protect glioma cells from apoptosis [350]. Indeed, several other reports identify 
SPHK1 as a key mediator of AKT phosphorylation in melanoma cells [351], ovarian cancer 
cells [352], chronic myeloid leukaemia cells [187] and in glioblastoma cells [353]. 
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1.14 The JAK/STAT Pathway 
 
Janus Activated Kinase (JAK) and Signal Transducers and Activators of Transcription 
(STAT) signalling has been widely studied by researchers worldwide due to its fundamental 
importance in cell proliferation, migration, apoptosis and immune response [354, 355]. This 
signalling pathway links cell membrane receptors to gene expression, therefore it is of no 
surprise that JAK/STAT signalling pathways are currently used as targets in different disease 
states such as cancer and chronic inflammation. JAK/STAT signalling is activated by the 
binding of different molecules such as growth factors (eg. G-SCF, GM-CSF, GH), Interferons 
(eg. IFNα, γ, β), or interleukins (eg. IL-2, IL-4, IL-6, IL-7, IL-9, IL-10, IL-12, IL-15, IL-19, IL-20, IL-
21) to their specific receptors [356]. JAKs are receptor-associated protein kinases, 
comprising a family of four members: JAK1, JAK2, JAK3 and TYK2 (Tyrosine Kinase 2). JAK1, 
JAK2 and TYK2 are ubiquitously expressed and JAK3 is mainly expressed in leukocytes [357]. 
JAK activation is driven by the phosphorylation of tyrosine residues releasing the blockade of 
the catalytic site. Upon stimulation JAKs can either form homodimers (eg. JAK1/JAK1) or 
heterodimers (eg. JAK1/JAK3) [358]. JAKs can also play an active role in transcriptional 
regulation as it has been shown that JAK2 can translocate to the nucleus and regulate the 
phosphorylation of tyrosine 41 on histone 3, indicating its involvement in the regulation of 
target genes and/or its own expression. A schematic representation of JAK/STAT pathway 
and their different activators is shown in figure 1.10. 
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a) 
b) 
Figure 1.10: Schematic representation of STAT1 activation pathway. a) Activation of Receptor 
tyrosine kinases (RTKs) induces JAK phosphorylation, which allows the binding of  multiple 
signalling regulators such as STATs. Upon binding, STATs can form homo or heterodimers 
before translocation to the nucleus were they act in the transcription of several genes. JAKs can 
also form homo or heterodimers and act as a transcription factor. b) Activation of RTKs by 
different agonists leads to the recruitment of different JAK family members. This in turn will 
lead to the recruitment of different STATs that can induce the transcription of several sets of 
genes.   
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1.14.1 STATs 
 
At present, seven different members of the STAT family of transcription factors are 
known: STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6 [359]. They share 
functionally and structurally conserved domains, including an amino-terminal domain (NH2), 
DNA binding domain (DBD), linker domain, SH2/tyrosine activation domain and coiled–coiled 
domain (CCD). The carboxy-terminal transcriptional activation domain (TAD) differs between 
STATs and contributes to STAT specificity [360].  
JAK phosphorylation induces the formation of docking sites enabling the recruitment 
of multiple signalling regulators such as STATs. This binding is mediated by the Src 
homology domain (SH2) that is present in all STAT proteins [361]. The JAK-mediated tyrosine 
phosphorylation of STATs promotes rapid translocation of the latter to the nucleus, where 
they accumulate and bind to DNA, promoting gene expression. Upon phosphorylation of the 
SH2 domain, STATs can form either homodimers or heterodimers, which plays an important 
role in their ability to act as transcription factors (Figure 1.9a). Different STATs can be 
activated by several cytokines and growth factors leading to the activation of distinct sets of 
genes. Nuclear accumulation of STATs may take hours, however their activity decays with 
time as a result of down-regulation of receptors and a decrease in JAK and STAT 
transcriptional activity. STATs can be re-exported back to the cytoplasm, where they can be 
re-activated for a second round of signalling.  
STATs can also be negatively regulated by phosphatases such as SHP-2 and TC-PTP 
that induce their dephosphorylation, or through nuclear export. The balance between the 
multiple nuclear export sequence (NES) and nuclear localisation sequence (NLS) elements 
are crucial for STATs location and consequently their activity [362]. Another negative 
regulation mechanism arises from SOCS (suppressors of cytokine signalling), which act as 
negative feedback regulators [363]. Although STAT phosphorylation correlates with nuclear 
accumulation, some reports indicate that unphosphorylated STATs can be shuttled from the 
cytoplasm to the nucleus [364]. Indeed, unphosphorylated forms of STAT1 and STAT3 were 
able to induce transcriptional activation of several genes, interestingly these genes differ 
from those activated upon stimulation [365]. Apart from phosphorylation, STATs have also 
been reported to be regulated by methylation and acetylation. STAT1 methylation on Arg13 
increased its transcriptional activity (Mowen et al., 2001), whereas acetylation at Lys410 and 
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Lys413 residues was crucial for NF-KB activation and subsequent increase in cell apoptosis 
[366]. 
 
1.14.2 STAT1: Cancer and Inflammation 
 
Constitutive activation of STAT proteins has been observed in many human cancers. 
While STAT3 role in promoting cellular processes such as proliferation, migration, invasion 
and angiogenesis is associated with tumour growth and metastasis [367, 368], STAT1 role in 
cancer remains unclear as to whether it acts as a pro- or anti-cancer molecule. The vast 
majority of studies on STAT1 in cancer attribute a pro-apoptotic and tumour suppressor role 
to STAT1. This is shown in studies where the STAT1 loss of function and expression in cancer 
cells has been correlated with breast cancer, melanoma, leukaemia and lymphoma [354]. In 
support, mice with a homozygous deletion of STAT1 developed tumours more rapidly than 
the wild type controls [369]. These studies suggest that STAT1 not only acts as a tumour 
suppressor but also the loss of STAT1 signalling can further increase oncogenesis [354, 369].  
With STAT1 being the main if not only mediator of IFN signalling, it has led to the 
hypothesis that STAT1 anti-proliferative effects are partially mediated by the presence of 
IFN-γ. The ability of IFN-γ to modulate tumour cell immunogenicity may lead to tumour 
growth advantages in IFN-/STAT1 deficient cells [370]. Moreover, IFN-γ increases HLA class I 
activity which, in turn, increases tumour recognition by lymphocytes leading to tumour 
growth reduction [371].  
STAT1 knockout mice proved particularly sensitive to viral and microbial pathogens 
and showed reduced responses to IFN [372]. In human patients with a defective STAT1 axis a 
very similar effect was observed as these patients were more susceptible to mycobacterial 
infection [373]. In addition to its role in the response to intracellular bacteria, STAT1 target 
genes have been shown to promote inflammation and inhibit proliferation [362]. 
Despite the predominant inference of STAT1 as an anti-tumorogenic regulator some 
evidence indicates that STAT1 could also play a role in cell survival and/or growth. STAT1 
was found to act as a tumour promoter in leukemia development [374], while in prostate 
cancer cells (DU-145) STAT1 expression was induced upon docetaxel treatment and its 
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expression was higher in docetaxel resistant DU-145 than in wild type cells. Remarkably 
STAT1 knockdown by siRNA re-sensitised DU-145 to docetaxel treatment. The authors did 
not observe any difference in STAT3 levels throughout the treatments [375]. In Wilm’s 
tumour cells (WT), STAT1 phosphorylation on S727 was found in 90% of the analysed 
tumours; an inactivating mutation of S727 proved to reduce colony formation in 80% in WT 
cells and increase apoptosis under stress conditions [376] reinforcing the role of STAT1 as 
pro-survival regulator. Another study indicated that STAT1 was responsible for the activation 
of genes normally activated by STAT3, including Bcl2I1 and Myc in glioma cells.  
 
1.14.3 STAT1 and SPHK1/S1P 
 
To date, very few studies have associated the SPHK1/S1P pathway with STAT1. A 
Weins et al. study indicated that VEGFA secretion from macrophages upon S1P stimulation 
was STAT1 dependent. In addition, a second activation loop induced by VEGFA autocrine 
function induced formation of STAT1/STAT3 heterodimer that bound to the HO-1 promoter 
and consequently induced the expression of proteins such as  Bcl-2, Bcl-X(L) and anti-
inflammatory adenosine receptor A(2A) [377].  
A more recent study correlated the levels of intracellular S1P with the amplification of 
infectious influenza virus. The authors conclude that the over-expression of S1P increases 
susceptibility to influenza virus infection, whereas over-expression of S1P lyase had an 
opposite effect. Also STAT1 phosphorylation increased only in S1P lyase over-expressing cells 
after infection with the virus, whereas blocking of STAT1 elevated the levels of replication of 
the virus within the same cells. This indicates that S1P lyase acts through STAT1 in 
controlling the host defence against influenza virus infection [378]. It is clear that, to date, 
STAT1 and SPHK1/S1P cross-regulation or co-dependency has not been described. 
Nonetheless, SPHK1/S1P regulation of or by STAT1 should not be discarded, indeed SPHK1 
genomic DNA was found to contain several possible binding sites for STAT1. CHIP-Seq 
analysis performed on HeLA-S3 and K562 (leukaemia cell lines) after IFN-y treatment 
indicated that STAT1 binds to SPHK1 DNA in either the coding region or upstream of the 
coding region, possibly in the SPHK1 promoter region indicating that STAT1 can acts a SPHK1 
transcription factor (UCSC Genome Bioinformatics, genome.ucsc.edu).   
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1.15 Hypothesis and aims 
 
Inflammation is a new hallmark of cancer and several types of immune cells interplay 
with cancer cells to exert pro- or anti-tumour effects. Important processes involved in 
cancer-associated inflammation, such as cell proliferation, survival, cytokine and chemokine 
production are also known to be regulated by the SPHK1/S1P pathway. The ability of S1P to 
regulate immune cell trafficking coupled with the role of SPHK1 in the regulation of pro-
inflammatory mediators suggests the potential involvement of these pathways in 
inflammation-related cancer progression. This has significant implications as evidence 
suggests that inflammatory microenvironment is pro-tumorigenic with macrophages and 
monocytes being important contributors to the development and maintenance of a pro-
cancer inflammatory microenvironment. In this work, I hypothesise that a possible 
dysregulation of the SPHK1/S1P pathway may play a role in supporting cancer-related 
inflammatory response. The aims of this project are:  
a) To elucidate whether SPHK1 is a mediator of the interaction of monocytes such as 
human leukemic monocyte, U937 and THP-1 cells with prostate cancer cells (PC-3 
cells) and a regulator in the recruitment of these cells to the tumour site. 
b) To investigate whether the SPHK1/S1P pathway is dysregulated in prostate cancer 
cells and/or monocytes (U937 and THP-1), study the molecular mechanisms by which 
tumour cells benefit from this interaction and identify the soluble mediators 
involved. 
c) To investigate SPHK1/S1P involvement in monocyte-mediated prostate cancer cell 
chemoresistance  
This study will provide a scientific basis for the involvement of the SPHK1/S1P pathway in 
tumour-mediated inflammation and its potential as a target for an anti-cancer therapy. 
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2. Materials and Methods 
 
2.1 Materials 
2.1.1 Mammalian cell culture 
 
Cell Line Cell type Type of tumour Origin Medium and Additives 
PC-3 
[379] 
Prostate Adenocarcinoma Bone 
RPMI 1640, 2mM 
glutamine, 100U/ml 
penicillin, 0.1mg/ml 
streptomycin, 10% 
fetal calf serum (FCS) 
 
DU-145 
[380] 
Prostate Adenocarcinoma Brain 
MDA-MB-
231 
[381] 
Breast Adenocarcinoma Pleural effusion 
BT549 
[382] 
Breast/ 
mammary 
gland 
Ductal Carcinoma Breast 
C4-2 
[383] 
Prostate Adenocarcinoma 
Left 
supraclavicular 
lymph (LnCaP 
derivative cell line) 
THP-1 
[384] 
Monocyte 
Acute monocytic 
leukemia 
Blood 
U937 
[385] 
Monocyte 
histiocytic 
lymphoma 
Pleura/pleural 
effusion 
RAW 264.7 
[386] 
Macrophage 
Abelson murine 
leukemia virus-
induced tumor 
 
PC-3/OFP Prostate  
Empty vector 
phmKO2 
RPMI 1640, 2mM 
glutamine, 100U/ml 
penicillin, 0.1mg/ml 
streptomycin, 10% 
fetal calf serum (FCS), 
1mg/ml G418 
PC-3/OFP-
SPHK1 
Prostate  
Overexpression of 
SPHK1: phmKO2-
SPHK1 
Table 2.1: Cell lines and respective media for mammalian cell culture  
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2.1.2 Antibodies used in Western blotting, ChIP, Immunohistochemistry and Flow 
Cytometry 
 
Protein Species Clone Manufacturer Application Dilution 
ERK1/2 
(phospho) Mouse 9106 Cell signalling Western Blot 1:1000 
ERK1/2 (Total) Rabbit 9102 Cell signalling Western Blot 1:1000 
AKT (phospho) Rabbit 4051 Cell signalling Western Blot 1:1000 
AKT (Total) Rabbit 9272 Cell signalling Western Blot 1:1000 
NF-KB 
(phospho) Rabbit 3031 Cell signalling Western Blot 1:1000 
Tubulin Mouse T9026 Sigma-Aldrich Western Blot 1:5000 
GAPDH Mouse sc-69778 Santa Cruz Biotechnology Western Blot 1:5000 
PARP Rabbit 9532 Cell signalling Western Blot 1:1000 
STAT1 
(phospho) Rabbit 9171 Cell signalling 
Western Blot 1:1000 
ChiP 1:100 
IgG Rabbit sc-2027 Santa Cruz ChiP 1:100 
STAT 1 (Total) Rabbit 610120 BD Bioscience Western Blot 1:1000 
STAT3 
(phospho) Rabbit 9131 Cell signalling Western Blot 1:1000 
STAT 3 (Total) Rabbit c-20 Santa Cruz Western Blot 1:1000 
HLA ABC (Class 
I) Mouse MCA81F Serotec Flow Cytometry 1:20 
Anti-Rabbit Goat 7074 Cell Signalling Western 1:2000 
Anti-mouse Goat 7076 Cell Signalling Western 1:2000 
SPHK1 Mouse/Rabbit AP7237 Cambridge Bioscience 
Immunohistochemistr
y 1:50 
Table 2.2: Antibodies used for Western Blotting, Chromatin Immunoprecipitation, 
Immunohistochemistry and Flow cytometry 
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2.1.3 siRNA oligonucleotides 
 
Target Sequence Sense 5’ to 3’ 
SPHK1 UCACGCUGAUGCUCACUGA 
AKT 
1.CAUCACACCACCUGACCAA          2.ACAAGGACGGGCACAUUAA 
          3.CAAGGGCACUUUCGGCAAG         4.UCACAGCCCUGAAGUACUC 
ERK1 1.AGACUGACCUGUACAAGUU         2.CCAAUAAACGGAUCACAGU 3.CCUGCGACCUUAAGAUUUG         4.GACCGGAUGUUAACCUUUA 
ERK2 1.UCGAGUAGCUAUCAAGAAA         2.CACCAACCAUCGAGCAAAU           3.GGUGUGCUCUGCUUAUGAU        4.ACACCAACCUCUCGUACAU 
Non-targeting UUCUCCGAACGUGUCACGU 
Table 2.3: siRNA oligonucleotide sequences used throughout this study 
 
2.1.4 Primers used in real-time PCR and ChIP 
 
Target Application Forward (5’ to 3’) Reverse (5’ to 3’) Company 
SPHK1 (h) qRT-PCR TATGAATGCCCCTACTTGGTATTG GCCTCGCTAACCATCAATTCC Primer Design 
SPHK1 (m) qRT-PCR TCCAGAAACCCCTGTGTAGC CCGCACGTACGTAGAACAGA Invitrogen 
MCP-1 qRT-PCR ACCGAGAGGCTGAGACTAAC AATGAAGGTGGCTGCTATGAG Primer Design 
IL-6 qRT-PCR AAATTCGGTACATCCTCGACG GTTGTTTTCTGCCAGTGCCTCT Invitrogen 
IRF1 qRT-PCR CTTCGCCGCTAGCTCTACAACAG GCTCCGGGTGGCCTCGGTTCG Invitrogen 
GAPDH qRT-PCR Not disclosed by the company Not disclosed by the company Primer Design 
YWHAZ qRT-PCR Not disclosed by the company Not disclosed by the company Primer Design 
UBC qRT-PCR Not disclosed by the company Not disclosed by the company Primer Design 
SPHK1 (A) ChiP AGGTGCAGGACCCATCATT CTCCGAGAAACAGGAACGAG Invitrogen 
SPHK1 (B) ChiP ACTGGCCTCCAAAGAAGTGA GATTGGAAAGCCAAGCATGT Invitrogen 
SPHK1 (C) ChiP GCGAAGTTGAGCGAAAAGTT CAAGCTCAGCCCACGTCT Invitrogen 
SPHK1 (D) ChiP CACGGGGCTCTGACTCAT CGCCGTGTGACTAAGCCTAC Invitrogen 
SPHK1 (E) ChiP GTCAATTACCGGGGTGTTTC CGCTGAGAAAACAAAACCAA Invitrogen 
Table 2.4: List of primers used in real-time PCR and Chromatin Immunoprecipitation 
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 2.1.5 Recombinant proteins 
 
Name Product Characteristics Concentration Company 
S1P 62570 Stock (2mM): Reconstituted in DMSO 1μM Avanti Polar Lipids 
IL-6 200-06 Stock (100μg/ml): Reconstituted in PBS/0.1%BSA 100ng/ml PeproTech 
MCP-1 279-MC-010 Stock (100μg/ml): Reconstituted in PBS/0.1%BSA 100ng/ml R&D systems 
IFN-γ 300-02 1.0 mg/ml: Reconstituted in water 500 IU/ml PeproTech 
Docetaxel 01885 Stock (20mM): In DMSO solution 5nM or 20nM Sigma-Aldrich 
SKi-II 10009222 
Stock (50mg/ml): In DMSO solution ( 50mg/ml ) in vivo 
Calbiochem 
Stock (20mM): In DMSO solution 10μM 
Table 2.5: Recombinant proteins and drugs used throughout the study  
 
2.1.6 Buffers used in Western blotting 
 
Reagent Components 
TG solution (10x) 288g glycine, 60g Tris dissolved in 2L ddH2O 
1x SDS running buffer 200ml 10xTG, 20ml SDS (20%) dissolved in 2L ddH2O 
1x Transfer buffer 200ml 10xTG, 400ml methanol dissolved in 2L ddH2O 
Phosphate-buffered saline-
Tween 20 (PBS-T wash buffer) 0.05% Tween 20 dissolved in 1xPBS 
Dried skimmed milk powder 
blocking buffer 
5% dried skimmed milk powder dissolved in 
PBS-T wash buffer 
Table 2.6: Western Blotting buffers 
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 2.1.7 Components of SPHK1 buffer 
 
Name For 1 ml buffer take 
SPHK1 buffer 
Component Concentration Final Concentration 
Tris HCl buffer pH 7.4 200µl of 0.1M 20 mM 
Glycerol 200µl neat 20% 
B-mercaptoethanol 1µl of 14.3M 1 mM 
EDTA 100µl of 10mM 1 mM 
PMSF 10µl of 0.1M 1 mM 
NaF 30µl of 0.5M 15 mM 
Leupeptin 10µl of 1mg/ml 10 µg/ml 
Aprotinine 10µl of 1mg/ml 10 µg/ml 
Soybean trypsin 
inhibitor 10ul of  1mg/ml 10 ug/ml 
4-Deoxypyridoxine 10 µl of 50mM 0.5mM 
B-glycerophosphate 20µl of 2M 40 mM 
Sodium orthovanadate 10µl of 0.1M 1 mM 
H2O distilled 483µl  
Table 2.7: SPHK1 buffer components 
 
2.1.8 SPHK1 Activity Assay 
 
Name Components Company 
SPHK1 buffer Up to 170 µl/reaction  
Sphingosine 10 µl 1 mM sphingosine/assay Sigma-Aldrich 
MgCl2 2μl  of20mM Sigma-Aldrich 
ATP 0.2µl of 10mM/sample Sigma-Aldrich 
(γ-32P)- ATP 1ul ATP-32P (10uCi/sample) Perkin-Elmer 
SPHK1 washing 
solution 
per reaction: 200μl ddH2O, 20μl HCl 1M, 240μl KCl 2N, 506μl 
chloroform, 533μl methanol Sigma-Aldrich 
Stop solution per reaction: 50μl 1M HCl, 800μl Chloroform/Methanol/HCl, 240μl CHCl3 and 240μl 2M KCl Sigma-Aldrich 
Dissolving 
Solution per sample: 40 μl Chloroform/Methanol (2:1, v/v) Sigma-Aldrich 
Migratory 
Solution 
200-300ml 1-butanol/ethanol/acetic acid/water (80:20:10:20, 
v/v) Sigma-Aldrich 
Table 2.8: Reagents used in SPHK1 activity assay 
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2.2 Methods 
 
2.2.1 Mammalian cell culture 
 
Cells were cultured and maintained in RPMI 1640 containing 10% FBS as well as 
50U/ml Penicillin, 50μg/ml Streptomycin and 2mM glutamine at 37°C in a humidified 
atmosphere of 5% CO2. Adherent cell lines were passaged twice a week or upon reaching 80-
90% confluency. The passage consisted of removal of spent media followed by incubation 
with trypsin [2.5 mg/ml trypsin in 0.02% (w/v) EDTA/0.09% (w/v) NaCl] at 37°C until cells 
detached from the culture plate. The cells were then plated into a new culture dish, at the 
ratio of 1:10. Suspension cells (U937, THP-1 and RAW264.7) were passaged 2-3 times per 
week depending upon cell confluency. The passage consisted of removing 2ml of media 
(containing suspended cells) into a new culture dish with 18ml of fresh complete media. PC-
3 cells transfected with phmKO2 or phmKO2-SPHK1 vector were cultured in complete media 
with the addition of G418 to ensure selection of transfected cells only.  The cells lines used in 
this study were routinely tested for mycoplasma levels. PC-3 cells were authenticated for 
genotype phenotype.  
 
2.2.2 Freezing and thawing of mammalian cells 
 
A minimum of 1x106 cells per vial were resuspended in RPMI media with 10% FCS 
(v/v) and 2mM L-glutamine, containing 10% DMSO. Cells were frozen to -80˚C in an 
isopropanol freezing chamber for at least 24 hours. The following day vials were transferred 
to liquid nitrogen. To thaw cells, frozen vials were placed on dry ice for 15 minutes and then 
transferred directly into a 37˚C water bath. After complete thawing, cells were transferred to 
a 25 ml cell culture flask containing complete RPMI medium and left incubating overnight at 
37˚C in a humidified atmosphere containing 5% CO2. The following day, media was removed 
in order to remove the DMSO and new media was added until the next passage.  
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2.2.3 Transwell Assay 
PC-3 cells were seeded into the bottom chamber of the transwell at 1x105 cells per 
well in 2ml of complete medium, as shown in the figure below (Fig.2.1). 
 
Figure 2.1 Schematic representation of the transwell model used during this study. 
After 24 hours, cells were carefully washed twice with PBS before adding 1.5ml of 
serum-free medium for a further Ϯϰ ŚŽƵƌƐ Ăƚ ϯϳ϶ ĂŶĚ ϱй K2. Transwells (VWR, cat# 
353493) were placed into each well of the 6-well plates for 20 minutes before the addition 
of U937 to the upper chamber at 1x106 cells into 1ml of serum-free medium. At each of the 
indicated time points, U937 cells were removed from the upper chamber together with the 
media. Media and cells were then centrifuged at 2500rpm for 5 minutes Ăƚϰ϶͕ƐƵƉĞƌŶĂƚĂŶƚ
was collected and transferred to a different micro-centrifuge tube and frozen at -ϮϬ϶͘hϵϯϳ
cell pellets were re-suspended in PBS to remove any traces of media and centrifuged as 
described previously. Cell pellets were then frozen at -ϮϬ϶͘hϵϯϳĐĞůůƐƚŚĂƚǁĞƌĞĂĚŚĞƌĞŶƚ
to the transwell were washed with PBS and lysed with specific lysis buffer according to the 
future assay. Simultaneously, media from the bottom chamber was collected into 2ml micro-
centrifuge tubes followed by centrifugation and collection of the media into a new tube. PC-
3 cells were washed with PBS directly in the plates, and a specific lysis buffer was added to 
the cells. Lysed cells were scraped from the 6-wells, transferred to a micro-centrifuge tube 
and frozen at -20϶C. 
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2.2.4 Sulphorhodamine B (SRB) Assay 
 
Cells were placed into a 24-well plate in complete media at 40% confluency. 24 hours 
later, cells were washed with PBS, and serum-free medium was added for another 24 hours 
before the addition of 2x105 U937 cells to the top chamber of the transwell. After 24, 48 and 
72 hours of co-culture, 500μl of 40% (v/v) trichloroacetic acid (TCA) was added to the 
bottom of each well after removing the upper chamber. TCA was added and incubated at 
4⁰C for one hour to fix the cells. Plates were then gently washed with water and air-dried 
overnight. 300μl of 0.4% (w/v) SRB in 1% acetic acid was added to each well and plates were 
incubated for one hour at room temperature. Plates were then washed four times in 1% 
acetic acid and left to air-dry overnight. 300μl of 10mM Tris-HCl pH8.0 was then added to 
each well and plates were incubated for one hour at room temperature with shaking. 100μl 
of dissolved SRB solution from each well of the 24-well plate was then added in duplicate to 
wells of a 96-well plate and absorbance was read at 492nm. 
  
2.2.5 RNA interference 
 
RNA interference (RNAi) was performed using short-interfering (si) RNA 
oligonucleotides. Cells were transfected with siRNA (5nM or 20nM) using OligofectamineTM 
reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. Briefly, cells 
were plated into 6-well plates 24 hours prior to the transfection. The specific target was 
down-regulated using 200pmol siRNA combined with 8µl Oligofectamine in Opti-MEM 
(Invitrogen). Cells with oligo-lipid complexes were incubated at 37⁰C in 5% CO2 atmosphere 
for four hours and subsequently RPMI 1640 media containing 30% FCS was added. All 
experiments included cells transfected with a non-targeting siRNA (siNT) as a control. 
Protein and mRNA knockdown were assessed 48 or 72 hours post-transfection using western 
blotting and/or quantitative real-time PCR. 
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2.2.6 In vivo PC-3 xenograft tumour establishment 
 
Human prostate cancer xenografts were established in nude mice by subcutaneous 
injection of 30μl 1:1 mixture of 10^6 PC-3 cells with Matrigel (BD Bioscience Cat# 354248) in 
both flanks of the mouse (Male BALBc/nude 7 week old mice). Tumours were left to 
establish for 11 days until visible. At this point mice were divided into two groups of five, and 
treated with either SKi-II (50mg/ml) or DMSO. SKi-II and DMSO were equally diluted in PBS 
before each injection. Mice were injected every two/three days with the final treatment one 
day before sacrifice (day20). In total mice were treated five times in a space of nine days. 
Tumours were measured using calipers and tumour volume was calculated by the following 
formula: (length x length)*width/2= mm3. Relative tumour volume was calculated by 
normalising with the first day of treatment (day 0). The statistical significance of differences 
between the means of two groups was evaluated by unpaired Student’s t test.  
 
2.2.7 Immunohistochemistry 
 
Sections of 4 µm thickness from paraffin-embedded PC-3 xenograft tumours and 
spleen were dewaxed by immersing sections in xylene for 5 minutes in a total of 3 times. 
Then sections were rehydrated by washing in 100%, 90%, 70% and 50% ethanol for 5 
minutes for a total of two washes per condition. Sections were then incubated with 0.3% 
hydrogen peroxide for 30 minutes to block endogenous peroxidase activity. After washing 
twice with PBS, antigen retrieval was performed by adding the sections to pre-warmed 0.01 
M citrate buffer (pH 6.0) and microwaving for 20 minutes at 750W. Slides were left to cool to 
room temperature and washed three times with PBS for a period of 5 minutes each. Sections 
were then blocked to reduce primary antibody background in 10% goat serum (DaKO,cat# 
E0466) for one hour at room temperature. Next, slides were incubated with the primary 
antibody SPHK1 (1:100 in goat serum) overnight at 4⁰C. After washing with PBS, the sections 
were incubated with goat anti-rabbit immunoglobulin (1:200), for 45 minutes. Slides were 
washed three times for 5 minutes, followed by peroxidase conjugated with streptavidin 
(1:100) for 30 minutes. After washing with PBS, sections were developed with activated 3,3-
diaminobenzidine-tetrahydrochloride solution (Sigma-Aldrich, Dorset, UK) and 0.1% 
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H2O2 until brown, and counterstained with Cole’s hematoxylin (Vector Laboratories, 
Burlingame, CA, USA) for one minute. Sections were then dehydrated, mounted on glass 
microscopy slides using Pertex mountant (CellPath, Hemel Hempstead, UK) and processed by 
microscopy. Sections were scored blindly by a qualified histopathologist. 
 
2.2.8 Sphingosine kinase-1 Assay 
 
PC-3 and U937 cell pellets were resuspended in SPHK1 buffer, sonicated for 3-5 
seconds and centrifuged at 20000xg for 30 minutes at 4°C. The protein concentration of the 
supernatant was measured by Bradford protein assay (Bio-Rad Laboratories, Hercules, CA, 
USA) according to the manufacturer’s instructions. The enzymatic assay was performed with 
50-100 µg protein. The remaining components of this reaction were prepared as followed; 
10 µl of 50 mM sphingosine (Avanti Polar Lipids) in ethanol was transferred into a new 2 ml 
safe-lock tube, before being evaporated in a heat block at 40oC for 5-10 minutes. 
Sphingosine was resuspended in 500µl 0.25% triton and sonicated for 15 minutes in a water 
bath. As a standard, two 2ml micro-centrifuge tubes containing 10µl of 50 µM sphingosine in 
ethanol were dried, resuspended and sonicated as described above. The volume of triton 
added to resuspend sphingosine was 10 µl. To each of the standards 1 or 2µl of SPHK1 was 
added before sonication. For each reaction, 2µl of 20mM MgCl2, 0.2µl of 10mM ATP, 6.8µl of 
H2O were mixed with 180µl of total protein or SPHK1 buffer for the standards. 10µl of 50 
mM sphingosine (resuspended in triton) were added to each mixture before the addition of 
1µl 10 µCi [γ-32P]-ATP (Perkin-Elmer, Waltham, MA). The mixture was incubated between 45 
minutes and 1 hour at 37 °C in a 5% CO2. To stop the reaction, solutions were added in the 
following order; 50µl 1M HCl, 800µl Chloroform/Methanol/HCl mix, 240µl CHCl3 and 240µl 
KCL 2M, before being vortexed and centrifuged for 10 minutes at 2500rpm. The lower 
(organic) phase was transferred into a new 2ml micro-centrifuge tube with 800µl of SPHK 
washing solution. Samples were centrifuged as described previously and the lower phase 
was again transferred into a new 1.5ml micro-centrifuge tube and left to vaporise overnight. 
The samples were solubilized in 40µl Chloroform/Methanol (2:1 v/v) and added to a thin 
layer chromatography on silica gel G60 plate (Whatman, GE Healthcare, Waukesha, WI, 
USA). The plate was placed into a closed container with 200-300ml of 1-
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butanol/ethanol/acetic acid/water (80:20:10:20 v/v) and left to migrate for a minimum of 4 
hours. Plates were left to dry for another 30 minutes under the fume hood before being 
visualised by autoradiography. The radioactive spots were quantified using standards and 
ImageJ software. Sphingosine kinase specific activity was expressed as pmol of sphingosine-
1-phosphate formed per minute per mg protein (pmol/min/mg). The values displayed in the 
results chapter are shown as percentage relative to the control or untreated sample.   
 
2.2.9 RNA preparation 
 
To avoid RNA degradation, all used equipment was cleaned with RNaseZap® (Ambion, 
Applied Biosystems, Foster City, CA, USA). Total RNA was isolated using the RNeasy® Mini kit 
from Qiagen according to the manufacturer’s instructions. Briefly, cells were washed once 
with PBS and collected using 350µl or 700µl of RLT buffer depending on cell number. 70% 
ethanol was added in an equal volume to RLT buffer before being transferred to an RNeasy 
column. RNA bound to the column was washed with RW1 (750 µl) and twice with RPE (500 
µl). RNA was eluted with 40-60µl of RNAse free water and stored at -80°C. RNA 
concentration was determined using the NanoDrop (ND-100-Spectrophotometer, NanoDrop 
Technologies). For the subsequent real-time PCR, a high quality of RNA was required. All 
used RNAs had high purity, meaning an OD260/OD280 ratio of 2, and a low salt concentration, 
meaning an OD230/OD260 ratio of at least 1.6 when to be used for cDNA synthesis and real-
time PCR. 
 
2.2.10 cDNA synthesis 
  
The reverse transcription was performed according primer design protocol (Precision 
nanoScript TM Reverse Transcription kit, cat#RT-nanoScript). Briefly, 0.5-1μg of total RNA 
was mixed with 1μl of random hexamers and up to 14μl of sterile water. This reaction mix 
was incubated at 65°C for 10 minutes and placed on ice for 5 minutes. Then, 2μl of 10mM 
deoxynucleotide-triphosphate (dNTPs), 2μl of 100nM Dithiothreitol (DTT), 2μl of 10x 
nanoscript Buffer and 1μl reverse transcriptase were added to the mix and cDNA synthesis 
was carried out at 55°C for 20 minutes, followed by 15 minutes at 75°C to inactivate the 
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reverse transcriptase enzyme. The cDNA was stored at -20°C. ABI Thermal Cycler (Applied 
Biosystems) was used for all incubation steps. 
 
2.2.11 Quantitative real time PCR (qPCR) 
 
Quantitative PCR was performed using SYBR Green master mix (asymmetrical cyanine 
dye) containing ROX as a reference dye (primer design). 10µl of SYBG was added to 1µl of 
primer mix (containing forward and reverse primers), 4µl of nuclease free-water and 5µl of 
cDNA (5ng/µl) of each sample. Primers were designed and optimised by Primer Design for a 
product length of approximately 100bp. Each sample was analysed in triplicate. After adding 
the samples and the mix, the Fast Optical 96-well reaction plate was sealed with an Optical 
Adhesive Cover and centrifuged for 2 minutes at 3000xg. The quantitative PCR was 
performed using an ABI PRISM 7900 sequence detection system (Applied Biosystems). 
Thermal cycling conditions were as follows: 10 minutes at 95°C, 40 cycles of 15 seconds at 
95°C and 60 seconds at 60°C followed by the dissociation step: 15 seconds at 95°C, 15 
seconds at 60°C and 15 seconds at 95°C. Data was analyzed using the ΔΔCT method and the 
expression of target genes such as SPHK1 TATGAATGCCCCTACTTGGTATTG (FWD) and 
GCCTCGCTAACCATCAATTCC (REV) was normalised to the expression of three housekeeping 
genes. The house keeping genes that were used are GAPDH (Glyceraldehyde-3-phosphate 
dehydrogenase), YWAZH (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein) and UBC (Ubiquitin C).  
 
2.2.12 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 
western blotting  
 
Cell lysates in 1x SDS-loading dye were boiled at 95⁰C for 5 minutes before being 
loaded onto an acrylamide gel. Proteins were separated using a 5% acrylamide stacking gel 
[5% (v/v) acrylamide, 0.125 M Tris, pH 6.8, 0.1% (w/v) SDS, 0.075% (w/v) APS and 0.083% 
(v/v) TEMED], and a 7.5 or 12.5% acrylamide resolving gel [7.5-12.5% (v/v) acrylamide, 0.375 
M Tris pH 8.8, 0.1% (w/v) SDS, 0.06% (w/v) APS, 0.07% (v/v) TEMED] depending on the size 
of proteins being analysed. Gels were run using 1x SDS running buffer at 120 V until the dye 
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reached the bottom of the gel. Separated proteins were transferred onto PVDF membrane 
(Millipore, Billerica, MA, USA) in 1x transfer buffer (table 2.1.6) at 100V for 1 hour using tank 
blotting system (Bio-Rad) in wet transfer conditions. In order to prevent non-specific binding 
of antibody, PVDF membranes were incubated with 5% non-fat dried milk powder in 0.05% 
Tween-20 in 1xPBS (PBST)) with gentle shaking for one to two hours at room temperature. 
Membranes were then washed with PBST for 2-3 times for 10 minutes before being 
incubated with a primary antibody. Primary antibodies were diluted in 5% (w/v) BSA/PBST 
containing sodium azide and incubated overnight at 4 ˚C with gentle shaking. Membranes 
were then washed three times for 10 minutes in PBS-T. Secondary antibodies conjugated to 
horseradish peroxidase (HRP) against mouse or rabbit IgG (DAKO, Glostrup, Denmark) were 
diluted in 5% (w/v) milk/ PBS-T and incubated for 1 to 2 hours at room temperature. 
Membranes were washed again 3-4 times for 5 minutes with agitation before being exposed 
to ECL reagents (Millipore, Watford, UK) and exposed to Kodak GRI autoradiography film. 
Band intensities were measured and quantified by ImageJ. 
 
2.2.13 ELISA-Enzyme-linked immunosorbent assay 
 
ELISA kits for MCP-1, IL-6, TNF-α and IL-10 were purchased from R&D Systems (Duo 
set). Capture antibodies were diluted in PBS according to the manufacturer’s instructions 
and 100μl was added to each well (96-well plate) and left incubating overnight, at room 
temperature. Plates were then carefully washed three times with 0.05% PBS tween (PBS-T) 
and 300μl of 1% BSA was added to each well for a minimum of 1 hour. Plates were then 
washed at least 3 times with PBS-T before 100μl of media from each sample was added in 
duplicate and left incubating overnight at 4⁰C. Simultaneously, recombinant protein 
corresponding to the specific target was diluted according to manufacturer’s protocol and 
added into separate wells in order to obtain a standard curve (R&D DuoSet). Plates were 
then washed with PBS-T for at least 3 times before the addition of 100μl of the detection 
antibody (concentrations used according to the manufacturer’s protocol) for two hours at 
room temperature. After washing with PBS-T, 100μl of diluted Streptavidin-HRP was added 
to each well and incubated for 20 minutes in the dark. This was followed by a washing step 
with PBS-T and the addition of 100μl of substrate solution (R&D Systems # DY999) for 20 
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minutes in the dark. The reaction was stopped by the addition of 50μl of 2N H2SO4 (R&D 
Systems # DY994) when samples were turning blue. The optical density of each well was 
measured using a microplate reader (Tecan Sunrise) set at 450nm with wavelength 
correction at 540nm.  
 
2.2.14 Human cytokine profile array A 
 
Proteome Profiler Array, Human Cytokine Array Panel A was obtained from R&D 
Systems (ARY005). This array consisted of 36 different molecules (i.e. cytokines, chemokines, 
growth factors) spotted in duplicate onto four membranes. Experiments were performed as 
recommended by the manufacturer’s instructions. Briefly, membranes were incubated with 
2ml of buffer 4 for one hour on a rocking platform. 1.5ml media of each sample was 
incubated with 15μl of Detection Antibody cocktail and left incubating for one hour at room 
temperature. This solution was then added to the membrane upon the removal of the 
blocking buffer and left incubating overnight at 4⁰C on a rocking platform. Membranes were 
then washed in 20ml of washing buffer before the addition of 1.5ml of diluted Streptavidin-
HRP (buffer 5) for 30 minutes at room temperature on a rocking platform. Washing was 
performed on each membrane and Chemiluminescent HRP Substrate (Millipore) was added 
for 1-5 minutes. X-ray film was used to visualise the positive signals. Intensity of each signal 
was measured using ImageJ software.   
 
2.2.15 Sphingosine kinase inhibitor treatment 
 
SKi-II was resuspended in DMSO to a stock concentration of 20mM, aliquoted and 
stored at -20°C. U937 cells (1x106 per well) were incubated with 10nM of SKi-II for up to 24 
or 48 hours at 37°C and 5% CO2 to test SPHK1 inhibition. In a co-culture system, cells were 
treated with SKi-II for 24 hours at a final concentration of 10nM. Cells were washed to 
remove any traces of SKi-II to avoid leaking into PC-3 cells.  
 
 
85
2.2.16 Chromatin Immunoprecipitation (ChIP) 
 
 PC-3 cells were seeded in 6-well plates at a density of 0.5x106 cells and allowed to 
adhere overnight. A total of four 6-well plates was used for this assay. U937 cells were added 
to the top chamber of the transwell for two hours to two of the 6-well plates. Cross-linking 
of proteins to DNA was performed by adding, drop-wise directly to the PC-3 cells, 40µl of 
37% (w/v) formaldehyde per 1ml of medium for 10 minutes at RT. 50µl of 2.5M glycine/1ml 
of medium was added for 5 minutes at RT in order to stop the cross-linking reaction. Cells 
were then washed twice with ice-cold PBS and IP buffer containing protease inhibitors 
(Roche, Diagnostic Ltd, West Sussex, UK) was added to the cells before being scraped and 
collected into 50 ml tube on ice. After centrifugation at 12,000g for 1 minute, the resulted 
nuclear cell pellet was sonicated three times for 10 minutes in 1ml of IP buffer containing 
inhibitors. Fractions were centrifuged at 12,000g for 10 minutes at 4⁰C and supernatant was 
divided into 1/10 (imput) and the remaining equally divided before the addition of STAT1, 
histone and IgG antibodies overnight at 4⁰C. The following day, samples were centrifuged at 
12,000g for 10 minutes and supernatant was incubated with protein G - Dynabeads (30µl per 
IP sample) three times with IP buffer protein G – Dynabeads were blocked overnight with 
sheared salmon sperm DNA and BSA (30µl/sample). The beads were eluted with IP buffer 
and incubated at 4˚C for at least 45 minutes on a rotating platform (20-30 rotations per min). 
Beads were washed 3-4 times with IP buffer without the inhibitors. Chelex was added to the 
washed beads, followed by vortexing, and boiled for 10 minutes. Tubes were centrifuged at 
12,000xg for 1 minute at 4˚C. 80µl of the supernatant was collected. The DNA in the imput 
was precipitated with 2.5-3 volumes of ethanol and incubated overnight at 4⁰C. After 
centrifugation (14,000xg for 30 minutes at 4⁰C) the supernatant was discarded and pellet 
left to dry. Pellets were dissolved in 100ml 10% (w/v) Chelex 100 suspension, and boiled for 
10 minutes. The same procedure was performed for the imput as to IP samples. STAT1 
binding site to SPHK1 DNA were assessed by qRT-PCR using primers described in table 
(2.1.4). Each sample was normalised to imput and results are shown in percentage of 
STAT1/imput.  
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2.2.17 Flow cytometry 
 
HLA Class I expression was assessed by flow cytometry as a read-out for how MCP-1, 
IL-6 and IFN-γ treatment would affect STAT1 activated molecules. PC-3 cells were treated 
with MCP-1 (100ng/μl), IL-6 (100ng/μl) and IFN—γ (500IU) for 24 and 48 hours. Cells were 
then washed, resuspended with ice-cold PBS and incubated with or a FITC-conjugated anti-
HLA-Class I-A,-B, -C antibody for 45 minutes at 4 °C in the dark. After three washes with ice-
cold PBS, cells were finally fixed in 1% (v/v) PFA in PBS and analysed on a flow cytometer 
FACSCanto (Becton, Dickinson and Company, Erembodegem Belgium). 
 
 
2.2.18 SPHK1 plasmid construct (phmKO2_ MNLinker) 
 
2.2.18.1 Restriction and ligation 
 
In order to obtain a fluorescent tagged SPHK1 protein, SPHK1 cDNA was digested 
from pcDNA-3.1 vector and cloned into phmKO2-MNLinker vector (cat#AM-V0140) that 
encodes a monomeric version of the fluorescent protein CoralHue. Briefly, pcDNA3.1 vector 
was digested with BamHI and NotI respectively according to manufacturer's instructions 
(NEB). SPHK1 cDNA was subsequently purified using QIAquick Gel Extraction Kit (Qiagen) 
according to manufacturer's instructions. SPHK1 was then inserted into phmKO2-MNLinker 
previously digested with both BamHI and NotI. Ligation was performed using 100ng of 
digested vector with a 3-fold molar excess of insert and Quick Ligation Kit (NEB) according to 
the manufacturer's instructions. Vector and insert were incubated with 1μl T4 ligase for 15 
minutes at room temperature. 
 
2.2.18.2 Transformation 
 
Plasmid was heat shock transformed into One Shot TOP10 competent cells 
(Invitrogen, CA, USA) according to the manufacturer's instructions. 2μl ligation mix plasmid 
and 50μl competent cells were incubated for 30 minutes on ice, 30 seconds at 42°C and 
again placed on ice. Pre-warmed S.O.C. medium (Invitrogen) was added and cells were 
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incubated for 1 hour at 37°C and 225rpm. The cell suspension was spread on LB agar plates 
supplemented with 50μg/ml Kanamycin. Positive clones were amplified and purified using 
QIAPrep Spin Miniprep kit (Qiagen, Hilden, Germany). The successful ligation of vector was 
verified by digestion with BamHI and NotI and visualised on agarose gel. 
 
 
2.2.18.3 Plasmid DNA purification 
 
Positive clones were sequenced and the verified plasmid was amplified. Large scale 
plasmid DNA purification was performed using the Plasmid Maxi Kit (Qiagen) according to 
manufacturer's instructions. Briefly, 400ml transformed E.coli culture having been incubated 
for 15 hours at 37°C and 200rpm were pelleted, lysed and applied to a column. Plasmid DNA 
was resuspended in water and DNA concentration was quantified. The concentration was 
measured at 260 and 280nm absorbance using the NanoDrop (Fisher Scientific). Samples 
with the OD260=280 ratio above 1.8 were used. 
 
2.2.19 Data representation and Statistical Analysis 
 
The statistical significance of differences between the means of two groups was 
evaluated by unpaired Student's t test. All statistical tests were two-sided. Calculations were 
performed using Instat (GraphPad Software). 
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3. Monocyte effect on prostate and breast cancer cell proliferation 
3.1 Introduction 
 
Immune cells such as monocytes and macrophages have the capability to migrate to 
various parts of the body in response to specific stimuli. Histological data collected by 
several groups shows a strong infiltration of myeloid cells in malignant tumours which is 
associated with a poor clinical prognosis [227, 233, 239, 387]. In chronic inflammatory 
diseases, such as chronic inflammation or Crohn’s disease, these cells are highly present and 
a correlation of these inflammatory diseases with cancer initiation and progression has been 
previously described. Conversely, the use of anti-inflammatory drugs has led to a reduction 
of cancer risk [226, 388]. Therefore, strong evidence exists to suggest that immune cells play 
an active role in tumour progression and promote tumour survival [389]. Within the tumour 
surroundings, the presence and recruitment of such cells creates a highly diverse 
microenvironment rich in cytokines and chemokines. These soluble factors act in a paracrine 
manner with positive effects on cancer progression and development [228, 390].  
Genes that are involved in the regulation of these soluble factors are often candidates 
for the development of anticancer drugs. SPHK1 is one such gene that has been shown to be 
up-regulated in several types of cancer [391], [199, 204] and to be involved in cytokine 
regulation [270], [268]. This has led to the hypothesis that SPHK1 plays a role in 
inflammatory-mediated cell interactions; in this study I investigate whether SPHK1 is a key 
mediator of the interaction of monocytes/macrophage with cancer cells and a key regulator 
in the recruitment of these cells to the tumour site.  
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3.2 Co-culture with monocytes has differential effects on prostate cancer cell lines 
 
To elucidate the role of SPHK1 in the interactions between prostate cancer cells and 
macrophages/monocytes during inflammation-related cancer progression, a prostate cancer 
cell line (PC-3) was co-cultured with a monocytic cell line (U937) in a transwell system. PC-3 
cells were selected as a PCa cell line due to its highly metastatic phenotype and its androgen 
independency. This cell line  is well characterised and has been widely used in several studies 
involving PCa [344]. U937 cells are also well characterised as a monocytic cell line and have 
been widely used in studies investigating the role of monocytes in cancer development [246, 
247]. Similarly, THP-1 cells are another well characterised monocytic cell line widely used to 
evaluate the role of monocytes in several diseases including cancer [384, 392]. 
 The transwell membrane pore size selected was 0.45 μm diameter so that only soluble 
molecules could be exchanged between the two cell types. For this purpose PC-3 cells were 
cultured in 6 well-plates for 24 hours before the addition of U937 cells to the upper 
chamber. In full media conditions PC-3 showed a mild increase in proliferation throughout 
the indicated time points which did not prove to be statistically significant (Fig.3.1a). Under 
starvation conditions (serum-free medium) PC-3 cells also showed an increase in cell 
proliferation when in co-culture with U937 cells. This effect was observed in a time-
dependent manner, with a positive impact after 24 hours proving statistically significant 
from 48 hours onwards (Fig 3.1b).  
To investigate the impact of SPHK1 signalling on PC-3 interactions with U937 cells, PC-3 
cells were transfected with siRNA targeting SPHK1 for 48 hours prior to the addition of U937 
cells. As expected, PC-3 cells transfected with siRNA for SPHK1 exhibited less cell 
proliferation in comparison with PC-3 cells transfected with the non-targeting siRNA 
(Fig.3.1c). As seen previously, PC-3 cells proliferated significantly more in the presence of 
U937 cells; interestingly SPHK1 knockdown in PC-3 cells completely abolished the effect of 
U937 cells on PC-3 cell proliferation. This effect was significant from 72 hours onwards, 
indicating a role for SPHK1 in communication between the cell types, likely in the regulation 
of the secretion of certain factors. 
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a) 
c) 
Figure 3.1: PC-3 cell proliferation in co-culture with U937 cells. PC-3 cells were cultured in a) 
full media or b) serum-free media for 24 hours before the addition of U937 cells which were 
added to the upper chamber and left incubating for up to 96 hours. c) PC-3 cells were 
transfected with siRNA targeting SPHK1 (siSPHK1) or non-targeting control siRNA  (siNT) for 
24hours before cells were washed with PBS and cultured in serum-free media for another 24 
hours. U937 cells were then added to the upper chamber and left incubating for the indicated 
duration. SRB solution was added to the bottom chamber to determine PC-3 cell proliferation. 
Data shown is the mean  SEM of triplicate measurements for each sample and is 
representative of three independent experiments. Statistical analysis was performed using 
student’s t-test relative to each individual time point. a-b) ns p>0.05, *p<0.05, **p<0.01, for 
PC-3 vs. PC-3+U937; c) *p<0.05, **p<0.01,for siNT vs. siNT+U937; §§p<0.01, §§§p<0.001 for 
siNT+U937 vs. siSPHK1+U937.  
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Following the previous assay, it was important to evaluate the effect of U937 cells on 
other prostate cancer cell lines. For this purpose DU-145 (Fig.3.2a) and c4-2 (Fig.3.2b) cells 
were co-cultured in the presence or absence of U937 cells for up to 72 hours. DU-145 
showed a decrease in their proliferation when in the presence of U937 cells, an effect that 
was constant across all time points studied (Fig.3.2a). Similarly for c4-2 cell proliferation, the 
addition of U937 cells also proved to have an inhibitory effect on these prostate cancer cells, 
from 24 hours of co-culture there was a small decrease in c4-2 proliferation when in 
comparison with these cells cultured alone (Fig.3.2b).  
 
3.3 Co-culture with monocytes has differential effects on breast cancer cell lines 
 
To clarify whether the increase in cell proliferation was a universal event or a cell-tumour 
specific occurrence, BT549 and MDA-231 breast cancer cell lines were co-cultured with U937 
cells.  The metastatic characteristic of these cells and their triple negative genotype were taken into 
consideration to this study as they represent a proximal model to PC-3 cells which are androgen 
independent and highly metastatic prostate cancer cells. 
 BT549 cells showed an increase in cell proliferation upon the addition of U937 cells, 
which was significant following 48 and 72 hours of co-culture (Fig.3.3a). Regarding MDA-231 
cells, an increase in cell proliferation was also observed in the presence of U937 cells from 
24 hours onwards; however although reproducible, this effect did not prove statistically 
significant (Fig.3.3b). 
 
3.4 Effects of other monocytes or macrophages on PC-3 cells proliferation   
 
To understand whether the U937-induced increase in PC-3 cell proliferation was 
monocyte-type specific, THP-1 cells were used as an alternative monocytic cell line for use in 
the co-culture model. THP-1 cells are a well characterised monocytic cell line as often used in 
to characterise the function and regulation of monocytes [392].  
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In full media conditions PC-3 cell proliferation was not affected by the presence of THP-1 
cells (Fig.3.4a). Under starvation conditions, THP-1 cells increased PC-3 cell proliferation 
from 24 hours of co-culture onwards; however this increase did not prove statistically 
significant (Fig.3.4b). Similarly to that observed for U937 cells, this effect was not apparent 
when SPHK1 was targeted by siRNA in PC-3 cells as SPHK1 knockdown reduced cell 
proliferation and abolished the mild proliferative effects of THP-1 cells.  (Fig.3.4c).  
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Figure 3.2: Prostate cancer cell proliferation in co-culture with U937 cells. a) DU-145 and b) 
C4-2 cells were cultured in serum-free media for 24 hours prior to the addition of U937 cells. 
U937 cells were added to the upper chamber and left incubating for up to 72 hours. SRB 
solution was added to the bottom chamber to determine PC-3 cell proliferation. Data shown is 
the mean  SEM of  three independent experiments performed in duplicate. Statistical analysis 
was performed using student’s t-test relative to each individual time point. a-b) ns p>0.05 for 
DU-145 vs. DU-145+U937 or c) C4-2 vs. C4-2+U937. 
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Figure 3.3: Breast cancer cells proliferation in co-culture with U937 cells. a) BT549 and b) 
MDA-231 cells were cultured in serum-free media for 24 hours prior to the addition of U937 
cells. U937 cells were added to the upper chamber and left incubating for up to 72 hours. SRB 
solution was added to the bottom chamber to determined BT549 or MDA-231 cell 
proliferation. Data shown is the mean  SEM of  three independent experiments performed in 
duplicate. Statistical analysis was performed using student’s t-test relative to each individual 
time point; ns p>0.05, *p<0.05, for BT549 vs. BT549+U937 or MDA-231 vs. MDA-231+U937. 
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Figure 3.4: PC-3 cell proliferation in co-culture with THP-1 cells. PC-3 cells were cultured in a) 
full media or b) serum-free media for 24 hours before the addition of THP-1 cells. THP-1 cells 
were added to the upper chamber and left incubating for up to 72 hours. c) PC-3 cells were 
transfected with siRNA targeting SPHK1 (siSPHK1) or non-targeting control siRNA  (siNT) for 
24hours before cells were washed with PBS and cultured in serum-free media for another 24 
hours. U937 cells were then added to the upper chamber and left incubating for the indicated 
duration. SRB solution was added to the bottom chamber to determine PC-3 cell proliferation. 
Data shown is the mean  SEM of three independent experiments performed in triplicate. 
Statistical analysis was performed using student’s t-test relative to each individual time point; a-
b) ns p<0.05 for PC-3 vs PC-3 + THP-1; c) §§§p<0.001 for siNT+THP-1 vs. siSPHK1+THP-1. 
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Next, it was important to evaluate the effect of macrophages upon PC-3 cell 
proliferation. The use of a macrophage cell line (RAW 264.7) had no positive effect on PC-3 
cell proliferation, in fact from 48 hours onwards there was a non-significant decrease in 
proliferation in either full media conditions (Fig.3.5a) or under starvation (Fig.3.5b). With the 
same purpose of testing macrophage cells in co-culture, THP-1 cells were differentiated into 
a macrophage-like cell type with PMA for 24 hours, after which non-adherent cells were 
removed and differentiated adherent THP-1 cells were added to the PC-3 cells. A modest, 
albeit transient, positive effect on PC-3 cell proliferation was observed after 24 hours which 
was followed by a reduction at 72 hours (Fig.3.5c).   
 
3.5 Effect of increasing SPHK1 in PC-3 cell proliferation during co-culture 
 
cDNA encoding human SPHK1 was cloned into the phmKO2-MNLinker expression vector 
as described in section (section 2.2.3), with SPHK1-mKO2 constitutively expressed in PC-3 
cells, as verified by fluorescent microscopy (Fig.3.6a). SPHK1 mRNA levels were quantified 
using qPCR. Figure 3.6b shows a 4-fold increase in SPHK1 expression in PC-3 transfected with 
SPHK1-mKO2 (PC-3/OFP-SPHK1) when compared with PC-3 cells transfected with an empty 
vector (PC-3/OFP). The next step was to evaluate if an over-expression of SPHK1 would 
result in an increase in cell proliferation. As seen in figure 3.6c, the over-expression of SPHK1 
did not lead to a significant increase in PC-3 cell proliferation. However, the addition of U937 
cells was shown to have very little effect on PC-3/OFP cell proliferation in this experiment 
(Fig.3.6d) as seen previously with parental PC-3 cells (Fig.3.1b).  
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a) 
b) 
Figure 3.5: PC-3 cell proliferation upon co-culture with macrophages. PC-3 cells were 
cultured in a) full media or b-c) serum-free media for 24 hours before the addition of 
macrophages. a-b) RAW264.7 mouse macrophages were added to the upper chamber and 
left incubating for up to 72 hours c) THP-1 cells were pre-treated with PMA (100nM) for 24 
hours before being added to PC-3 cells for up to 72 hours. SRB solution was added to the 
bottom chamber to determined PC-3 cell proliferation. Data shown is the mean  SEM of two 
independent experiments performed in duplicate. 
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Figure 3.6: SPHK1 over-expression in PC-3 cells. PC-3 cells were transfected with a phmKO2 
vector constitutively expressing SPHK1 or phmKO2 vector for control. Cell sorting was performed 
to isolate only OFP positive cells while G418 was used as a selective agent. a) Fluorescence 
microscopy was used to detect OFP positive cells (orange) and b) qRT-PCR was performed to 
verify SPHK1 over-expression. c) PC-3 tagged OFP- SPHK1 and OFP alone were cultured in the 
absence or d) presence of U937 cells for the indicated time points. SRB solution was added to the 
bottom chamber to determined PC-3 cell proliferation. Data shown is the mean  SEM of two 
independent experiments performed in duplicate. Statistical analysis was performed using 
student’s t-test relative to each individual time point; ns p>0.05, ***p<0.001 for PC-3 OFP vs. PC-
3 OFP-SPHK1. 
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3.6 Effect of SPHK1 inhibition on PC-3 growth in an in vivo model 
 
 The effect of SPHK1 on tumour growth and recruitment of monocytes/macrophages 
was examined in vivo in collaboration with Dr. Alwyn Dart and Dr. Greg Brook. PC-3 cells 
over-expressing GFP were subcutaneously implanted with matrigel in the flanks of nude 
mice. Following tumour establishment, mice were divided into two groups and treated every 
two or three days by subcutaneous injection with 50μL SPHK1 inhibitor SKi-II (50mg/kg) or 
DMSO (control) diluted in PBS. The addition of SKi-II significantly reduced the tumour growth 
upon comparison with the control group (Fig.3.7a). Interestingly, after just one dose (day 2) 
of SKi-II, the tumour volume had decreased with respect to the control group, and by day 9 
the relative tumour volume was reduced to approximately the size observed prior to 
treatment. The control group showed a constant increase in tumour volume, with an 
approximate 2.5-fold increase by day 9. After collection, tumours were divided into several 
parts and frozen for multiple analyses. Immunohistochemistry was used to measure cell 
proliferation in each tumour, with Ki67 staining used as a marker of cell proliferation. Ki67 is 
a nuclear protein present during all phases of cell cycle but is notable by its absence from 
resting cells which allows the specific detection of proliferative cells. Figure 3.7b-c 
represents the differences in Ki67 staining between the two groups showing a reduction in 
proliferative cells in tumours from mice treated with SKi-II. H&E staining (Hematoxylin and 
eosin) was performed for visualisation of nuclear and cell structure (Fig.3.7b). 
To evaluate whether SPHK1 was differentially expressed in SKi-II treated mice with 
respect to untreated control mice, immunohistochemistry analysis was performed on each 
tumour (Fig.3.8a). SPHK1 intensity was scored as high (2) or low (1) by blind scoring of each 
tumour section and showed no significant differences between control or treated tumours 
(Fig.3.8b). To further analyse SPHK1 levels, RNA was extracted from each tumour and SPHK1 
mRNA expression levels were determined by qRT-PCR after 4 treatments (day 9). As seen in 
figure 3.8c, the effect of SKi-II on tumour volume was paralleled with a significant reduction 
of SPHK1 expression in human PC-3 cells. Mouse cells of the tumour microenvironment were 
also evaluated for SPHK1 levels in order to determine the effect of the SKi-II inhibitor in the 
tissues surrounding the tumour; a similar reduction in SPHK1 expression was observed, 
although did not prove statistically significant (Fig. 3.8d).  
100
a) 
bii) 
Figure 3.7: PC-3 Xenograft from nude mouse model. 1x106 PC-3 cells tagged with GFP were 
subcutaneously injected into nude mice, left to grow for ten days before the addition of SKi-II 
(50mg/ml) every three days for a total of four treatments (black arrows). DMSO was used as a 
control. a) Tumours  were  collected and volumes  were measured using calipers (section 2.2.6). 
b) Immunohistochemistry was performed  for the  cell proliferation  marker Ki67, bi) each data 
point represents the average three scorings of Ki67 positive cells per tumour section, bii) 
representative staining for each condition. Hematoxylin and Eosin (H&E) staining was used to 
verify cell structure. Student’s t-test was used to determine statistical significance for SKi-II 
treated vs. control xenografts; ns p>0.05, *p<0.05, **p<0.01. 
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a) 
Figure 3.8: Immunohistochemistry analysis of PC-3 Xenograft tumours after SKi-II treatment.  
Immunohistochemistry was performed for SPHK1 and H&E. a) Representative staining of each 
condition. b) SPHK1 intensity was determined by blind scoring of each tissue sample. c) Human 
SPHK1 and d) mouse Sphk1 expression  was determined by qRT-PCR of RNA extracted from each 
tumour sample, and expression levels were normalised using three housekeeping genes, GAPDH, 
YWHAZ and UBC. Data shown is the normalised relative quantification (NRQ) of each sample. 
Student’s t-test was used to determine statistical significance for SKi-II treated vs. control 
xenografts; ns p>0.05, *p<0.05. 
 
SPHK1 
Control 
SKi-II 
H&E 
Control SKi-II
0.0
0.5
1.0
1.5
*
H
um
an
 S
P
H
K
1 
ex
pr
es
si
on
(N
R
Q
)
Control Ski-II
0
1
2
3
S
P
H
K
1 
In
te
ns
ity
b) 
c) d) 
Control SKi-II
0
1
2
3
ns (p=0.102)
M
ou
se
 S
ph
k1
 e
xp
re
ss
io
n
(N
R
Q
)
102
Next it was important to determine whether SKi-II treatment would affect the number of 
infiltrating monocytes and macrophages within the tumour. For this purpose MAC2 antibody 
was used as a monocyte/macrophage positive marker during immunohistochemistry analysis 
(Fig.3.9a). Each MAC2 stained section was blind scored and, as seen in figure 3.9b, did not 
show a significant difference amongst treated versus untreated mice. It must be noted that 
the antibody showed a lack of specificity and in order to have a more accurate analysis 
staining with other monocyte/macrophage antibodies such as CD68, CD14 and F4/80 were 
also tested, with no success. 
Nonetheless, the MAC2 antibody when used in spleens of PC-3 xenograft mice proved to 
be very specific and reliable in its staining profile. This analysis was performed to determine 
whether the use of SKi-II treatment would reduce the number of migratory 
monocyte/macrophages present. As seen in figure 3.10b the use of SKi-II did not reduce the 
number of infiltrating monocytes/macrophages in the spleen upon comparison with 
untreated mice.   
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Figure 3.9: Immunohistochemistry analysis of PC-3 Xenograft tumours after SKi-II treatment.  
Immunohistochemistry was performed for MAC2 and H&E. a) Representative staining of each 
condition.  b) Data shown is percentage of MAC2 positive staining as determined by blind scoring 
of each tissue sample within a field of approximately 100 cells. Student’s t-test was used to 
determine statistical significance for SKi-II treated vs. control xenografts; ns p>0.05. 
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MAC2 
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Figure 3.10: Immunohistochemistry analysis of PC-3 Xenograft mice spleens after SKi-II 
treatment. Immunohistochemistry was performed for MAC2 and H&E. a) Representative staining 
of each condition.  b) Data shown is percentage of MAC2 positive staining as determined by blind 
scoring of each tissue sample within a field of approximately 100 cells. Student’s t-test was used 
to determine statistical significance for SKi-II treated vs. control xenografts; ns p>0.05. 
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3.7 Discussion 
 
The tumour microenvironment is one of the most rapidly growing areas of cancer cell 
biology research. It is readily accepted that tumour cells interact with their surroundings in 
order to create favourable conditions for their growth and progression. Tumour-stromal cell 
interactions are crucial for tumour development, with monocytes and macrophages being 
the main types of immune cells whose involvement has been described in tumour 
progression [233, 393]. In this context, it has been shown that co-inoculation of PC-3 and 
U937 cells in male athymic mice significantly increases tumour growth when compared with 
PC-3 cells injected alone [246], whilst another study indicates that THP-1 cells and blood 
derived monocytes were able to induce colon cancer cell proliferation and increase colony 
formation [248]. Here, in this study, it is shown that co-culturing cancer cells and monocytes 
can result in a beneficial effect on cancer cell proliferation; indeed PC-3 cells cultured with 
U937 (Fig.3.1b) and THP-1 cells (Fig.3.4b), to a lesser extent, provide an example of such an 
effect. Moreover, in BT549 (Fig.3.3a) and MDA-231 breast cancer cells (Fig.3.3b) a similar 
effect was observed, with the beneficial effect more accentuated and statistically significant 
in BT549 cells. It is to be noted that in breast cancer cell models the increase in proliferation 
was not as accentuated as that observed in PC-3 cells when in culture with U937; one 
plausible explanation could be the longer doubling time of these cells, MDA-231 at 25-35 
hours and BT549 at 25-30 hours, in comparison to PC-3 cells doubling every 10-20 hours, 
which would result in a lower increase in the same period of time. Indeed, the characteristics 
of each cell line together with the culture conditions appear crucial in cancer cell 
development and may not always confer a beneficial effect on cancer cell proliferation. This 
is evident in the case of DU-145 (Fig.3.2a) and C4-2 (Fig.3.2b), other prostate cancer cell 
lines, models of CRPC, whereby the addition of U937 cells appeared to invoke a slight 
inhibitory effect on cancer cell proliferation. Likewise, PC-3 cell proliferation was also 
inhibited when co-cultured with RAW264.7 macrophages (Fig.3.5a-b) and THP-1-derived 
macrophages (Fig.3.5c). The influence of culture conditions is exemplified by the finding that 
in full media conditions U937 (Fig.3.1a) and THP-1 cells (Fig.3.4a) induced a lower level of 
proliferation in PC-3 cells when compared with the increase observed upon serum-free 
culture. Altogether these results indicate that tumour-monocyte or macrophage interactions 
vary from cell to cell with the outcome being determined by the signalling profile of each cell 
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type. A more extensive analysis of factors secreted by different cancer cell types would 
afford a better understanding and elucidation of the mediators of these interactions and 
could provide useful insights into the differential effects on cancer cells. 
The involvement of SPHK1 in cell proliferation has been described previously; indeed 
SPHK1 silencing has been shown to reduce MCF-7 cell growth and glioblastoma cell 
proliferation by 2.5-fold [215, 353]. In support, our group has shown in a prostate cancer cell 
model (PC-3) that the knockdown of SPHK1 by siRNA can lead to a significant reduction in 
cell proliferation [78]. In this study I aimed to evaluate if monocytes were able to overcome 
the inhibitory effect on PC-3 cell proliferation induced by SPHK1 knockdown. As expected, 
the importance of SPHK1 on cell proliferation was confirmed as its knockdown reduced PC-3 
cell proliferation; more importantly the inhibitory effects observed were not altered by the 
presence of U937 (Fig.3.1c) or THP-1 cells (Fig.3.4c). Several explanations can thus be 
inferred from these findings; a) SPHK1 plays a central role in PC-3 proliferation and it's 
absence renders ineffective any stimulus that could trigger proliferation (e.g U937 or THP-1 
cell presence); b) the factors secreted by monocytes are mediated by SPHK1 in PC-3 cells 
(discussed in chapter 4 and 5); or c) soluble factors secreted by PC-3 cells in the absence of 
SPHK1 are different from those secreted by parental PC-3, which could modulate the 
monocytic response towards PC-3 cells. While these data support an interpretation that 
monocytes are unable to increase cell proliferation in SPHK1 siRNA targeted PC-3 cells, a 
question remains whether soluble factors involved in the interaction between monocytes 
and cancer cells may be regulated by SPHK1. This aspect will be further discussed in chapters 
4 and 5.  
Over-expression of SPHK1 is credited in the literature for increasing proliferation in 
intestinal epithelial cells [394] and colon cancer cells [395]; the effect of SPHK1 over-
expression upon PC-3 cell proliferation together with its effect on U937-induced cancer cell 
proliferation was therefore evaluated in this study. The constitutive over-expression of 
SPHK1 in PC-3 cells did not result in a significant increase in PC-3 cell proliferation (Fig.3.5c) 
and no further increase in proliferation was observed upon co-culture with U937 cells 
(Fig.3.5d). The hypothesis that increased SPHK1 would lead to an increase in SPHK1-
mediated signalling molecules, in turn activating U937 cells to promote PC-3 cell 
proliferation, is not supported by these findings. Nonetheless this result should be analysed 
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carefully as the proliferation of PC-3 cells transfected with an empty vector (PC-3/OFP) 
(Fig.3.6c) was markedly lower than in parental PC-3 cells (Fig.3.1.a-b) and in the presence of 
U937 cells (Fig.3.1b) indicating a possible negative effect of the transfected plasmid DNA 
upon cell proliferation. Such an effect could mask not only the positive influence of SPHK1 
on PC-3 proliferation but also the SPHK1-induced proliferative effects of U937s on PC-3 cells.   
 The effect of SPHK1 modulation on tumour growth and monocyte/macrophage 
interaction was next examined in vivo. SKi-II inhibition of tumour growth supported my 
previous findings that identified SPHK1 as a key element for tumour growth and progression. 
Indeed, the 2.5-fold decrease in tumour volume caused by the SPHK1 inhibitor (Fig.3.7a) 
together with a significant reduction in cell proliferation (Fig.3.7b-c) indicates its clinical and 
potential therapeutic value. These findings are supported by other in vivo studies showing 
SPHK1 involvement in tumour growth; SPHK1 inhibition by FTY720 led to a decrease of PC-3 
cell growth, metastasis and increase in apoptosis in a time and concentration dependent 
manner [144]. Moreover, Ski-I induced reduction of tumour size in a NSCLC xenograft model 
[349], whilst in breast cancer the tumour reduction was accompanied by a reduction in the 
number of metastasis to lymph nodes and lungs [396]. 
An important observation is that SPHK1 expression for both human and mouse tissue 
was reduced by SKi-II treatment (Fig.4.7b-c). This effect could be attributed to the ability of 
SKi-II to regulate SPHK1 though inhibition of SPHK1 enzymatic activity or by rendering it 
ineffective via the induction of proteosomal degradation as described in previous studies 
[397-399]. The reduction in SPHK1 levels is also believed to cause inhibition of SPHK1-
activated signalling-related proteins, affecting not only intracellular pathways that are 
involved in SPHK1 transcription, but also the secretion of extracellular proteins that in turn 
will affect the tumour microenvironment [270, 326]. In this study, the impact of SPHK1 
inhibition in an in vivo mouse model did not correlate with a decrease in macrophage 
infiltration (Fig.3.9). These results should however be interpreted with caution as MAC2 
staining did not meet an acceptable quality to be considered a viable and specific marker for 
macrophage and monocyte staining. A strong background in tumour sections associated 
with non-specific cell staining is the most likely reason as to why these results may not be 
accurate. Nonetheless, MAC2 staining of the spleen showed good levels of cell specificity 
and was deemed reliable in its staining profile. This indicated that preparation of the tumour 
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sections, rather than poor specificity of the antibody itself, was the most likely cause of the 
unreliable staining profile. This could also explain the apparent lack of reduction of SPHK1 as 
observed by immunohistological analysis of SKi-II treated tumour preparations as well as the 
unreliable performance of other monocyte/macrophage markers tested such as CD68, F4/80 
and CD14. It is therefore important to optimize and clarify the quality of the tumour sections 
in order to obtain more assured conclusions regarding the role of SPHK1 in monocyte 
infiltration, and subsequently be able to determine if, within the tumour sections, the 
presence of monocytes is localised with high SPHK1 expression. Possible future approaches 
to resolve the high background staining observed could entail the fixing of new tumour 
sections onto new slides or the use of frozen sections to increase antibody specificity and 
binding. With respect to macrophage staining the use of antibodies such as cd11b or cd11c 
could offer an alternative to the antibodies explored to date and may provide an increased 
specificity to the cell type. The use of two different antibodies in mirror sections could also 
further validate the presence of infiltrating macrophages in the tumour.         
  Altogether this data supports the role of SPHK1 as a key mediator in cancer cell 
proliferation, with both in vitro and in vivo models showing an anti-proliferative effect on 
cancer cells when SPHK1 was inhibited. The ability of monocytes to induce cancer cell 
proliferation appears to vary amongst different cell types; however SPHK1 inhibition was 
able to suppress this positive effect, identifying SPHK1-targeted therapy as a potential 
approach for prostate cancer associated with a high inflammatory condition.    
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4. The role of tumour cell-derived SPHK1 in intercellular interactions 
4.1 Introduction 
 
The inflammatory tumour microenvironment contains an abundance of cytokines, 
chemokines and growth factors that are secreted by both tumour cells and stromal cells 
such as macrophages [226, 244]. Recent studies reveal that direct communication between 
macrophages and tumour cells is critical to the invasion and egress of tumour cells into 
blood vessels, and to subsequent metastasis [387, 389]. Indeed, tumour cells have the ability 
to recruit myeloid derived cells, such as monocytes and macrophages, through the 
production and secretion of various stimulatory molecules such as growth factors, cytokines 
and chemokines [232, 304]. The presence of infiltrating cells within the tumour is thought to 
induce the activation of important signalling pathways such as PI3K/AKT or MAPK/ERK1/2, 
known promoters of cancer development [328, 400, 401]. In this context, it is becoming 
clear that a more effective approach to new cancer drugs should not only target molecules 
involved in pro-tumorigenic events within the cancer cells but also molecules that are able to 
modulate the tumour cell microenvironment. As such, the role of the SPHK1/S1P pathway in 
immune cell trafficking and inflammatory events such as cytokine release, together with 
regulation of and its ability to be regulated by important intracellular signalling mediators 
such as AKT and ERK1/2, has led to the hypothesis that SPHK1/S1P could be an important 
mediator of tumour-monocyte interactions. Therefore I aimed to study the role of 
SPHK1/S1P in tumour-monocyte interactions, understand the molecular mechanisms by 
which tumour cells benefit from this interaction, and identify the soluble mediators 
involved.  
 
4.2 The role of SPHK1 in PC-3 prostate cancer cells during co-culture with U937 cells 
 
SPHK1 regulation was monitored in PC-3 cells following their co-culture with U937 
cells (Fig.4.1). SPHK1 activity in cell lysates was assessed though its incubation with 
Sphingosine and radiolabeled ATP-P32. The formation of S1P with incorporated P32 was 
measured as an indication of SPHK1 activity. 
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SPHK1 activity was increased by 30% in PC-3 cells following one and three hours of 
co-culture with U937 cells when compared with PC-3 cells cultured alone (Fig.4.1a). A 
smaller non-significant increase in SPHK1 activity was observed following five and eight 
hours of co-culture, whilst 24 hours of co-culture led to a 70% increase in SPHK1 activity in 
PC-3 cells.  
 Alongside an increase in SPHK1 activity, SPHK1 transcript levels were also observed 
to be altered in PC-3 cells upon co-culture with U937 cells. As shown in figure 4.1b, there 
were initial (one and three hour) and later (24 hour) increases in SPHK1 expression levels 
observed in PC-3 cells following their co-culture with U937 cells when compared with PC-3 
cells cultured alone. After one and three hours of co-culture there were respective 1.8- and 
2-fold increases observed in SPHK1 expression in PC-3 cells; this was followed by a reduction 
in expression in PC-3 cells after five and eight hours of co-culture in comparison with one 
and three hours (Fig.4.1b). In concomitance with SPHK1 activity, at 24 hours there was a 2-
fold increase of SPHK1 mRNA in PC-3 cells. 
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Figure 4.1: SPHK1 activity and expression levels in human PC-3 cells following their co-culture 
with U937 cells. PC-3 cells were seeded in the bottom chamber under serum-free media 24 
hours before the addition of U937 cells for the indicated duration. a) SPHK1 activity and b) 
SPHK1 expression were determined in PC-3 cell lysates containing equal amounts of protein or 
mRNA using radiolabelling and qRT-PCR respectively. For qRT-PCR, SPHK1 mRNA expression 
levels were normalised using three housekeeping genes, GAPDH, YWHAZ and UBC. Data shown 
is the mean ± SEM of three independent experiments performed in duplicate. Statistical 
analysis was performed using student’s t-test relative to each individual time point. ns p>0.05, 
*p<0.05, **p<0.01, ***p<0.001 for PC-3 cells vs. PC-3 + U937 cells. 
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To study the possible mechanisms of SPHK1 regulation in the co-culture system, I 
investigated the signal transduction pathways that have previously been shown to be 
involved in both the tumour microenvironment and in SPHK1 regulation. In this context, Akt 
is a well documented regulator of several pro-survival pathways involved in tumour 
development and inflammatory processes and importantly is regulated by SPHK1. To 
evaluate its levels in PC-3 cells during co-culture with U937 cells, a western blotting assay 
was performed at the indicated time points (Fig.4.2a). 
 My data show that upon one hour of co-culture a highly significant increase in Akt 
phosphorylation of approximately 3-fold was evident. Furthermore, following three hours of 
co-culture, U937 cells were still able to induce Akt phosphorylation in PC-3 cells when 
compared with PC-3 cells cultured alone. This increase is lower than that observed at one 
hour; however the 2-fold increase in Akt phosphorylation observed at three hours proved to 
be statistically significant (Fig.4.2a-b). In a later stage of co-culture (24 hours), Akt 
phosphorylation was not affected by the presence of U937 cells (Fig.4.2a)  
To further investigate Akt regulation by SPHK1, siRNA was used to target SPHK1 at a 
transcriptional level in PC-3 cells. To assess the efficacy of the RNAi, qRT-PCR was performed 
using cDNA derived from mRNA extracted from PC-3 cells. SPHK1 expression was shown to 
be down-regulated by approximately 70%, independently of the presence of U937 cells 
(Fig.4.2e). The use of a non-targeting siRNA (siNT) showed a similar pattern of Akt 
phosphorylation as shown in figure 4.2a, with an increase in Akt phosphorylation at one and 
three hours followed by no effect at 24 hours (Fig.4.2c and d). SPHK1 knockdown induced a 
significant down-regulation in Akt phosphorylation upon one, three and 24 hours of co-
culture and abolished the effect of U937 cells (Fig.4.2c). Notably, SPHK1 knockdown didn’t 
affect the total Akt levels, indicating a possible role for SPHK1 in Akt phosphorylation. 
Another known regulator of SPHK1 is ERK1/2; in this study I attempted to measure ERK1/2 
phosphorylation levels in PC-3 cells during co-culture. However it was not possible to detect 
any level of ERK1/2 phosphorylation in the absence or presence of monocytes, which could 
be explained by the fact that PC-3 cells have almost undetectable levels of phosphorylated 
ERK1/2. It was therefore not possible to assess whether the increase in SPHK1 activity and 
expression was correlated with ERK1/2 phosphorylation.  
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Figure 4.2: AKT regulation in PC-3 cells during co-culture with U937 cells. PC-3 cells were seeded 
in the bottom chamber under serum-free media 24 hours before the addition of U937 cells for 
the indicated duration. a) AKT phosphorylation and total levels were determined by western 
blotting b) quantified by Image J software and normalised to GAPDH. c-d) PC-3 cells were 
transfected with siRNA targeting SPHK1 (siSPHK1) or non-targeting control siRNA  (siNT) for 24 
hours before cells were washed with PBS and cultured in serum-free media for 24 hours. U937 
cells were then added to the upper chamber and left incubating for the indicated duration. AKT 
phosphorylation and total levels were determined as described above (a-b). e) SPHK1 expression 
in U937 cell lysates was determined by qRT-PCR. Three housekeeping genes, GAPDH, YWHAZ and 
UBC were used for normalisation Data shown is representative of a), c) three independent 
experiments and b), d-e) the mean ± SEM of three independent experiments. Statistical analysis 
was performed using student’s t-test relative to each individual time point. ns p>0.05, *p<0.05, 
**p<0.01, ***p<0.001 for b) PC-3 vs. PC-3+U937 or d-e) siNT PC-3 vs. siNT PC-3 + U937 or siNT 
PC-3 + U937 vs. siSPHK1 + U937.  
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4.3 Impact of Akt and ERK1/2 regulation in PC-3 prostate cancer cells during co-culture 
with U937 cells 
 
Following on from initial findings, the next step was to evaluate the role of Akt and 
ERK1/2 signalling pathways in SPHK1 regulation during co-culture. In a similar manner to 
that described for SPHK1, PC-3 cells were transfected with siRNAs targeting Akt or ERK1/2. 
As seen in figure 4.3a, Akt knockdown led to an increase in SPHK1 expression after one hour 
of co-culture, this effect was further increased by the presence of U937 cells (Fig.4.3ai). For 
the remaining two time points the presence of U937 did not induce an increase in SPHK1 
expression in Akt siRNA-treated PC-3 cells (Fig.4.3aii and iii).  
With regards to the effect on SPHK1 mRNA levels, ERK1/2 knockdown proved to have 
no effect on SPHK1 basal expression in PC-3 cells cultured alone for the indicated time points 
(Fig.4.3ai-iii). However, following just one hour of co-culture, in PC-3 cells where ERK1/2 
mRNA was targeted, the previously observed U937-dependent increase in SPHK1 expression 
was abolished in these cells (Fig.4.3ai). ERK1/2 knockdown was confirmed by total forms of 
the protein and not specifically for its phosphorylated variants, as ERK1/2 phosphorylation 
levels in PC-3 cells proved very difficult to determine (Fig.4.3b). 
As for ERK1/2 and Akt cross-regulation, it was apparent that ERK1/2 knockdown 
reduced Akt phosphorylation in non U937-stimulated PC-3 cells at all time points (Fig.4.3b). 
Moreover, in PC-3 cells with ERK1/2 knockdown the presence of U937 cells led to an 
increase in Akt phosphorylation after one hour of co-culture; however this U937-induced 
effect on Akt phosphorylation was not observed after three and 24 hours of co-culture 
(Fig.4.3b). As for Akt siRNA-mediated PC-3 cells there was no effect in Akt phosphorylation 
levels as shown for one and three hours of co-culture. Nonetheless, Akt knockdown inhibits 
U937-induced increase in Akt phosphorylation in PC-3 cells, importantly this inhibitory effect 
was observed across all time points. At the 24 hour time point, i.e. 72 hours post-siRNA 
transfection, phosphorylated Akt basal levels were reduced when compared alongside PC-3 
cells transfected with a non-targeting siRNA (Fig.4.3b).     
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Figure 4.3a: Effect of AKT and ERK1/2 knockdown on SPHK1 expression in PC-3 cells during co-
culture with U937 cells. PC-3 cells were transfected with siRNA targeting SPHK1 (siSPHK1), AKT 
(siAKT), ERK1/2 (siERK1/2), or non-targeting control siRNA (siNT) for 24 hours before cells were 
washed with PBS and cultured in serum-free media for 24 hours. U937 cells were then added to 
the upper chamber and left incubating for the indicated duration. SPHK1 expression in U937 cell 
lysates was determined by qRT-PCR. Three housekeeping genes, GAPDH, YWHAZ and UBC were 
used to normalise. Data shown for is the mean ± SEM of two independent experiments.  
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Figure 4.3b: Effect of AKT and ERK1/2 knockdown in PC-3 cells during co-culture with U937 
cells. PC-3 cells were transfected with siRNA targeting SPHK1 (siSPHK1), AKT (siAKT), ERK1/2 
(siERK1/2) or non-targeting control siRNA (siNT) for 24 hours before cells were washed with PBS 
and cultured in serum-free media for 24 hours. U937 cells were then added to the upper 
chamber and left incubating for the indicated duration. AKT phosphorylation and total levels, 
and ERK1/2 total levels were determined by western blotting, quantified by Image J software 
and normalised to alpha-tubulin. Data shown is representative of one independent experiment.  
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4.4 Effect of THP-1 monocytic cell line on SPHK1 levels in PC-3 cells 
 
The ability of THP-1 cells to confer a positive effect on PC-3 cell proliferation (chapter 
3, Fig.3.3b), akin to that observed for U937 cells, prompted a preliminary investigation of 
THP-1 involvement in SPHK1 regulation in PC-3 cells. As seen in figure 4.4a, after one hour of 
co-culture SPHK1 activity in PC-3 cells increased by approximately 40% upon THP-1 
stimulation. This effect is transient as for the remaining studied timed points there was no 
THP-1 induction on SPHK1 activity in PC-3 cells (Fig.4.4a). As for SPHK1 mRNA expression 
levels, no effect was observed after only one hour of co-culture. However, for the remaining 
time points, THP-1 cells were able to induce an increase in SPHK1 expression, being more 
accentuated after 24 hours of co-culture (Fig.4.4b).  In addition, it was important to 
understand if the increase in SPHK1 levels was accompanied by an alteration in Akt 
phosphorylation. Indeed, in PC-3 cells the presence of THP-1 led to an increase in Akt 
phosphorylation at all time points, this positive effect being more accentuated after three 
hours of co-culture with a 3.7-fold increase (Fig.4.4c).  
 
4.5 Effect of U937 monocytic cell line on SPHK1 levels in MDA0-231 breast cancer cells 
 
In order to evaluate the ability of U937 cells to regulate SPHK1 in another cancer cell 
line, MDA-231 cells were co-cultured with the monocytes. SPHK1 activation in MDA-231 was 
triggered by the presence of U937 cells upon three hours of co-culture, however this effect 
was transient as for the remaining six and 24 hour time points, the U937-induced increase in 
SPHK1 activity was not observed (Fig.4.5a). SPHK1 expression was transiently elevated by 
the presence of U937 cells; this effect was only observed after six hours of co-culture 
(Fig.4.5b). In terms of the molecular mechanism underpinning this activation, ERK1/2 
phosphorylation levels were measured across the same time points described previously. As 
seen in figure 4.5c, the addition of U937 cells to MDA-231 led to a clear up-regulation of 
ERK1/2 phosphorylation at all studied time points. It is Important to note that the Akt 
phosphorylation levels were measured without success, as the basal levels and/or the 
monocyte-induced phosphorylation levels were too low to be detected by western blotting 
(data not shown).  
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Figure 4.4: SPHK1 activity and expression levels in human PC-3 cells following their co-culture 
with THP-1 cells. PC-3 cells were seeded in the bottom chamber under serum-free media 24 
hours before the addition of THP-1 cells to the upper chamber for the indicated duration. a) 
SPHK1 activity and b) SPHK1 expression was determined in PC-3 cell lysates containing equal 
amounts of protein or mRNA respectively using radiolabelling and qRT-PCR respectively. For qRT-
PCR, SPHK1 mRNA expression levels were normalised using three housekeeping genes, GAPDH, 
YWHAZ and UBC. c) AKT phosphorylation and total levels were determined by western blotting, 
quantified by Image J software and normalised to GAPDH Data shown is a-b) mean ± SEM of two  
independent experiments and c) representative  of one independent experiment. 
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Figure 4.5: SPHK1 activity and expression levels in human MDA-231 cells following their co-
culture with U937 cells. MDA-231 cells were seeded in the bottom chamber under serum-free 
media 24 hours before the addition of U937 cells to the upper chamber for the indicated 
duration. a) SPHK1 activity and b) expression were determined in MDA-231 cell lysates 
containing equal amounts of protein or mRNA respectively using radiolabelling and qRT-PCR 
respectively. For qRT-PCR, SPHK1 mRNA expression levels were normalised using three 
housekeeping genes, GAPDH, YWHAZ and UBC. c) ERK1/2 phosphorylation and total levels were 
determined by western blotting, quantified by Image J software and normalised to GAPDH. Data 
shown is a-b) mean ± SEM of two independent experiments and c) representative  of one 
independent experiment. 
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4.6 Signalling mediators involved in PC-3/U937 cell interactions during co-culture 
 
The ability of U937 to regulate SPHK1 in PC-3 cells by increasing its activity and mRNA 
levels led to the hypothesis that S1P, produced by SPHK1 activation, could be acting in an 
autocrine manner. To investigate this, PC-3 cells were treated with S1P for several time 
points up to a maximum of 24 hours. S1P treatment provoked a significant increase in SPHK1 
expression after one hour of treatment. At three hours the S1P-induced increase in SPHK1 
expression was not significant, whilst at 24 hours there was no effect on mRNA levels when 
compared with untreated PC-3 cells (Fig.4.6a). Akt phosphorylation was also increased by 
S1P treatment; this effect was observed at three hours and more accentuated at 24 hours 
(Fig.4.6b) with a 1.5- and 2.5-fold increase respectively. 
 
4.6.1 The role of MCP-1 in PC-3/U937 co-culture 
 
The cytokine MCP-1 has been reported to be up-regulated in tumours [320, 402], is 
identified as a key chemo-attractant for monocytes and macrophages [259, 403] and can be 
regulated by SPHK1 [324]. To investigate whether MCP-1 could be involved in PC-3-
monocyte interactions the conditioned media of PC-3 co-cultured with U937 cells was 
analysed by ELISA. MCP-1 secretion was increased by the presence of U937 cells after three 
hours of co-culture, with the highest levels observed after 24 hours (Fig.4.7a). Interestingly, 
the siRNA-mediated inhibition of SPHK1 expression in PC-3 cells led to a significant decrease 
in MCP-1 secretion at three and 24 hours with a 3- and 2-fold drop respectively. Basal levels 
of MCP-1 in the media of PC-3 cells cultured alone have shown no difference upon SPHK1 
inhibition, suggesting SPHK1 independence (Fig.4.7b). In this context, I wanted to ascertain 
whether MCP-1 secreted levels were accompanied by an increase in MCP-1 at the 
transcriptional level. It was of note that MCP-1 mRNA levels were increased at three hours 
and more significantly at 24 hours upon PC-3 co-culture with U937 cells (Fig.4.7c). 
Furthermore, MCP-1 basal expression was not affected by SPHK1 knockdown; however an 
effect was observed in PC-3 cells that were co-cultured with U937 cells. By comparing PC-3 
transfected with non-targeting or SPHK1-targeting siRNA in the presence of U937 cells, it is 
clear that MCP-1 expression is reduced in the siSPHK1 PC-3 cells, with the result being more 
significant following three hours of co-culture (Fig.4.7d).  
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Figure 4.6: Effect of S1P in PC-3 cells signalling pathways and cytokine production. a) PC-3 cells 
were seeded in a 6 well plate for 24 hours before the addition of S1P at a final concentration of 
1μM. a) SPHK1 expression in PC-3 cell lysates was determined by qRT-PCR. Three housekeeping 
genes, GAPDH, YWHAZ and UBC were used to normalise. b) AKT phosphorylation and total levels 
were determined by western blotting, quantified by Image J software and normalised to alpha 
tubulin. Data shown a) is the mean ± SEM of three independent experiments and b) 
representative  of two independent experiments. Statistical analysis was performed using 
student’s t-test relative to each individual time point, a) ns p>0.05, *p<0.05 for PC-3 vs. PC-3+S1P. 
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Figure 4.7: MCP-1 regulation in PC-3 cells during co-culture. a,c) PC-3 cells were seeded in the 
bottom chamber under serum-free media 24 hours before the addition of U937 cells for the 
indicated duration. b,d) PC-3 cells were transfected with siRNA targeting SPHK1 (siSPHK1), or non-
targeting control siRNA (siNT) for 24 hours before cells were washed with PBS and cultured in 
serum-free media for 24 hours. U937 cells were then added to the upper chamber and left 
incubating for the indicated duration. a-b) MCP-1 concentration in the media of the lower 
compartment where PC-3 cells were present was determined by ELISA. Media was incubated with 
MCP-1 specific antibodies and a standard curve was used to quantify the relative amount of MCP-1 
in each sample. Protein concentration of each cell lysate was used for normalisation. c-d) MCP-1 
expression in PC-3 cell lysates was determined by qRT-PCR. Three housekeeping genes, GAPDH, 
YWHAZ and UBC were used to normalise. Data shown is mean ± SEM of three independent 
experiments. Statistical analysis was performed using student’s t-test relative to each individual 
time point, ns p>0.05, *p<0.05, **p<0.01, ***p<0.001 for a,c) PC-3 vs. PC-3+U937 or b,d) 
siNT+U937 vs. siSPHK1+U937.  
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As a consequence of my initial findings, it was important to clarify the role, if any, of 
SPHK1 in MCP-1 regulation. For this purpose, I generated a stable PC-3 cell line that 
constitutively over-expresses human SPHK1. Using qRT-PCR, an 8-fold increase in MCP-1 
mRNA levels was observed in PC-3 cells over-expressing SPHK1 (PC-3/OFP-SPHK1) in 
comparison with PC-3 cells transfected with an empty vector (Fig.4.8ai). In concomitance, 
secreted MCP-1 levels in the supernatant were also increased by approximately 4-fold in PC-
3/OPF-SPHK1 cells (Fig.4.8aii).   
To assess the impact of SPHK1 over-expression on MCP-1 during co-culture, PC-3 cells 
over-expressing SPHK1 were co-cultured with U937 cells. ELISA of the supernatant showed 
that MCP-1 secretion was significantly up-regulated in the presence of U937 cells at one, 
three and 24 hours (Fig.4.8aiii). Surprisingly, there was no increase in MCP-1 mRNA levels 
upon co-culture with U937 cells at any of the studied time points (Fig.4.8aiv) suggesting that 
the increase in MCP-1 is mainly due to its secretion from the monocytes (revised on chapter 
5). SPHK1 expression was also measured in this co-culture and surprisingly no increase was 
observed when U937 cells were present (Fig.4.8av). Interestingly, the increase in MCP-1 
secretion was partially reduced by the use of siRNA targeting SPHK1 in these stable PC-3 cells 
(Fig.4.8b). 
 
To elucidate whether MCP-1 has a role in SPHK1 regulation and Akt phosphorylation, 
human recombinant MCP-1 was added to PC-3 cells for the indicated time points. My results 
showed that MCP-1 addition had no effect on SPHK1 mRNA levels (Fig.4.9a) or Akt 
phosphorylation (Fig.4.9b) at any of the indicated time points.  
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Figure 4.8: MCP-1 regulation and secretion in PC-3 cells over-expressing SPHK1. a) PC-3 cells 
over-expressing SPHK1 (PC-3/OFP-SPHK1) or empty phmKO2 vector (PC-3/OFP) were cultured for 
24 hours. i) MCP-1 expression in PC-3 cell lysates was determined by qRT-PCR. Three housekeeping 
genes, GAPDH, YWHAZ and UBC were used to normalise. ii) MCP-1 concentration in the media was 
determined by ELISA. Media was incubated with MCP-1 specific antibodies and a standard curve 
was used to quantify the relative amount of MCP-1 in each sample. Protein concentration of each 
cell lysate was used for normalisation. iii-v) PC-3/OFP and PC-3/OFP-SPHK1 cells were seeded in 
the bottom chamber under serum-free media 24 hours before the addition of U937 cells for the 
indicated duration. c) MCP-1 concentration in the media was determined by ELISA as described in 
ii), iv) MCP-1 and v) SPHK1 expression was determined by qRT-PCR as described in i). Data shown 
is mean ± SEM of three independent experiments. Statistical analysis was performed using 
student’s t-test relative to each individual time point. ns p>0.05, *p<0.05, **p<0.01, ***p<0.001 
for i-ii) PC-3/OFP vs. PC-3/OFP-SPHK1 or c) PC-3/OPF-SPHK1 vs. PC-3/OFP-SPHK1 + U937 cells. 
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Figure 4.8: MCP-1 secretion in PC-3 cells over-expressing SPHK1. PC-3 cells over-expressing 
SPHK1 (PC-3/OFP-SPHK1) or empty phmKO2 vector (PC-3/OFP) were transfected with siRNA 
targeting SPHK1 (siSPHK1), or non-targeting control siRNA (siNT) for 24 hours before cells were 
washed with PBS and cultured in serum-free media for 24 hours. U937 cells were then added to 
the upper chamber and left incubating for the indicated duration. MCP-1 concentration in the 
media was determined by ELISA. Media was incubated with MCP-1 specific antibodies and a 
standard curve was used to quantify the relative amount of MCP-1 in each sample. Protein 
concentration of each cell lysate was used for normalisation. Data shown is representative of 
one independent experiment performed in duplicate.  
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Figure 4.9: Effect of human recombinant MCP-1 on SPHK1 and AKT activation.  a) PC-3 cells were 
transfected with siRNA targeting SPHK1 (siSPHK1) or non-targeting control siRNA (siNT) 48 hours 
before the addition of human recombinant MCP-1 (rhMCP-1) at a final concentration of 100ng/μl. 
a) SPHK1 expression in PC-3 cell lysates was determined by qRT-PCR. Three housekeeping genes, 
GAPDH, YWHAZ and UBC were used to normalise. b) PC-3 cells were seeded in a 6-well plate for 24 
hours before the addition of MCP-1 as described above a), i) AKT phosphorylation and total levels 
were determined by western blotting, ii) quantified by Image J software and normalised to GAPDH. 
Data shown is mean ± SEM of a) three independent experiments and b) two independent 
experiments. Statistical analysis was performed using student’s t-test relative to each individual 
time point. a) ns p>0.05  for siNT vs. siNT+MCP-1 
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4.6.2 The role of IL-6 in PC-3/U937 co-culture 
 
IL-6 has been shown to modulate prostate cancer survival and proliferation [404] and 
is also under the regulatory control of SPHK1 [270, 294]. Consequently, I decided to explore 
any possible involvement of IL-6 in either SPHK1 up-regulation or Akt phosphorylation. As 
previously described for MCP-1, an ELISA was performed on PC-3 cell supernatant as a first 
step, in order to determine whether IL-6 secretion was affected by the presence of U937 
cells. Figure 4.10a indicates that the presence of U937 cells does not lead to a significant 
increase in IL-6 secretion during co-culture with PC-3 cells. A similar effect was observed at 
the transcriptional level in PC-3 cells, where IL-6 expression did not change with the 
presence of U937 cells. Also, SPHK1 down-regulation by siRNA showed no effect on IL-6 
expression (Fig.4.10b).  
 
Next I wished to determine whether SPHK1 could directly regulate IL-6. For this 
purpose a quantitative RT-PCR was performed on cDNA derived from cell lysates of PC-3 
over-expressing SPHK1. The analysis showed an increase in IL-6 transcripts of approximately 
2.5-fold in comparison with PC-3 containing an empty vector (Fig.4.11a). In accordance with 
these findings, IL-6 levels in the supernatant were also increased when SPHK1 was over-
expressed, with a more accentuated effect observed after 24 hours of culture (Fig.4.11b). 
Furthermore, PC-3/OFP-SPHK1 cells were co-cultured with U937 cells, in order to assess any 
effect on secreted IL-6 protein levels and mRNA expression in PC-3 cells upon the presence 
of U937. As anticipated, with the presence of U937 cells increased levels of IL-6 were 
detected in the supernatant of PC-3. Interestingly, this increase was observed at a very early 
stage of co-culture (one hour) and increased to its highest level at 24 hours (Fig.4.11c). 
Surprisingly this increase in secretion was not accompanied by an increase in IL-6 mRNA 
expression (Fig.4.11d) suggesting once more that IL-6 increase is mainly due to presence of 
the monocytes (revised on Chapter 5).  
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Figure 4.10: IL-6 regulation and secretion in PC-3 cells over-expressing SPHK1. a) PC-3 cells 
were seeded in the bottom chamber under serum-free media 24 hours before the addition of 
U937 cells for the indicated duration. IL-6 concentration in the media was determined by ELISA. 
Media was incubated with IL-6 specific antibodies and a standard curve was used to quantify the 
relative amount of IL-6 in each sample. Protein concentration of each cell lysate was used for 
normalisation. b) PC-3 cells were transfected with siRNA targeting SPHK1 (siSPHK1) or non-
targeting control siRNA (siNT) for 24 hours before cells were washed with PBS and cultured in 
serum-free media for 24 hours. U937 cells were then added to the upper chamber and left 
incubating for the indicated duration. IL-6 expression in PC-3 cell lysates was determined by 
qRT-PCR. Three housekeeping genes, GAPDH, YWHAZ and UBC were used to normalise. Data 
shown is mean ± SEM of a) three independent experiments and b) two independent 
experiments. Statistical analysis was performed using student’s t-test relative to each individual 
time point. a) ns p>0.05  for siNT vs. siNT+U937. 
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Figure 4.11: IL-6 regulation and secretion in PC-3 cells over-expressing SPHK1. PC-3 cells 
over-expressing SPHK1 (PC-3/OFP-SPHK1) or empty phmKO2 vector (PC-3/OFP) were cultured 
for 24 hours. a) IL-6 expression in PC-3 cell lysates was determined by qRT-PCR. Three 
housekeeping genes, GAPDH, YWHAZ and UBC were used to normalise b) IL-6 concentration 
in the media was determined by ELISA. Media was incubated with IL-6 specific antibodies and 
a standard curve was used to quantify the relative amount of IL-6 in each sample. Protein 
concentration of each cell lysate was used for normalisation. c-d) PC-3/OFP and PC-3/OFP-
SPHK1 cells were seeded in the bottom chamber under serum-free media 24 hours before the 
addition of U937 cells for the indicated duration. c) IL-6 concentration in the media was 
determined by ELISA as described in b), d) IL-6 expression was determined by qRT-PCR as 
described in a). Data shown is mean ± SEM of a-b) three and c-d) two independent 
experiments. Statistical analysis was performed using student’s t-test relative to each 
individual time point. ns p>0.05, *p<0.05, **p<0.01, for a-b) PC-3/OFP vs. PC-3/OFP-SPHK1 or 
c) PC-3/OPF-SPHK1 vs. PC-3/OFP-SPHK1 + U937 cells. 
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It was also important to understand whether IL-6 could affect SPHK1 and/or Akt 
regulation. For this purpose human recombinant IL-6 was added to the PC-3 cells at a final 
concentration of 100ng/ml, arrived at by preliminary titration to determine an effective 
working concentration (data not shown). The addition of IL-6 to PC-3 cells led to a significant 
early increase in SPHK1 mRNA at three hours, albeit by only 20% (Fig4.12a). As for the 
remaining time points, IL-6 did not induce SPHK1 expression. The early effect on SPHK1 
mRNA levels following the addition of IL-6 was further explored by investigating whether IL-6 
showed any effect on SPHK1 activation at the protein level. Using a radiolabeling assay, 
SPHK1 activity was measured in PC-3 cells following the addition of recombinant IL-6. The 
cytokine rapidly induced SPHK1 activation; 15 minutes after treatment SPHK1 activity 
increased by approximately 50%. However it appeared to be a transient process as the 
positive effect was lost for the remaining time points (Fig.4.12b). Furthermore, IL-6 
treatment did not induce Akt phosphorylation in PC-3 cells at any studied time point 
(Fig.4.12c).  
As described previously in chapter 3, section 3.7, PC-3 xenografts showed a decrease 
in SPHK1 expression after SKi-II treatment and this was observed in both human and host 
mouse cells. To further extend this study and to understand if in an in vivo setting MCP-1 
and IL-6 expression in PC-3 cells were affected by SPHK1 modulation, an analysis of mRNA 
expression levels of these two molecules in the same xenografts was performed using 
human specific primers. With regards to MCP-1, a significant decrease in mRNA expression 
was observed in mice treated with SKi-II upon comparison with respective controls 
(Fig.4.13a). No effect was apparent on IL-6 expression following treatment with SKi-II 
(Fig.4.13b).  
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Figure 4.12: Effect of human recombinant IL-6 on SPHK1 and AKT in PC-3 cells. PC-3 cells were 
seeded in a 6-well plate under serum-free media 24 hours before the addition of IL-6 at a final 
concentration of 100ng/μl for the indicated duration. a) SPHK1 expression and b) SPHK1 activity 
were determined in PC-3 cell lysates containing equal amounts of mRNA or protein using qRT-
PCR and radiolabelling respectively. For qRT-PCR, SPHK1 mRNA expression levels were 
normalised using three housekeeping genes, GAPDH, YWHAZ and UBC. c) AKT phosphorylation 
and total levels were determined by western blotting. Data shown is mean ± SEM of a) three b) 
one and c) two independent experiments. Statistical analysis was performed using student’s t-
test relative to each individual time point, a) ns p>0.05, *p<0.05 for PC-3 vs. PC-3+IL-6. 
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Figure 4.13: Effect of SKi-II on MCP-1 and IL-6 expression in PC-3 xenograft model. 
1x106 PC-3 cells tagged with GFP were subcutaneously injected into nude mice, and left 
to grow for ten days before the addition of SKi-II (50mg/ml), every three days for a total 
of four treatments (chapter 3, fig. 3.7). DMSO was used as a control. Tumours  were  
collected and volumes were measured using calipers. a) MCP-1 expression and b) IL-6 
expression were determined by qRT-PCR of RNA extracted from each tumour sample, 
and expression levels were normalised using three housekeeping genes, GAPDH, 
YWHAZ and UBC. Data shown is the normalised relative quantification (NRQ) of each 
sample. Student’s t-test was used to determine statistical significance for SKi-II treated 
vs. control xenografts; ns p>0.05, *p<0.05. 
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As both MCP-1 and IL-6 levels in the media were up-regulated during the co-culture 
of PC-3 and U937 cells, it was of interest to evaluate their ability to regulate one another. As 
seen in figure 4.14a, the addition of rhMCP-1 to PC-3 led to an approximate 1.5- and 1.8-fold 
increase in IL-6 mRNA expression levels after three and eight hours respectively (Fig.4.14a). 
This effect is not mediated by SPHK1 as siRNA-mediated knockdown did not affect the MCP-
1-induced increase in IL-6mRNA, at any of the studied time points (Fig.4.14a). The addition 
of rhIL-6 to PC-3 proved to have a positive impact on MCP-1 expression, as characterised by 
an approximate 1.8-fold increase after three hours of treatment (Fig.4.14b). This effect was 
deemed transient as after eight and 24 hours there was no significant increase in IL-6 mRNA. 
As previously observed in SPHK1 siRNA transfected PC-3 cells, the IL-6-induced effect on 
MCP-1 expression was not mediated by SPHK1 as no changes were observed in MCP-1 
expression after SPHK1 knockdown (Fig.4.14b).      
Initial results indicated that S1P is involved in SPHK1 regulation (Fig.4.6a), it was 
therefore important to evaluate its effect on MCP-1 and IL-6 expression. For this purpose PC-
3 cells were treated with S1P for different time points up to 24 hours. MCP-1 expression was 
increased by approximately 2-fold in S1P-treated PC-3 cells after one hour, whereas at three 
and 24 hours the increase observed was not significant (Fig.4.15a). In a similar manner to 
that observed for MCP-1 expression, S1P treatment of PC-3 cells led to an increase in IL-6 
expression after one and three hours. Indeed, there was an approximate 4-fold increase 
after one hour whilst at three hours the S1P-induced effect on IL-6 expression resulted in an 
approximate 2-fold increase (Fig.4.15b).     
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Figure 4.14: Effect of SPHK1 in the IL-6/MCP-1 axis in PC-3 cells. PC-3 cells were 
transfected with siRNA targeting SPHK1 (siSPHK1) or non-targeting control siRNA (siNT) 
for 24 hours before cells were washed with PBS and cultured in serum-free media for 24 
hours. a) MCP-1 (rhMCP-1) or b) IL-6  were then added at final concentration of 
100ng/μl for the indicated times. a) IL-6 expression and b) MCP-1 expression in PC-3 cell 
lysates was determined by qRT-PCR. Three housekeeping genes, GAPDH, YWHAZ and 
UBC were used to normalise. Data shown is mean ± SEM of three independent 
experiments. Statistical analysis was performed using student’s t-test relative to each 
individual time point, ns p>0.05, *p<0.05, **p<0.01 for a) siNT vs. siNT+MCP-1. 
siNT+MCP-1 vs. siSPHK1 +MCP-1 or b) siNT vs. siNT+IL-6 or siNT+IL-6 vs. siSPHK1 +IL-6.  
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Figure 4.15: Effect of S1P on MCP-1 and IL-6 expression in PC-3 cells. PC-3 cells were 
seeded in a 6-well plate under serum-free media 24 hours before the addition of S1P at 
a final concentration of 1μM for the indicated duration. a) MCP-1 expression and b) IL-6 
expression in PC-3 cell lysates was determined by qRT-PCR. Three housekeeping genes, 
GAPDH, YWHAZ and UBC were used for normalisation. Data shown is mean ± SEM of 
three independent experiments. Statistical analysis was performed using student’s t-
test relative to each individual time point, ns p>0.05, *p<0.05 for PC-3 vs. PC-3 + S1P. 
a) 
b) 
136
According to my results it is clear that IL-6 and MCP-1 are involved in PC-3–U937 cell 
interactions, also it appears that their regulation is affected by SPHK1 levels, however my 
data indicates that other factors may be involved in SPHK1 and Akt phosphorylation. 
Therefore, to study a broader range of signalling molecules that 1) could be involved in PC-3-
U937 interactions; or 2) are under SPHK1, and ERK1/2 regulation and therefore affecting the 
monocytic response, a proteome profiler assay was performed using media from PC-3 cells 
transfected with a non-targeting siRNA (siNT). SPHK1 down-regulation was validated by qRT-
PCR and a 70% decrease in SPHK1 mRNA levels was observed when compared with PC-3 
cells transfected with a non-targeting control siRNA (Fig.4.16ai). For ERK1/2 a clear decrease 
in ERK1/2 protein levels upon knockdown was observed by western blotting (Fig.4.16aii). 
The supernatant from each condition was then individually incubated with a pre-probed 
membrane containing 36 different targets for soluble molecules such as cytokines, 
chemokines and growth factors. Each membrane contains three reference spots 
(Fig.4.16aiii) in order to normalise each spot intensity to its own membrane. As the 
reference spot only indicates Streptavidin-HRP intensity for each membrane a further 
normalisation was made with the total protein levels of each transfected PC-3 cells. 
Therefore the quantification showed in figure 4.16aiv is corrected for the variations in cell 
number caused by the effects of the different siRNA on PC-3 cells. The assay indicated that 
growth regulatory hormone alpha (GROα) and granulocyte macrophage colony-stimulating 
factor (GM-CSF) secretion were affected by SPHK1, as its knockdown decreased secretion of 
both of these molecules (Fig.4.16iii and iv). As this assay was only performed once, further 
analysis is necessary to validate these results and confirm their role in tumour-monocyte 
interactions. Other target molecules were detected in this assay; however their secretion 
patterns were not affected by any of the siRNAs, indicating that they were not regulated by 
SPHK1 or ERK1 (Fig.4.17ai-ii) Nonetheless, their possible roles in myeloid and tumour cell 
regulation should not be disregarded.   
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Figure 4.16: Proteome Profiler Assay: targets regulated by SPHK1 and ERK1/2. PC-3 cells were 
transfected with siRNA targeting SPHK1 (siSPHK1), ERK1/2 (siERK1/2) or non-targeting control 
siRNA (siNT) for 48 hours. PC-3 cell lysates were collected for a) mRNA, b) western blotting and c) 
proteome profiler assay. a) SPHK1 expression was determined by qRT-PCR where three 
housekeeping genes, GAPDH, YWHAZ and UBC were used for normalisation. b) ERK1/2 total levels 
were determined by western blotting, with tubulin used as a loading control. c) Media was 
collected and centrifuged in order to remove non-adherent cells. Each media was incubated 
individually with a pre-probed membrane. Signal intensity for each of the 36 molecules on the 
membrane was measured using Image J software and the average intensity from the duplicate 
samples calculated. The results obtained for selected molecules are presented graphically and 
were normalised to the protein content; data is representative of a single experiment.  
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i) 
siSPHK1 
siNT 
siERK1/2 
Higher exposure 
7 8 9 10 
11 
7 8 9 10 
11 
7 8 9 10 
11 
Lower exposure 
1 2 
3 
4 
5 
6 
1 2 
3 
4 
5 
6 
1 2 
3 
4 
5 
6 
Position Target 
Abbreviation/ 
Alternative 
nomenclature 
1, 2, 3 Reference Spot 
4 Interleukin-8 IL-8 
5 Macrophage migratory inhibitory factor MIF-1/GIF/DER6 
6 Plasminogen activator inhibitor-1 PAI-1/SERPIN E1 
7 CD40 Ligand CD154 
8 Growth regulated oncogene-alpha GROα/CXCL1 
9 Granulocyte-macrophage colony-
stimulating factor 
GM-CSF/ 
CSFa/CSF-2 
10 Soluble Intracellular adhesion molecule 1 siCAM-1/CD54 
11 Interleukin-23 IL-23 
ii) 
Figure 4.17a: Proteome Profiler Assay: identified targets. a) PC-3 cells were transfected with 
siRNA targeting SPHK1 (siSPHK1), ERK1/2 (siERK1/2) or non-targeting control siRNA (siNT) for 
48 hours. Media was collected and centrifuged in order to remove non-adherent cells. Each 
media was incubated individually with a pre-probed membrane. This figure represents 
different exposures with respect to figure 4.16a. b) The table shows the identified targets, 
and corresponding alternative nomenclature.  
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Figure 4.17b: Proteome Profiler Assay: Graphical analysis of unmodified targets. The results 
obtained in figure 4.17 are presented graphically and were normalised to the protein content. 
Data is representative of a single experiment.  
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4.7 Discussion  
 
The increase in SPHK1 enzymatic activity and expression in PC-3 cells (Fig.4.1a and b) 
when co-cultured with U937s in a transwell model, supports the concept of tumour-immune 
cell interactions through signalling molecules that lead to an alteration of gene regulation. 
Indeed, SPHK1 activity seems to be continuously induced by the presence of U937 cells 
(Fig.4.1a). Rather than a consequence of an increase in SPHK1 mRNA, it is proposed that the 
initial increase in activity could also result from the presence of a strong activator, possibly 
secreted by monocytes, that is capable of inducing SPHK1 phosphorylation and activation. It 
is known that SPHK1 has intrinsic activity which can be further increased by several 
membrane receptors or signalling molecules. Billich et al showed that TNF-alpha and IL-
1beta induced SPHK1 activation after only ten minutes in A549 epithelial lung carcinoma 
cells. However, no corresponding increase was found in mRNA levels even after 2.5 hours, 
suggesting that the observed increase in activity most likely resulted from a post-
translational or post-transcriptional modification [326]. Conversely, in the transwell model 
described in this study, an increase in SPHK1 mRNA levels is evident at the earliest timepoint 
tested (one hour), suggesting that transcriptional activation could also be related to 
increased SPHK1 activity. In accordance, PMA was shown to rapidly induce SPHK1 activation 
and later increase corresponding mRNA levels in a leukemic cell line [184]. A biphasic 
activation of SPHK1 is documented in the literature [190, 405] and could explain the later 24 
hour increase in SPHK1 mRNA observed using the transwell model (Fig.4.1b). The same 
interpretation could be inferred from the findings that in both PC-3 cells co-cultured with 
THP-1 (Fig.4.4) and MDA-231 co-cultured with U937 cells (Fig.4.5) there is an early activation 
in SPHK1 activity followed by a later increase in mRNA expression levels. Nonetheless, it is 
important to note that SPHK1 activation and expression may not be regulated by the same 
soluble signalling molecules during co-culture; with this being a dynamic interaction 
between the two cell types it is reasonable to assume that the media content changes over 
time. The significance of the inferences from co-culture experiments using THP-1 (Fig.4.4) 
and MDA-231 (Fig.4.5) cells could be established by increasing the number of experimental 
repeats. 
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Mechanistically, both Akt and ERK1/2 appear to play a role in this interaction. AKT 
phosphorylation in PC-3 cells was highly increased by the presence of U937 (Fig.4.2a) and 
THP-1 cells (Fig.4.4c); this activation in PC-3 cells correlated with increased SPHK1 activity 
and expression (Fig.4.1 and Fig.4.4), suggesting a possible cross-regulation between Akt and 
SPHK1. Indeed, this was further supported by the finding that U937-induced Akt 
phosphorylation was abrogated in PC-3 transfected with SPHK1 siRNA (Fig.4.2c), indicating 
that Akt is under the regulatory control of SPHK1 independent of the presence of U937 cells. 
This regulation appears most likely to be post-translational, as the total Akt levels were not 
affected by SPHK1 siRNA. This specific effect on Akt phosphorylation was also reported by 
another group using either chemical inhibition or siRNA mediated knock-down of SPHK1 in 
PC-3 cells (Cho, Lee et al. 2011). Likewise, in glioblastoma and ovarian cancer cells SPHK1 
inhibition reduced Akt phosphorylation whilst concurrently inhibiting tumour growth [352, 
353], reinforcing the concept that Akt is a downstream target of SPHK1 and its inhibition is 
strongly correlated with anti-proliferative effects in cancer cells. In this study I showed for 
the first time that U937 cells-induced Akt phosphorylation in PC-3 cells is dependent upon 
SPHK1 activation in the latter cells, implying that SPHK1 inhibition is required to block 
monocyte-induced activation of this important signalling pathway. The precise mechanisms 
underlying this phenomenon remain unclear; indeed, a direct interaction between SPHK1 
and Akt, leading to AKT phosphorylation, or a regulation of Akt by molecules that are under 
SPHK1 regulatory control are both plausible and require further elucidation. In this regard, a 
recent study proposed a model whereby activation of Akt2, but not Akt1 or Akt3, was shown 
to induce S1P formation via SPHK1 transcriptional regulation; S1P extracellular binding to its 
receptor would then create a positive feed-back loop through PI3K/Akt2/mTOR [406]. 
However, the authors failed to prove that S1P levels were being elevated by SPHK1 
activation or that S1P was indeed activating Akt2; nonetheless this report comes in support 
of another report identifying Akt2 as a positive regulator of SPHK1 [187]. In fact the 
regulatory effect of Akt2, but not Akt1, on SPHK1 could explain why in this study Akt1 siRNA 
transfected PC-3 cells did not show any significant reduction in SPHK1 expression (Fig.4.3a). 
 In addition, my results show that the addition of S1P to PC-3 cells leads to SPHK1 
transcriptional activation as well as Akt phosphorylation (Fig.4.6). Interestingly, Akt 
phosphorylation is preceded by an increase in SPHK1 mRNA, suggesting that this event may 
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be a prerequisite for Akt phosphorylation and raising the hypothesis that S1P could be 
involved in Akt activation. Unfortunately, it was not possible to verify S1P levels during co-
culture and therefore assert with a higher degree of confidence that S1P was indeed 
required for Akt activation upon monocyte stimulation. S1P levels are usually increased in 
response to an increase in SPHK1 expression, and whilst I could not verify this in my system, 
this hypothesis provides a possible explanation for the simultaneous up-regulation of SPHK1 
(mRNA and activity) and AKT phosphorylation during co-culture.   
As mentioned initially, the MAPK pathway, more specifically ERK1/2, was also 
hypothesised as a possible regulator for SPHK1 due to its well documented ability to 
phosphorylate and activate this kinase [182]. ERK1/2 knockdown by siRNA abrogated the 
U937-induced increase of SPHK1 expression (Fig.4.3ai-iii) suggesting an important role for 
ERK1/2 in SPHK1 activation. In PC-3 cells ERK1/2 phosphorylation could not be detected and 
it was therefore not possible to assess if ERK1/2 phosphorylation was differentially regulated 
in PC-3 cells during co-culture. However in a breast cancer cell line, MDA-231, ERK1/2 
phosphorylation was clearly increased by the presence of U937 cells across all studied time 
points (Fig.4.5c). This effect was accompanied by an increase in SPHK1 activity (Fig.4.5a) at 
three hours and a later increase in SPHK1 mRNA expression levels after six hours of co-
culture (Fig.4.5b). It is therefore reasonable to hypothesise that in PC-3 cells ERK1/2 
phosphorylation could be involved in SPHK1 activation and could indeed act as an important 
regulator of molecules under SPHK1 regulatory control. In fact, an interesting observation 
arises from the finding that ERK1/2 knockdown regulates U937-induced Akt phosphorylation 
in PC-3 cells; this effect was observed after three and 24 hours of co-culture (Fig.4.3b). It is 
plausible that SPHK1 inhibition by siERK1/2 would block SPHK1 signalling and consequently 
Akt phosphorylation, as seen previously in this study (Fig.4.2c). It is also important to note 
that SPHK1 and ERK1/2 knockdown had no effect on U937-induced Akt phosphorylation in 
PC-3 cells after one hour of co-culture (Fig.4.3b), indicating an ability of U937 cells to 
regulate Akt independently of SPHK1 and ERK1/2 levels in PC-3 cells. To note that the 
significance these experiment (Fig.4.3b) could be established by increasing the number of 
experimental repeats as it was only performed once. 
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4.7.1 Candidate signalling molecules involved in PC-3/U937 co-culture: Effect on SPHK1 
and Akt phosphorylation  
 
In order to explore and interrogate any molecules that could be involved in the 
aforementioned pathways my first approach was to evaluate the cytokine levels of MCP-1, 
IL-6, TNF-α, IFN-γ and IL-10. These 4 cytokines and one chemokine were initially chosen to 
evaluate the pro-inflammatory and anti-inflammatory microenvironment present during co-
culture due to their role in modulating monocytes and macrophages into either pro- or anti-
inflammatory phenotypes. Surprisingly, TNF-α, IFN-γ and IL-10 were not detected in co-
culture assays presumably due to their low levels (data not shown). MCP-1 and IL-6 are 
cytokines well documented to be highly expressed in tumour and tumour stromal cells such 
as monocytes and macrophages [286, 291, 322]. My data supports the theory that MCP-1 
(Fig.4.7) and, to a lesser extent, IL-6 levels (Fig.4.10) are increased in tumour-monocyte 
interactions. In terms of MCP-1 this increase was observed at a transcriptional level 
(Fig.4.7c) and extracellular protein (Fig.4.7a), whilst SPHK1 RNA-interference reduced U937-
mediated up-regulation of MCP-1 expression (Fig.4.7d) and extracellular secretion (Fig.4.7b). 
In contrast, SPHK1 over-expression significantly increased MCP-1 expression (Fig.4.8ai) and 
secretion (Fig4.8aii); an effect that was accentuated by the presence of U937 cells 
(Fig.5.8aiii), and partially reduced by SPHK1 siRNA (Fig.4.8b). This data not only supports 
other studies indicating that MCP-1 was under the regulatory effect of SPHK1 but also 
indicates that the presence of monocytes can further stimulate its production. Indeed Sica et 
al. showed that macrophages can be recruited to the tumour site by MCP-1, and once 
resident within the tumour site they increase the secretion of MCP-1 [407]. Particularly in 
prostate cancer studies, MCP-1 was found to be four-fold higher in the tumour-bone 
microenvironment when compared to non-neoplastic bone [320] whilst MCP-1 can act as a 
direct mediator of prostate cancer cell growth, invasion and migration [323]. A more recent 
study has shown that MCP-1 production was inhibited in a SPHK1 deficient mouse model 
[293] whlist TNF-alpha induced MCP-1 expression was dependent upon SPHK1 activation 
([326]. In this study I show for the first time that in a PC-3/U937 co-culture model, MCP-1 
stimulation in PC-3 by U937 cells is partially dependent on SPHK1. In support, SKi-II treated 
mice carrying PC-3 xenografts showed lower levels of human MCP-1 mRNA when compared 
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with the control group (Fig.4.13a), an effect that was accompanied by a reduction in SPHK1 
expression in both mouse and human cells (Chapter 3, figure 3.7d-e).   
It is Important to note that MCP-1 failed to induce SPHK1 transcriptional activation 
(Fig.4.9a) as well as Akt phosphorylation in PC-3 cells (Fig.4.9b); indeed this latter event was 
unexpected as several other studies using the same cell line (PC-3) have indicated MCP-1 as 
a strong activator of Akt phosphorylation in a time and concentration-dependent manner 
[323, 408, 409].   
Interestingly, in my study S1P was found to induce MCP-1 expression in PC-3 cells 
(Fig.4.15a) which, together with an S1P-induced increase in SPHK1 expression and Akt 
phosphorylation (Fig.4.6) supports the concept that MCP-1 is being positively regulated by 
the activation of a signalling loop between SPHK1/S1P/Akt. In support of this theory, in 
human aortic endothelial cells and mast cells S1P was shown to increase MCP-1 mRNA and 
protein secretion levels via an SPHK1-dependent mechanism [324, 325]. It is reasonable to 
propose that increased MCP-1 levels during co-culture could result from an initial SPHK1 
activation triggered by other monocytic secreted molecules, or that MCP-1 could be 
produced directly by monocytes in response to tumour cells (Reviewed and discussed in 
Chapter 5, Figure 5.5). Indeed this latter explanation could also be implied from the fact that 
in PC-3 cells over-expressing SPHK1 no increase in either MCP-1 (Fig.4.8aiv) or SPHK1 mRNA 
(Fig.4.8av) levels was detected upon co-culture with U937 cells, despite the increase in MCP-
1 secreted protein (Fig.4.8aiii). 
With regards to IL-6, the increased levels in PC-3 media (Fig.4.10a) did not correlate 
with an increase in mRNA in these cells (Fig.4.10b). However, over-expression of SPHK1 in 
PC-3 cells increased levels of IL-6 mRNA and protein secretion (Fig.4.11a and b); an effect 
that was further increased (secreted protein only) by co-culture with U937 cells (Fig.4.11c 
and d). The lack of increase in IL-6 expression could be interpreted as SPHK1 having little 
effect on IL-6 expression, although I did see a 2.5-fold increase in PC-3/OFP-SPHK1 cells. The 
increase in SPHK1 during co-culture may not be significant enough to induce IL-6 expression, 
indicating that the observed increase in IL-6 in the media could result from U937 cells 
(described in chapter 5). Furthermore, it must be considered that IL-6 could be regulating 
SPHK1, as is supported by my findings whereby recombinant IL-6 induced SPHK1 activation 
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and increased its mRNA levels (Fig.4.12a-b). This finding is supported by a report stating that 
in multiple myeloma cells IL-6 was shown to induce SPHK1 activation and cell proliferation 
[294]. Further, Kun-Yun et al showed that IL-6 initially secreted from macrophages induces a 
later surge in IL-6 secretion in human colon cancer cells [402]. Due to its paracrine action, it 
is possible that in my co-culture system monocytes initially secrete IL-6 in response to PC-3 
cells during the early stages of co-culture and this leads to a subsequent later IL-6 secretion 
from PC-3 cells. Furthermore, IL-6 expression was also transiently induced by the addition of 
exogenous MCP-1 (Fig.4.14a) or S1P (Fig.4.15b) raising the hypothesis that during co-culture 
of PC-3 with U937 cells the dynamic balance of these factors, coupled with variations in their 
levels throughout time, could explain the activation of important signalling pathways such as 
Akt or SPHK1.   
The proteome screening assay was performed with the purpose of studying a wider 
range of cytokines or chemokines potentially secreted by PC-3 cells. I also sought to 
understand if these cytokines were regulated by SPHK1, ERK1/2 or Akt, and finally to 
determine whether they act in a paracrine and/or autocrine manner. siRNA-mediated SPHK1 
knockdown in PC-3 cells showed that granulocyte colony stimulating factor (GM-CSF) and 
growth regulated oncogene-alpha (GROα) were reduced in comparison with PC-3 
transfected with a non-targeting siRNA. To date, there are no reports associating SPHK1 with 
GM-CSF. GM-CSF is known to stimulate the production, survival and proliferation of myeloid 
cells such as macrophages [410]. As such, it emerges as an important regulator 
of myeloproliferative disorders and myeloid leukaemias, more specifically, in a mouse model 
GM-CSF was identified as being crucial for the maintenance of juvenile myelomonocytic 
leukemia [411]. An interesting report shows that GM-CSF not only led to an increase in cell 
growth, but also activated Akt phosphorylation in several lung cancer cells 
[412]. Furthermore, it showed that Akt up-regulation led to an increase in GM-CSF, 
indicating a possible autocrine function of GM-CSF through Akt. An autocrine function of 
GM-CSF has also been reported in human glioma cells [413] and malignant B-lymphocytes 
[414]. Other reports indicate that in the prostate cancer cell lines DU-145 and PC-3, GM-CSF 
increases cell proliferation [415, 416]. At present there are no reports associating SPHK1 
with GM-CSF, however in correlation with my data, GM-CSF could play a role in cell 
proliferation, with SPHK1 being an important mediator. It could also be involved in Akt 
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phosphorylation in PC-3 and in the modulation of the monocytic response towards PC-3 
cells. 
With respect to GROα, its regulation by SPHK1 is not currently described in the 
literature. However a role in cancer has been reported; Reiland J. et al showed that PC-3 
cells increased their invasiveness by two-fold in response to GROα [417]. In support, more 
recent work has shown that GROα-induced increased in PC-3 and DU-145 cell proliferation 
was mediated by Akt [418]. An immunohistochemistry study on primary colorectal 
specimens showed a strong correlation between GROα expression and tumour size, lymph 
node metastasis and patient survival [419].  GROα is expressed by endothelial, epithelial, 
fibroblast and myeloid cells such as monocytes and macrophages and it is reported that in 
inflammatory sites its expression is significantly raised. A potential autocrine and paracrine 
role for GROα in my system remains to be elucidated; however, evidence suggests that its 
role in the tumour-monocyte interaction may be a worthwhile avenue of 
investigation. Other target molecules were detected in this assay (Fig.5.17), however their 
patterns of secretion were not affected by any of the siRNAs employed, indicating that they 
were not regulated by SPHK1 or ERK1. Nonetheless their potential roles in myeloid and 
tumour cell regulation should not be excluded and should be further validated by increasing 
the number of experimental repeats (proteome profiler assay). 
In summary, I show for the first time that in both prostate cancer cells (PC-3) and 
breast cancer cells (MDA-231) SPHK1 expression and activity is regulated by monocytes. This 
appears to be part of a highly dynamic process, whereby the constant exchange of signals 
dictates a molecule’s importance and regulation over time. I have shown that SPHK1 plays a 
central role in MCP-1, but not in IL-6 regulation. In fact conversely, IL-6 was proven to 
regulate SPHK1 at the protein and mRNA level, a phenomenon that was not observed for 
MCP-1. Evidence indicates that MCP-1 and IL-6 play an important role in these interactions 
as well as cross-regulation of one another, however the specifics of their roles and the co-
ordination of the timing of their actions is not yet fully understood. Akt has been shown to 
be positively affected by U937 cell stimulus; however this effect was blocked by SPHK1 
inhibition. The increase in Akt phosphorylation could be due to S1P, as both MCP-1 and IL-6 
fail to induce its phosphorylation. As a consequence GROα and GM-CSF, both identified as 
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being under SPHK1 regulatory control, could be potential candidates as their ability to 
activate Akt has been previously documented. A schematic representation of the above 
findings, highlighting the dynamic interactions between PC-3 and U937 cells as well as the 
role of SPHK1/S1P in this interaction is shown in figure 4.18a-b. 
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Figure 4.18a: Proposed model for SPHK1 activation in PC-3 during their co-culture with U937 
cells. 1) The secretion of unknown molecules by U937 cells leads to the activation of SPHK1 at 
mRNA levels and enzymatic activity and AKT phosphorylation. 2) SPHK1 is most likely to produce 
S1P that can itself lead to the increase of AKT phosphorylation as well as transcriptional 
activation of several genes, including SPHK1, IL-6 and MCP-1. 3) Monocytes induce IL-6 secretion 
whilst mRNA expression levels are not affected. Extracellular IL-6 can induce an increase in 
SPHK1 and MCP-1 mRNA expression levels as well as acting in an autocrine manner to promote 
its own expression. No effect on AKT phosphorylation. SPHK1 over-expression induces IL-6 
mRNA. 4) MCP-1 mRNA and secreted levels are up-regulated during co-culture with U937 cells, 
where secreted MCP-1 can induce IL-6 transcriptional activation but has no effect on SPHK1 or 
AKT phosphorylation. SPHK1 over-expression leads to an increase in MCP-1 mRNA expression. 
The sequence of events may not reproduce the real dynamics existing between PC-3 and U937 
cells as some of the represented events may occur simultaneously.  
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Figure 4.18b: Proposed model for intracellular pathways involved in SPHK1 regulation in PC-3 
cells during their co-culture with U937 cells. 1) SPHK1 knockdown by siRNA inhibits U937-
induced AKT phosphorylation. A decrease in SPHK1 levels would lead to a decrease in S1P 
production, which in turn affect AKT phosphorylation. MCP-1 expression and secreted levels are 
also reduced by SPHK1 down-regulation. Similarly, in PC-3 cells over-expressing SPHK1, the use of 
siRNA targeting SPHK1 reduces MCP-1 secreted levels. IL-6 mRNA or secreted protein was not 
affected by SPHK1 knockdown. 2) The use of siRNA targeting AKT1 did not have an effect on 
SPHK1 expression; a possible regulatory mechanism could involve AKT2 or AKT3 instead of AKT1. 
3) ERK1/2 knockdown abrogated the positive effect of U937 in SPHK1 mRNA expression, it also 
reduced AKT phosphorylation suggesting a possible regulatory mechanism of AKT via ERK1/2 and 
SPHK1. 4) SPHK1 or ERK1/2 knockdown decreases the extracellular levels of GRO and GM-CSF, 
two possible mediators involved in the PC-3/U937 interaction. 
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5. SPHK1 regulation in U937 cells upon co-culture with PC-3 cells: Role 
of AKT, ERK1/2 and cytokines/chemokines. 
 
5.1 Introduction 
 
The capacity of tumours to influence their surroundings has been widely reported 
[244, 420, 421]. Their ability to attract different cell types to their “neighbourhood” and alter 
the transcriptional response in these cells is identified as a very important event in tumour 
development. Monocytes and macrophages are well described in literature as one of the 
main components of tumour stoma and their presence is associated with tumour 
progression and aggressiveness [247, 389, 407]. Their interaction with cancer cells is thought 
to be a bidirectional dynamic process, in which signalling molecules such as cytokines and 
chemokines play an important role [390, 422]. In this context, the involvement of SPHK1 in 
cytokine production has been described. In microglia cells (brain resident macrophages) 
SPHK1 was found to regulate the expression of pro-inflammatory cytokines such as TNF-α 
and IL-1β. Interestingly, S1P added to these cells also induced the expression of these 
cytokines indicating an active role of SPHK1 and S1P in cytokine regulation [270]. Another 
study indicated that S1P secreted from cancer cells provoked the induction of Akt and 
ERK1/2 in macrophages [254], suggesting an important role of the SPHK1/S1P pathway in 
the macrophage response and in the activation of important associated signal transduction 
pathways. Here I aim to investigate whether SPHK1 regulation in monocytes is affected by 
PC-3 cells, and if by modulating SPHK1 in PC-3 cells this response is altered. Finally, I aim to 
uncover the molecular mechanisms and possible mediators behind SPHK1 activation in 
monocytes during co-culture with PC-3 cells.  
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5.2 SPHK1 regulation in U937 during co-culture with PC-3 cells 
 
Using the same co-culture model as described previously (Section 2.2.3), PC-3 
prostate cancer cells and the U937 monocytic cell line were co-cultured for up to 24 hours, 
followed by determination of SPHK1 levels in U937 cells. The presence of PC-3 cells induced 
a consistent increase in SPHK1 enzymatic activity in U937 cells, being significant at one, 
three and 24 hours (Fig.5.1a). SPHK1 activity was increased by 50% and 100% at one and 
three hours respectively, and by approximately 100% at 24 hours when U937 cells were co-
cultured with PC-3 cells. As for SPHK1 transcriptional regulation (Fig.5.1b), there was an 
initial increase in expression of approximately 1.2- and 2-fold at one and three hours 
respectively, and a later 1.5-fold increase at 24 hours when in co-culture with PC-3 cells. 
Despite a non-significant increase in SPHK1 enzymatic activity at five and eight hours 
induced by PC-3 cells (Fig.5.1a), this effect was not correlated with an alteration of SPHK1 
mRNA at the respective time points (Fig.5.1b). 
 
Following on from the previous experiment, it was important to evaluate whether 
the SPHK1 knockdown in PC-3 cells had any influence on SPHK1 regulation in U937 cells. The 
U937 cells co-cultured with PC-3 cells transiently transfected with SPHK1 siRNA (siSPHK1) 
showed a lower SPHK1 enzymatic activity in comparison to those co-cultured with a non-
targeting siRNA (siNT) (Fig.5.2). This effect was higher at one and three hours with a 
decrease of approximately 60%, followed by an approximate 30% decrease after 24 hours of 
co-culture (Fig.5.2). 
In terms of SPHK1 transcriptional activation in U937 cells, it was observed that the 
PC-3-induced increase in SPHK1 mRNA expression in U937 cells was reduced when SPHK1 
was knocked down in PC-3 cells (Fig.5.2b). In comparison with U937 cells co-cultured with 
siNT PC-3 cells, there was a reduction of 30%, 35% and 37% in SPHK1 expression at one, 
three and 24 hours respectively. In summary, the positive effect of PC-3 cells co-culture 
upon SPHK1 in U937 cells was entirely abolished when SPHK1 was knocked down in PC-3 
cells. 
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a) 
b) 
Figure 5.1: SPHK1 activity and expression levels in human U937 cells following their co-culture 
with PC-3 cells. PC-3 cells were seeded in the bottom chamber under serum-free media 24 
hours before the addition of U937 cells to the upper chamber for the indicated duration. a) 
SPHK1 activity and b) expression were determined in U937 cell lysates containing equal 
amounts of protein or mRNA using radiolabelling and qRT-PCR respectively. For qRT-PCR, SPHK1 
mRNA expression levels were normalised using three housekeeping genes, GAPDH, YWHAZ and 
UBC. Data shown is the mean ± SEM of three independent experiments performed in duplicate. 
Statistical analysis was performed using student’s t-test relative to each individual time point. ns 
p>0.05, *p<0.05, **p<0.01, for U937 vs. U937+PC-3.  
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Figure 5.2: SPHK1 activity and expression levels in human U937 cells following co-culture with 
PC-3 cells treated with RNAi. PC-3 cells were transfected with siRNA targeting SPHK1 (siSPHK1) 
or non-targeting control siRNA (siNT) for 24 hours before cells were washed with PBS and 
cultured in serum-free media for 24 hours. U937 cells were then added to the upper chamber 
and left incubating for the indicated duration. a) SPHK1 activity and b) expression were 
determined in U937 cell lysates containing equal amounts of protein or mRNA respectively using 
radiolabelling and qRT-PCR respectively. For qRT-PCR, SPHK1 mRNA expression levels were 
normalised using three housekeeping genes, GAPDH, YWHAZ and UBC. Data shown is the mean ± 
SEM of a) two or b) three independent experiments. Statistical analysis was performed using 
student’s t-test relative to each individual time point. ns p>0.05 for U937+ PC-3siNT vs. U937 + 
PC-3 siSPHK1 
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5.3 Signal transduction pathways in U937 cells during co-culture with PC-3 cells 
 
In order to elucidate the molecular mechanisms by which SPHK1 is regulated in U937 
cells during the presence of PC-3 cells, a western blotting assay was performed in U937 cells 
following co-culture with PC-3 cells, as described previously. As shown in figure 5.3a, there is 
an increase in Akt, ERK1/2 and NF-KB phosphorylation upon stimulation with PC-3 cells 
across all of the indicated time points. The 3-fold increase in Akt phosphorylation is 
significant at three and 24 hours (Fig.5.3bi). ERK1/2 phosphorylation levels significantly 
increase by 7- and 3-fold at three and 24 hours respectively, when compared with U937 cells 
cultured in the absence of PC-3 cells (Fig.5.3bii). The presence of PC-3 cells also had a 
positive impact on p65 phosphorylation (a subunit of NF-KB) in U937 cells (Fig.5.3biii); 
however the significance of this finding proved difficult to determine due to technical 
constraints.   
 
To further investigate the impact of SPHK1 absence on PC-3 cells, and the subsequent 
influence on the identified regulators of important signalling pathways in U937 cells, PC-3 
cells were transiently transfected with siRNA for SPHK1 and a non-targeting siRNA as a 
control, prior to co-culture with U937 cells for three or 24 hours (Fig.5.4a). Interestingly, Akt 
and NF-KB phosphorylation in U937 cells was affected in a similar way to that observed 
following SPHK1 knockdown in PC-3 cells, with a small reduction observed at three hours 
and a more accentuated effect seen at 24 hours (Fig.5.4ai-ii and bi). ERK1/2 phosphorylation 
was also affected by SPHK1 down-regulation in PC-3 cells (Fig.5.4ai); in this case the 
decrease in ERK1/2 phosphorylation at three hours was more accentuated than with Akt or 
NF-KB phosphorylation levels (Fig.5.4ai and b). Furthermore, this decrease in EKR1/2 
phosphorylation was also observed at 24 hours, with a 4-fold decrease in comparison with 
U937 co-cultured with a non-targeting siRNA (Fig.5.4ii).  
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Figure 5.3: Changes in U937 cells signal transduction pathways during co-culture with PC-3 
cells. PC-3 cells were seeded in the bottom chamber under starvation 24 hours before the 
addition of U937 cells to the upper chamber and co-cultured for the indicated duration. a) AKT, 
ERK1/2 and NF-KB phosphorylation and total levels were determined by western blotting, b) 
quantified by Image J software and normalised to GAPDH. Data shown is the mean ± SEM of 
three independent experiments with the exception of NF-kB phosphorylation levels that were 
only detected in two independent experiments. Statistical analysis was performed using 
student’s t-test relative to each individual time point. ns p>0.05, *p<0.05, **p<0.01, for U937 vs. 
U937+PC-3.  
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Figure 5.4: Changes in U937 cells signal transduction pathways during co-culture with siRNA-
SPHK1 treated PC-3 cells. PC-3 cells were transfected with siRNA targeting SPHK1 (siSPHK1), 
non-targeting control siRNA (siNT) or transfection reagent (TR) for 24 hours before cells were 
washed with PBS and cultured in serum-free media for 24 hours. U937 cells were then added to 
the upper chamber and left incubating for the indicated duration. a) AKT, ERK1/2 and NF-KB 
phosphorylation and total levels were determined by western blotting, b) quantified by Image J 
software and normalised to alpha-tubulin. Data shown is the representative of two independent 
experiments, with the exception of NF-kB phosphorylation levels that were only detected in one 
independent experiment.  
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Findings from these initial experiments led me to conclude that not only was it 
important to evaluate the role of SPHK1 in this interaction, but just as important was to 
determine how Akt and ERK1/2 activation in PC-3 cells are important for SPHK1 activation in 
U937 cells. For this purpose PC-3 cells were transiently transfected with Akt and ERK1/2 
siRNA separately (chapter 4, Fig.4.3b), before being added to U937 cells for the indicated 
time points. This transient transfection in PC-3 cells proved to impact on SPHK1 mRNA, with 
Akt and ERK1/2 knockdown inducing a similar response upon SPHK1 transcriptional 
regulation in U937 cells (Fig.5.5a). Following one hour of co-culture SPHK1 expression was 
increased by the presence of PC-3 cells and was not affected by the absence of Akt or 
ERK1/2 in PC-3 cells. However, after three and 24 hours of co-culture, SPHK1 expression in 
U937 cells was reduced when PC-3 Akt and ERK1/2 levels were decreased by siRNA-
mediated knockdown in comparison with U937 cells co-cultured with PC-3 treated with non-
targeting siRNA (Fig.5.5a).   
Using the previous experimental design as a basis, I sought to investigate if ERK1/2 or 
Akt knockdown in PC-3 cells would affect the phosphorylation levels of these molecules in 
monocytes. Western blotting was performed on U937 cell lysates following three hours of 
co-culture with PC-3 cells transfected with siRNA targeting SPHK1, Akt or ERK1/2. As shown 
in figure 5.5b, the initial increase in Akt phosphorylation induced by co-culture with PC-3 
cells transfected with a non-targeting siRNA, was reduced when Akt or ERK1/2 were 
targeted in PC-3 cells. A similar effect was observed when ERK1/2 was targeted in PC-3 cells; 
the expected positive effect of these cells on ERK1/2 phosphorylation, with a 3.2-fold 
increase compared to U937 cells alone, was reduced to 1.6- and 0.7-fold when PC-3 cells 
were transfected with siRNA targeting Akt and ERK1/2 respectively (Fig.5.5b).    
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a) 
b) 
Figure 5.5: Changes in SPHK1 and signal transduction pathways in U937 cells following co-
culture with PC-3 cells targeted with several siRNAs. PC-3 cells were transfected with siRNA 
targeting SPHK1(siSPHK1), AKT (siAKT), ERK1/2 (siERK1/2) or non-targeting control siRNA (siNT) 
for 24 hours before cells were washed with PBS and cultured in serum-free media for 24 hours. 
U937 cells were then added to the upper chamber and left incubating for the indicated duration. 
a) SPHK1 expression in U937 cell lysates was determined by qRT-PCR. Three housekeeping genes, 
GAPDH, YWHAZ and UBC were used to normalise SPHK1 expression. b) AKT and ERK1/2 
phosphorylation and total levels were determined by western blotting, quantified by Image J 
software and normalised to alpha-tubulin, values under the immunoblot represent the 
normalised fold difference to U937 cells cultured alone. Data shown is representative of a) two 
and b) one independent experiment. 
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5.4 Effect of PC-3 cells on SPHK1 levels in THP-1 monocytic cell line 
 
During co-culture the presence of THP-1 cells was shown to induce a modest increase 
in proliferation of neighbouring PC-3 cells (chapter 3, Fig.3.4). Based upon this observation, 
and with the supporting knowledge that SPHK1 activation in cancer cells is associated with 
cell proliferation, I decided to investigate whether SPHK1 was being activated in THP-1 cells 
upon co-culture with PC-3. For this purpose THP-1 cells were co-cultured with PC-3 cells in 
similar conditions as described previously for U937 cells. SPHK1 enzymatic activity was found 
to be increased in THP-1 cells after one hour of PC-3 cell co-culture (Fig.5.6a). This positive 
effect on SPHK1 activity was deemed transient as after three hours of co-culture no variation 
in activity was observed when compared to THP-1 cells cultured alone. Nonetheless, SPHK1 
biphasic activation appears to occur; this is shown by the later increase in SPHK1 activity 
when THP-1 were in the presence of PC-3 cells, an effect that is not observed when THP-1 
cells were cultured alone (Fig.5.6a).  
SPHK1 mRNA expression levels were also measured in THP-1 cells following their co-
culture with PC-3 cells (Fig.5.6b). After one and three hours of co-culture there were no 
observed differences in SPHK1 expression when THP-1 were cultured alone or co-cultured 
with PC-3 cells. However, after 24 hours of co-culture, the presence of PC-3 cells induced an 
approximate 1.5-fold increase in SPHK1 mRNA in THP-1 cells.     
To evaluate whether the molecular mechanisms underpinning the THP-1-induced 
effects in PC-3 cells were similar to those identified for U937 cells, it was important to 
determine if intracellular signalling pathways such as NF-KB, Akt or ERK1/2 were also being 
activated in THP-1 upon co-culture with PC-3 cells. Contrary to U937 cells (Fig.5.3a), co-
culture of THP-1 with PC-3 did not result in an increase of NF-KB, Akt or ERK1/2 
phosphorylation (Fig.5.6c). In fact, the presence of PC-3 cells induced a decrease in the 
phosphorylation levels of these molecules across all analysed time points (Fig.5.6c) 
 
.   
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a) 
b) 
c) 
Figure 5.6: SPHK1 activity and expression levels in human THP-1 cells following co-culture with PC-
3 cells. PC-3 cells were seeded in the bottom chamber under serum-free media 24 hours before the 
addition of THP-1 cells to the upper chamber for the indicated duration. a) SPHK1 activity and b) 
expression were determined in THP-1 cell lysates containing equal amounts of protein and mRNA 
respectively using radiolabelling and qRT-PCR respectively. For qRT-PCR, SPHK1 mRNA expression 
levels were normalised using three housekeeping genes, GAPDH, YWHAZ and UBC. c) NF-kB, AKT and 
ERK1/2 phosphorylation and total levels were determined by western blotting, quantified by Image J 
software and normalised to GAPDH. Data shown is a-b) mean ± SEM of two  independent 
experiments and c) representative  of one independent experiment. 
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5.5 Effect of MDA-231 breast cancer cells on SPHK1 levels in U937 monocytic cell 
line 
 
As observed with THP-1 cells inducing an increase in PC-3 cell proliferation, MDA-231 
cells were also more proliferative when in co-culture with U937. To evaluate whether SPHK1 
levels in U937 cells were affected in a similar way as to when in co-culture with PC-3 cells, a 
co-culture assay was performed with U937 cells and MDA-231 cells. As shown in figure 5.7a, 
the co-culture with MDA-231 induced a decrease in SPHK1 enzymatic activity in U937 cells 
after three hours. A further three hours later no difference in SPHK1 activity between U937 
cells cultured alone or co-cultured with MDA-231 was observed, whereas following 24 hours 
of co-culture MDA-231 were able to induce a modest increase in SPHK1 activity in U937 cells 
(Fig.5.7a). 
As with previous co-culture experiments, SPHK1 mRNA levels in U937 cells were also 
measured after being cultured alone or in the presence of MDA-231 cells. As shown in figure 
5.7b, MDA-231 induced a marginal decrease in SPHK1 mRNA levels of U937 cells across all 
studied time points, suggesting that the U937 cells-induced increase in MDA-231 
proliferation is not regulated by SPHK1 in U937 cells (Fig.5.7b).  
Next, it was important to analyse NF-KB, Akt and ERK1/2 phosphorylation levels in 
order to understand if phosphorylation events in these molecules were of a similar pattern 
to that observed for SPHK1. A western blotting analysis on U937 cell lysates revealed a MDA-
231-mediated increase of 1.4- and 1.5-fold in NF-KB and Akt phosphorylation levels 
respectively after three hours of co-culture (Fig.5.7c). This effect proved to be transient as 
following six and 24 hours of co-culture no differences in NF-KB and Akt phosphorylation 
levels were observed (Fig.5.7c). ERK1/2 phosphorylation was not altered at any of the 
studied time points.  
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Figure 5.7: SPHK1 activity and expression levels in human U937 cells following co-culture with 
MDA-231 cells. MDA-231 cells were seeded in the bottom chamber under serum-free media 24 
hours before the addition of U937 cells to the upper chamber for the indicated duration. a) SPHK1 
activity and b) expression were determined in U937 cell lysates containing equal amounts of protein 
and mRNA respectively using radiolabelling and qRT-PCR respectively. For qRT-PCR, SPHK1 mRNA 
expression levels were normalised using three housekeeping genes, GAPDH, YWHAZ and UBC. c) NF-
kB, AKT and ERK1/2 phosphorylation and total levels were determined by western blotting, 
quantified by Image J software and normalised to GAPDH. Data shown is representative of one 
independent experiment performed in duplicate (a-b). 
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5.6 Effect of conditioned media on U937 cells 
 
As shown previously, U937 and PC-3 cells are able to communicate though signalling 
molecules resulting in an activation of several intracellular pathways. To date, it remains 
unclear whether cancer cells act as the trigger to initiate the activation of these pathways or 
if the first stimulus is derived from a monocyte secreted molecule. In an attempt to further 
elucidate the roles of each cell type in the orchestration of the cross-talk, conditioned media 
from PC-3 cells cultured for 24 hours in starvation conditions was added to the bottom 
chamber of a transwell to mimic the presence of PC-3 cells. U937 cells were then added to 
the top chamber and allowed to incubate for the indicated time points (Fig.5.8a-b). As seen 
in figure 5.8a, SPHK1 mRNA expression levels in U937 cells were not altered by the presence 
of conditioned media when compared with serum-free co-culture alone. The presence of 
conditioned media negatively regulated Akt and ERK1/2 phosphorylation as in both cases a 
decrease in the phosphorylation levels of each in comparison with U937 cells cultured 
without conditioned media was observed (Fig.5.8b). These results indicate that the initial 
increase in SPHK1, Akt and ERK1/2 levels could result by an initial activation of PC-3 cells 
caused by U937 cells that, in turn, are activated by PC-3 cells in a secondary activation loop. 
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a) 
b) 
Figure 5.8: Effect of conditioned media on U937 cells. PC-3 cells were cultured for 24 hours 
under serum-free media. The conditioned media (CM) was collected and centrifuged to remove 
any PC-3 cells debris. CM was then added to the bottom chamber of the transwell and U937 cells 
were added to the top chamber and left incubating for the indicating time. a) SPHK1 expression 
in U937 cell lysates was determined by qRT-PCR. Three housekeeping genes, GAPDH, YWHAZ and 
UBC were used to normalise SPHK1 expression. b) AKT and ERK1/2 phosphorylation and total 
levels were determined by western blotting. Data shown is the a) mean of two and b) 
representative of one independent experiment. 
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5.7 The effect of S1P on U937 cells  
 
Previously, I hypothesised that an increase in SPHK1 would lead to the production 
and secretion of S1P that could act in a paracrine manner during co-culture. To understand if 
S1P could indeed be responsible for the activation of not only SPHK1 but also other 
important mediators such as Akt and ERK1/2, U937 cells were treated with exogenous S1P 
for the indicated times (Fig5.9). As shown in figure 5.9a, the addition of S1P led to an initial 
increase in SPHK1 enzymatic activity after three and six hours of treatment, followed by a 
decrease at 24 hours (Fig.5.9a). SPHK1 mRNA levels were also increased by S1P treatment; 
this effect was observed after 24 hours with an approximate 1.8-fold increase in comparison 
with non-treated U937 cells (Fig.5.9b).  
The addition of S1P to U937 cells also led to an increase in Akt phosphorylation with 
a constant activation throughout all the time points observed; this effect was most 
pronounced following one and 24 hours of S1P treatment (Fig.5.9c). In terms of ERK1/2 
phosphorylation, a similar constant activation was observed with the most accentuated 
differences observed at one and eight hours with a 1.4- and 2-fold increase respectively 
(Fig.5.9c).  
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Figure 5.9: Changes in SPHK1 and signal transduction pathways in U937 cells following S1P 
treamtent. a) U937 cells were seeded in a 6-well plate before the addition of S1P (1μM) for the 
indicated times. a) SPHK1 activity and b) SPHK1 expression were determined in U937 cell lysates 
containing equal amounts of protein or mRNA respectively using radiolabelling and qRT-PCR 
respectively. For qRT-PCR, SPHK1 mRNA expression levels were normalised using three 
housekeeping genes, GAPDH, YWHAZ and UBC. c) AKT and ERK1/2 phosphorylation and total levels 
were determined by western blotting in U937 cells, quantified by Image J software and normalised 
to GAPDH. Data shown is the representative of a), c) one and b) the ± SEM of two independent 
experiment performed in duplicate . 
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5.8 MCP-1 regulation in U937 cells during co-culture with PC-3cells 
 
With MCP-1 and IL-6 levels being increased in PC-3 cell media when co-cultured with 
U937 cells, it was important to evaluate their role in SPHK1 regulation and the activation of 
Akt and ERK1/2 in U937 cells. Interestingly, U937 MCP-1 expression is increased by the 
presence of PC-3 cells at three and 24 hours (Fig.5.10a). This increase is correlated to an 
increase in secreted MCP-1 levels in the media in which U937 cells were present (Fig.5.10b). 
ELISA analysis of U937 cell conditioned media showed a reduction in MCP-1 extracellular 
levels in comparison with U937 co-cultured with PC-3 transfected with a non-targeting 
siRNA, and abolished the effect of PC-3 cells when compared to U937 cells alone. (Fig.5.11a). 
However, this reduction was not accompanied by a reduction in MCP-1 expression in U937 
cells at any of the studied time points (Fig.5.11b). The effect of Akt and ERK1/2 knockdown 
in PC-3 also had an impact upon MCP-1 mRNA levels in U937 cells. Surprisingly, at one hour, 
MCP-1 expression was increased when these two molecules were subject to knockdown in 
PC-3 cells; however this effect was reversed at three hours where there is no increase in 
U937 cells cultured with PC-3 siAkt and a significant reduction in U937 cultured with PC-3 
siERK1/2 in comparison with U937 cultured with PC-3 siNT cells (Fig.5.11c).  
Previous results had shown that over-expression of SPHK1 led to an increase in MCP-
1 expression and secretion in PC-3 cells (chapter 4, Fig.4.7); therefore it was important to 
understand if this over-expression in PC-3 cells could have an impact on MCP-1 and SPHK1 
regulation in U937 cells during their co-culture. As described previously (chapter 4, Fig.4.8) 
PC-3 constitutively over-expressing SPHK1 (PC-3/OFP-SPHK1) and control vector (PC-3/OFP) 
were co-cultured with U937 cells for the indicated time points. U937 SPHK1 enzymatic 
activity showed an increase at 24 hours in response to both PC-3/OFP and PC-3/OFP-SPHK1 
(Fig5.12a). A similar effect was observed for SPHK1 mRNA, where no effect of altering the 
SPHK1 levels in PC-3 cells was detected (Fig.5.12b).  Similarly for MCP-1 expression, no 
difference was observed between PC-3/OFP and OFP-SPHK1 (Fig.5.13a). However, MCP-1 
levels in the media proximal to U937 cells were higher when these cells were co-cultured 
with PC-3/OFP-SPHK1 at three and 24 hours compared to PC-3/OFP. This effect was reduced 
when PC-3/OFP-SPHK1 were transfected with SPHK1 siRNA following three and 24 hours of 
co-culture, although the reduction did not prove to be statistically significant (Fig.5.13b).    
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a) 
b) 
Figure 5.10: MCP-1 regulation in U937 cells during co-culture. PC-3 cells were seeded in the 
bottom chamber for 24 hours under starvation before the addition of U937 cells to the upper 
chamber and co-cultured for the indicated duration. a) MCP-1 expression in U937 cell lysates 
was determined by qRT-PCR. Three housekeeping genes, GAPDH, YWHAZ and UBC were used to 
normalise MCP-1 expression. b) MCP-1 concentration in the media of the top compartment 
where U937 cells were present was determined by ELISA. Media were incubated with MCP-1 
specific antibodies and a standard curve was used to quantify the relative amount of MCP-1 in 
each sample. Protein concentration of each cell lysate was used for normalisation. Data shown 
is the mean ± SEM of  three independent experiments. Statistical analysis was performed using 
student’s t-test relative to each individual time point. ns p>0.05, *p<0.05, **p<0.01, for U937 
vs. U937+PC-3 
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a) 
b) 
c) 
Figure 5.11: MCP-1 regulation in U937 cells during co-culture with PC-3 treated with several 
targeting siRNAs. PC-3 cells were transfected with siRNA targeting SPHK1 (siSPHK1), AKT (siAKT), 
ERK1/2(siERK1/2) or non-targeting siRNA (siNT) for 24 hours before cells were washed with PBS 
and cultured in serum-free media for 24 hours. U937 cells were then added to the upper chamber 
and left incubating for the indicated duration. a) MCP-1 concentration in the media of the top 
compartment where U937 cells were present was determined by ELISA. Media were incubated 
with MCP-1 specific antibodies and a standard curve was used to quantify the relative amount of 
MCP-1 in each sample. Protein concentration of each cell lysate was used for normalisation. b-c) 
MCP-1 expression in U937 cell lysates was determined by qRT-PCR. Three housekeeping genes, 
GAPDH, YWHAZ and UBC were used to normalise MCP-1 expression. Data shown is the mean ± 
SEM of  a-b) three and c) one independent experiments performed in duplicate. Statistical analysis 
was performed using student’s t-test relative to each individual time point. ns p>0.05, *p<0.05, 
**p<0.01, for U937 vs. U937+siNTPC-3 or U937 + siCP-3 vs. U937 + siSPHK1 PC-3. 
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Figure 5.12: SPHK1 activity and expression levels in human U937 cells following co-culture 
with PC-3 cells over-expressing SPHK1. PC-3 cells over-expressing SPHK1 (PC-3/OFP-SPHK1) or 
empty phmKO2 vector (PC-3/OFP) were seeded in the bottom chamber for 24 hours under 
serum-free media before the addition of U937 cells to the upper chamber for the indicated 
duration. a) SPHK1 activity and b) expression were determined in U937 cell lysates containing 
equal amounts of protein or mRNA respectively using radiolabelling and qRT-PCR respectively. 
For qRT-PCR, SPHK1 mRNA expression levels were normalised using three housekeeping genes, 
GAPDH, YWHAZ and UBC. Data shown is the mean ± SEM of two independent experiments 
performed in duplicate.  
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Figure 5.13: MCP-1 expression and secretion in human U937 cells following co-culture with PC-3 
cells over-expressing SPHK1. a) PC-3 cells over-expressiong SPHK1 (PC-3/OFP-SPHK1) or empty 
phmKO2 vector (PC-3/OFP) were seeded in the bottom chamber under serum-free media 24 
hours before the addition of U937 cells to the upper chamber for the indicated duration. a) MCP-1 
expression in U937 cell lysates was determined by qRT-PCR. Three housekeeping genes, GAPDH, 
YWHAZ and UBC were used to normalise. b) PC-3/OFP-SPHK1 were transfected with siRNA 
targeting SPHK1 for 24 hours before cells were washed with PBS and cultured in serum-free media 
for 24 hours. U937 cells were then added to the upper chamber and left incubating for the 
indicated duration. In the other indicated co-culture (U937 + PC-3/OFP), cells were culture as 
described in (a) with the exception of the seeding that occurred 48 hours before the addition of 
U937 cells. MCP-1 concentration in the media of the top compartment where U937 cells were 
present was determined by ELISA. Media were incubated with MCP-1 specific antibodies and a 
standard curve was used to quantify the relative amount of MCP-1 in each sample. Protein 
concentration of each cell lysate was used for normalisation. Data shown is the mean ± SEM of a) 
two and b) three independent experiments performed in one single replicate. Statistical analysis 
was performed using student’s t-test relative to each individual time point. ns p>0.05, *p<0.05, 
**p<0.01, ***p<0.001 for U937 vs. U937+PC/OFP-3 or U937+PC-3/OFP vs. U937+PC-3/OFP-SPHK1 
or U937+PC-3/OFP-SPHK1 vs. U937+PC-3/OFP-SPHK1 (siSPHK1) . 
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With MCP-1 levels being increased during co-culture of U937 and PC-3 cells, it was 
natural to investigate the role of MCP-1 in SPHK1 regulation and activation of other 
signalling pathways, such as Akt and ERK1/2, in U937 cells. Human recombinant MCP-1 
(rhMCP-1) was added to U937 cells at a concentration of 100ng/ml, and resultant SPHK1 
enzymatic activity (Fig.5.14a) and transcriptional activation (Fig.5.14b) were measured at 
the indicated time points. rhMCP-1 induced a rapid increase in SPHK1 enzymatic activity 
until one hour; however this increase proved transient as no increase was observed at the 
later time points (Fig.5.14a). SPHK1 mRNA was increased by the addition of rhMCP-1 only 
after 24 hours (Fig.5.14b), suggesting a possible involvement of MCP-1 cascade signalling in 
SPHK1 transcriptional regulation. Furthermore, it was decided to investigate whether MCP-1 
was a key molecule in Akt and ERK1/2 phosphorylation in U937 cells. As seen in figure 5.14c, 
rhMCP-1 did not increase either Akt or ERK1/2 phosphorylation; in fact, there was a 
decrease at one and three hours, which was an unexpected finding. However as this 
experiment was performed only once, firm conclusions cannot be drawn from this 
preliminary data. 
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Figure 5.14: Effect of human recombinant MCP-1 on signal transduction pathways in U937 
cells. U937 cells were seeded in a 6-well plate before the addition of MCP-1 (100ng/μl) for the 
indicated times. a) SPHK1 activity and b) SPHK1 expression were determined in U937 cell lysates 
containing equal amounts of protein or mRNA respectively using radiolabelling and qRT-PCR 
respectively. For qRT-PCR, SPHK1 mRNA expression levels were normalised using three 
housekeeping genes, GAPDH, YWHAZ and UBC. c) AKT and ERK1/2 phosphorylation and total 
levels were determined by western blotting in U937 cells, quantified by Image J software and 
normalised to GAPDH. Data shown is the mean ± SEM of a-b) two and c) one independent 
experiment performed in duplicate . 
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5.9 IL-6 regulation in U937 cells during co-culture with PC-3 cells 
 
In order to understand the significance of the role of IL-6 in U937 cells during co-
culture with PC-3 cells a similar study to that designed for MCP-1 was performed. Firstly, IL-6 
expression and secretion levels were measured in U937 cells upon co-culture with PC-3 cells. 
As seen in figure 5.15a, IL-6 mRNA was increased in U937 cells when stimulated with PC-3 
cells; this effect was highest at one hour of co-culture. Analysis of IL-6 secretion in U937 cell 
supernatant showed an increase in IL-6 extracellular levels over time, with the highest levels 
of secretion observed upon 24 hours of co-culture (Fig.5.15b). The use of SPHK1 siRNA in PC-
3 cells, and subsequent co-culture with U937 cells, led to a modest reduction in IL-6 
expression in U937 cells at one and 24 hours, whilst at three hours a modest increase was 
observed. However, and despite no statistical analysis, this variation in IL-6 mRNA does not 
appear to be significant (Fig.5.16a). However, Akt or ERK1/2 siRNA transfected PC-3 cells 
induced different IL-6 mRNA responses in U937 cells. Akt knockdown in PC-3 cells had no 
effect on IL-6 expression at one hour, but was shown to decrease IL-6 transcriptional 
activation at three and 24 hours respectively (Fig.5.16b). The knockdown of ERK1/2 in PC-3 
cells reduced the previously observed increase in IL-6 mRNA induced by PC-3 cells 
transfected with non-targeting siRNA at one hour. This effect was also observed at three 
hours, albeit to a lesser extent (Fig.5.16b). Unfortunately IL-6 extracellular levels for the 
different siRNA co-cultures (Fig.5.16a and b) were not possible to obtain due to technical 
difficulties during the IL-6 ELISA. 
To further investigate the role of IL-6 in SPHK1, Akt and ERK1/2 regulation in U937 
cells, human recombinant IL-6 (rhIL-6) was added to U937 cells at a final concentration of 
100ng/ml. It was interesting to note that rhIL-6 induced a rapid SPHK1 transcriptional 
activation causing statistically significant 1.5- and 1.4-fold increases at one and three hours 
respectively (Fig.5.17a). In terms of Akt phosphorylation, IL-6 induced a modest 
phosphorylation after both 30 minutes and one hour of treatment (Fig.5.17b). ERK1/2 
phosphorylation was also increased with S1P treatment; this effect was apparent after 30 
minutes and greater after one hour. STAT3 phosphorylation was used as a positive control 
for IL-6 treatment (Fig.5.17a).  
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Figure 5.15: IL-6 regulation in U937 cells during co-culture. PC-3 cells were seeded in the bottom 
chamber under starvation 24 hours before the addition of U937 cells to the upper chamber and 
co-cultured for the indicated duration. a) IL-6 expression in U937 cell lysates was determined by 
qRT-PCR. Three housekeeping genes, GAPDH, YWHAZ and UBC were used to normalise. b) IL-6 
concentration in the media of the top compartment where U937 cells were present was 
determined by ELISA. Media were incubated with IL-6 specific antibodies and a standard curve 
was used to quantify the relative amount of IL-6 in each sample. Protein concentration of each cell 
lysate was used for normalisation. Data shown is the mean ± SEM of three independent 
experiments performed in duplicate. Statistical analysis was performed using student’s t-test 
relative to each individual time point. ns p>0.05, *p<0.05, **p<0.01, for U937 vs. U937+PC-3 
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Figure 5.16: IL-6 regulation in U937 cells during co-culture with PC-3 treated with several 
targeting siRNAs. a) PC-3 cells were transfected with siRNA targeting SPHK1 (siSPHK1), or non-
targeting siRNA (siNT) for 24 hours before cells were washed with PBS and cultured in serum-
free media for 24 hours. U937 cells were then added to the upper chamber and left incubating 
for the indicated duration. IL-6 expression in U937 cell lysates was determined by qRT-PCR. 
Three housekeeping genes, GAPDH, YWHAZ and UBC were used to normalise. b) PC-3 cells were 
transfected with siRNA targeting AKT (siAKT), ERK1/2 (siERK1/2) or non-targeting siRNA (siNT) 
were cultured as described above (a). IL-6 expression was determined by qRT-PCR as described 
above (a). Data shown is the a) mean ± SEM of two independent experiments performed in 
duplicate or b) fold-difference to control (U937 cell cultured alone) of a single biological 
replicate.  
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Figure 5.17: Effect of human recombinant IL-6 on signal transduction pathways in U937 cells.   
U937 cells were seeded in a 6-well plate before the addition of IL-6 (100ng/μl) for the indicated 
times. a) SPHK1 expression in U937 cell lysates was determined by qRT-PCR. Three housekeeping 
genes, GAPDH, YWHAZ and UBC were used to normalise. b) AKT, ERK1/2 and STAT3 
phosphorylation and total levels were determined by western blotting in U937 cells, quantified by 
Image J software and normalised to GAPDH. Data shown is the mean ± SEM of three independent 
experiments. Statistical analysis was performed using student’s t-test relative to each individual 
time point. ns p>0.05, *p<0.05, **p<0.01 or ***p<0.001 for U937 vs. U937+IL-6. 
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SPHK1 constitutive expression in PC-3 cells was previously shown to increase IL-6 
expression and secretion. In this regard it was important to evaluate if this over-expression 
in PC-3 cells would increase IL-6 levels in U937 cells during co-culture. After one hour, IL-6 
expression in U937 cells cultured with PC-3 over-expressing SPHK1 (PC-3/OFP-SPHK1) was 
up-regulated by approximately 1.8-fold in comparison with U937 cells cultured alone; 
however, no significant difference were observed when compared to U937 cells cultured 
with PC-3 cells containing the control vector (PC-3/OFP) (Fig.5.18a). A similar effect was 
observed on IL-6 extracellular levels where no differences were observed between PC-3 
over-expressing SPHK1 and the control vector (Fig.5.18b). The use of siRNA targeting SPHK1 
in PC-3 over-expressing SPHK1 did not make any difference to IL-6 extracellular levels in 
U937 cell proximity media (Fig.5.18b). 
 
5.10 Cross-regulation between MCP-1 and IL-6 in U937 cells 
 
With both IL-6 and MCP-1 being involved in the U937/PC-3 interaction, it was 
important to understand if there was any cross-regulation between these two proteins. 
Using cDNA from rhMCP-1-treated U937 cells, IL-6 expression was measured at the indicated 
time points (Fig.5.19). It was of great interest to note that MCP-1 can induce IL-6 
transcriptional activation in U937 cells, with the highest effect apparent after 24 hours 
(Fig.5.19a). In U937 cells, rhIL-6 led to a consistent increase of IL-6 transcriptional levels 
across all studied time points, with the highest increase being observed after three hours 
(Fig.5.19b). Furthermore, MCP-1 expression was induced in rhIL-6-treated U937 cells; an 
effect that was observed after only three hours and reaching its highest at 24 hours where a 
2-fold increase was observed (Fig.5.19c). This increase was accompanied by an increase in 
MCP-1 secretion, where IL-6 treatment led to a significant increase in MCP-1 secreted levels 
at eight and 24 hours (Fig.5.19d). These results not only indicate an autocrine role for IL-6 in 
U937 cells but also suggest that MCP-1 and IL-6 can regulate each other, most likely through 
the activation of their respective signalling cascades, resulting in an increase of their 
respective mRNA expression levels. 
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Figure 5.18: IL-6 expression and secretion in human U937 cells following co-culture with PC-3 
cells over-expressing SPHK1. a) PC-3 cells over-expressing SPHK1 (PC-3/OFP-SPHK1) or empty 
phmKO2 vector (PC-3/OFP) were seeded in the bottom chamber for 24 hours under serum-free 
media before the addition of U937 cells to the upper chamber for the indicated duration. a) IL-6 
expression in U937 cell lysates was determined by qRT-PCR. Three housekeeping genes, GAPDH, 
YWHAZ and UBC were used to normalise. b) PC-3/OFP-SPHK1 were transfected with siRNA 
targeting SPHK1 for 24 hours before cells were washed with PBS and cultured in serum-free media 
for 24 hours. U937 cells were then added to the upper chamber and left incubating for the 
indicated duration. In the other indicated co-culture  (U937 + PC-3/OFP) cells were culture as 
described in (a) with the exception of the seeding that occurred 48 hours before the addition of 
U937 cells. IL-6 concentration in the media of the top compartment where U937 cells were 
present was determined by ELISA. Media were incubated with IL-6 specific antibodies and a 
standard curve was used to quantify the relative amount of IL-6 in each sample. Protein 
concentration of each cell lysate was used for normalisation. Data shown is the mean ± SEM of a) 
two and b) three independent experiments performed in 1 single replicate. Statistical analysis was 
performed using student’s t-test relative to each individual time point. ns p>0.05, *p<0.05, 
**p<0.01, ***p<0.001 for U937 vs. U937+PC/OFP-3 or U937+PC-3/OFP vs. U937+PC-3/OFP-SPHK1 
or U937+PC-3/OFP-SPHK1 vs. U937+PC-3/OFP-SPHK1 (siSPHK1) . 
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Figure 5.19: Effect of the IL-6/MCP-1 axis in U937 cells. U937 cells were seeded in a 6-well plate 
before the addition of a) MCP-1 (100ng/μl) or b-d) IL-6 (100ng/μ) for the indicated times. a-b) 
IL-6 expression and c) MCP-1 expression in U937 cell lysates was determined by qRT-PCR. Three 
housekeeping genes, GAPDH, YWHAZ and UBC were used for normalisation. d) MCP-1 
concentration in the media was determined by ELISA. Media were incubated with MCP-1 
specific antibodies and a standard curve was used to quantify the relative amount of MCP-1 in 
each sample. Protein concentration of each cell lysate was used for normalisation. Data shown is 
the mean ± SEM of three independent experiments. Statistical analysis was performed using 
student’s t-test relative to each individual time point. ns p>0.05, *p<0.05, **p<0.01, for U937 
vs. U937+IL-6 or U937 vs. U937 + MCP-1. 
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Previously, I have shown that the addition of S1P to U937 cells resulted in an increase 
in SPHK1 activity and mRNA levels. Here, I sought to investigate whether S1P could also be 
involved in MCP-1 and IL-6 regulation and therefore contribute to the signalling loop 
involved in the regulation of these two inflammatory mediators. Figure 5.20a shows that S1P 
addition to U937 cells led to an increase in MCP-1 expression; this effect was only visible 24 
hours after S1P treatment, where a 1.2-fold increase was observed when compared to MCP-
1 expression in untreated U937 cells. IL-6 expression in S1P-treated U937 cells was also 
measured; figure 5.20b shows initial increases in IL-6 expression of 3- and 1.4-fold after one 
and three hours respectively. No differences in IL-6 expression were observed for the 
remaining time points. 
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Figure 5.20: Effect of S1P on IL-6 and MCP-1 mRNA expression in U937 cells U937 cells were 
seeded in a 6-well plate before the addition of S1P (1μM) for the indicated times. a) MCP-1 
expression and b) IL-6 expression in U937 cell lysates were determined by qRT-PCR. Three 
housekeeping genes, GAPDH, YWHAZ and UBC were used for normalisation. Data shown is the 
mean ± SEM of three independent experiments. Statistical analysis was performed using 
student’s t-test relative to each individual time point. ns p>0.05, *p<0.05 for U937 vs. 
U937+S1P. 
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5.11 Effect of SPHK1 inhibition in U937 cells on PC-3 cells during co-culture 
 
Finally, in order to understand if SPHK1 activation in U937 cells had an impact on 
SPHK1 levels in PC-3 cells, U937 cells were treated with SKi-II at a final concentration of 
20μM. U937 cells were treated with the inhibitor for 24 hours before media was removed 
and cells washed with serum-free medium to remove any traces of the inhibitor. Cells were 
then cultured up to a further 24 hours in order to evaluate the levels of SPHK1 repression 
caused by the inhibitor, during which time-point samples were captured. SPHK1 activity in 
U937 cells was markedly reduced at recovery start point after 24 hours in the presence of 
SKi-II (0 hours post-inhibitor removal, 24 hours total) (Fig.5.21a); this inhibitory effect was 
maintained for a further eight hours (32 hours total), with an approximate 50% reduction in 
SPHK1 activity. A 40% reduction in SPHK1 activity was still present 24 hours after SKi-II 
removal (48 hours total) (Fig.5.21a); the persistence of this reduction is of significance as it 
corresponds to the 24 hour duration of the co-culture model used in these studies. In terms 
of SPHK1 mRNA, no significant differences were observed upon SKi-II treatment (Fig.5.21b).  
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a) 
Figure 5.21: Effect of SKi-II on SPHK1 activity and expression in U937 cells. U937 cells were 
treated with SKi-II  (20μM) for 24 hours in complete media. Following this incubation, cells were 
centrifuged and washed two times with PBS to remove any traces of SKi-II inhibitor. U937 cells 
were then re-suspended  in serum –free media (0h(24h)) prior to culture into 6-well plates for a 
further 24 hours (24h(48h)). a) SPHK1 activity and b) expression were determined in U937 cell 
lysates containing equal amounts of protein or mRNA respectively using radiolabelling and qRT-
PCR respectively. For qRT-PCR, SPHK1 mRNA expression levels were normalised using three 
housekeeping genes, GAPDH, YWHAZ and UBC. Data shown is the mean ± SEM of two 
independent experiments performed in duplicate.  
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Following the assessment of SPHK1 levels after treatment with SPHK1 inhibitor, U937 
cells were treated for 24 hours prior to co-culture with PC-3 cells. As shown in figure 5.22ai, 
SPHK1 inhibition in U937 cells induced an increase in SPHK1 mRNA in PC-3 cells after one 
hour of co-culture; at three and 24 hours the effect was reversed and there was a reduction 
in SPHK1 mRNA of approximately 30% and 35% respectively in PC-3 cells when in 
comparison to those cultured with non-treated U937 cells. MCP-1 expression was also 
determined in the same PC-3 cells lysates as described above. Following one hour of co-
culture, U937 cells treated with the inhibitor induced a 50% increase in MCP-1 mRNA 
(Fig.5.22aii). This effect was reduced after three hours of co-culture, where no difference 
was observed for MCP-1 mRNA in PC-3 cells that were co-cultured with treated or non-
treated U937 cells. At a later stage of co-culture (24 hours) PC-3 cells co-cultured with SKi-II 
showed reduced levels of MCP-1 expression of approximately 20% in comparison with PC-3 
culture with non-treated U937 cells (Fig.5.22aii).   
As shown previously (chapter 4 , Fig.4.10), U937 cells induced an early increase in IL-
6 mRNA in PC-3 cells. Here I have shown that this effect was not affected by SPHK1 inhibition 
in U937 cells, as no reduction in IL-6 mRNA was identified in PC-3 cells after one hour 
(Fig.5.22iii). The remaining time points confirmed that SPHK1 inhibition in U937 cells did not 
affect IL-6 expression levels in PC-3 cells during co-culture (Fig.5.22iii). 
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Figure 5.22: Effect of SKi-II on SPHK1, MCP-1 and IL-6 expression in PC-3 cells during co-culture 
with U937 cells. PC-3 cells were seeded into the bottom chamber for 24 hours under starvation 
before the addition of U937 cells. Simultaneously, U937 cells were treated with and without SKi-
II  (20μM) for 24 hours in complete media. Following this incubation, cells were centrifuged and 
washed two times with PBS to remove any traces of SKi-II inhibitor. For control U937 cells the 
same procedure was followed as to SKi-II treated U937 cells. Cells were then re-suspended  in 
serum–free media before being added to the top chamber of the transwell with PC-3 cells 
cultured in the bottom chamber. a) SPHK1, b) MCP-1 and c) IL-6 expression in PC-3 cell lysates 
was determined by qRT-PCR. Three housekeeping genes, GAPDH, YWHAZ and UBC were used to 
normalise. Data shown is the mean ± SEM of one independent experiments performed in one 
single replicate.  
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5.12 Discussion 
 
Inflammatory cells are known to play a well-recognised role in cancer progression 
and their interactions with tumour cells are important determinants of tumour biology. 
Paracrine loops between tumour and immune cells have emphasised the potential role of 
some molecules in tumour development. In this study SPHK1 enzymatic activity (Fig.5.1a) 
and expression (Fig.5.1b) in U937 cells and THP-1 cells (Fig.5.6a-b) are increased during their 
co-culture with PC-3 cells. This indicates that soluble signalling molecules secreted from PC-3 
cells are inducing SPHK1 activation in monocytes. Surprisingly this activation only occurs 
when cells are in co-culture as the use of conditioned medium from PC-3 cells did not induce 
SPHK1 activation in U937 cells (Fig.5.8a). The activation of SPHK1 and other important 
signalling mediators (discussed later on) in U937 cells is therefore dependent on a 
bidirectional, rather than unidirectional, signalling loop whereby an initial “cross-talk” is 
crucial to trigger cell responses towards one another. 
The increase in SPHK1 enzymatic activity may result from a post-translational 
modification rather than as a consequence of mRNA increase. SPHK1 has been described to 
have intrinsic catalytic activity independent of post-translational modifications; however, 
upon phosphorylation induced by different growth factors its enzymatic activity can be 
further increased [175]. It is therefore possible that during co-culture the increase in SPHK1 
enzymatic activity in U937 cells is a result of a phosphorylation event caused by signalling 
molecules secreted from PC-3 cells. 
 For U937 cells the increase in SPHK1 activity is accompanied by an increase in SPHK1 
mRNA levels at one and more significantly at three hours of co-culture (Fig.5.1a-b). In this 
case, the increase in mRNA could lead to a later increase in SPHK1 activity; however, there is 
a possibility of these events occurring in an independent manner as the transcriptional 
activation and the kinase enzymatic increase may result from different signalling mediators.  
In THP-1 cells there was no increase in mRNA levels at an early stage of co-culture 
(Fig.5.6b), suggesting that the increase in SPHK1 activity (Fig.5.6a) was caused by signalling 
molecules secreted by PC-3 cells. The later increase, upon 24 hours of co-culture, in SPHK1 
activity could be due to an increase in SPHK1 mRNA. Indeed, SPHK1 biphasic activation has 
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been described, where an initial increase in SPHK1 enzymatic activity is followed by a later 
increase in mRNA expression levels [190, 405].  
 The SPHK1 response to stimuli has been reported previously [179, 423]; however in 
a co-culture system I show for the first time that SPHK1 is not only activated in tumour cells, 
but also in monocytes. Curiously, this double activation appears to be extremely coordinated 
as there is a “synchronised” increase in SPHK1 for both tumour (chapter 4, Fig.4.1a-b) and 
immune cells (Fig.5.1a-b). This suggests that SPHK1 is involved in the secretion of signalling 
molecules that are able to regulate its own expression in the “partner cells”, either through a 
common molecule (such as S1P, as discussed later on) or by several molecules, whose effect 
are time-dependent (as discussed in chapter 4). Interestingly, SKi-II treatment of U937 cells 
before co-culture with PC-3 cells provoked a reduction in SPHK1 mRNA in the latter cells 
(Fig.5.22); this finding reinforces the importance of SPHK1, with its activation in U937 cells 
seemingly a necessary factor for its activation in PC-3 cells. An interesting observation is 
made when siRNA is used to knockdown SPHK1 in PC-3 cells; this results in a lower SPHK1 
enzymatic activation and lower mRNA levels in U937 cells (Fig.5.2a-b). This data also show 
for the first time that SPHK1 is involved in the regulation of one or more soluble molecule/s 
messaging from PC-3 to U937 cells and is responsible for SPHK1 activation in monocytes.  
 A possible candidate for such a soluble molecule (apart from those identified using 
the proteome profiler assay, chapter 4, Fig.4.16) would be S1P as it is directly regulated by 
SPHK1 through sphingosine phosphorylation. The use of siRNA against SPHK1 in PC-3 cells 
would lead to a reduction of available S1P for U937 cells, leading to a lower activation of 
SPHK1 in U937 cells. The increase in SPHK1 activity and mRNA (Fig.5.9a-b), together with an 
induction of Akt and ERK1/2 phosphorylation (Fig.5.9c), by S1P in U937 cells strongly 
indicates S1P as a possible mediator of the U937/PC-3 cell interaction. A more recent study 
shows that in RAW264.7 macrophages treated with exogenous S1P, SPHK1 mRNA levels 
were increased in a concentration-dependent manner. This effect was also accompanied by 
an increase in S1P secretion, indicating the existence of a self-regulatory effect through a 
positive feed-back loop [424]. In this current study, the reduction in Akt and ERK1/2 
phosphorylation in U937 cells, caused by the use of SPHK1 siRNA in PC-3 cells (Fig.5.4), could 
also be credited to a reduction in S1P available in the media. The fact that S1P is able to 
activate both Akt and ERK1/2 phosphorylation levels in U937 cells supports the role of S1P as 
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a key mediator in PC-3/U937 cell interactions. Since both Akt and ERK1/2 are up-regulated 
during co-culture (Fig.5.3), a possible positive effect of Akt or ERK1/2 on S1P levels in U937 
cells (dependent or independent of SPHK1) should also not be excluded. Other regulatory 
soluble molecules, aside from S1P, could also have an effect on the regulation of Akt 
(including VGEF,cAMP and GM-CSF), ERK1/2 (including IL-6, CD40 and VGEF) or NF-KB (IL-1 
and TNF-α) in monocytes during cancer-monocyte interactions, including [226, 389]. 
 According to my results it is unlikely that S1P is being initially secreted from PC-3 
cells in the absence of U937 cells as conditioned media from PC-3 cells did not increase 
ERK1/2 phosphorylation or SPHK1 mRNA levels in U937 cells (Fig.5.8a-b). However, the 
presence of monocytes could lead to an increase in S1P secretion from PC-3 cells, triggering 
the U937 cells response. A study by Weigert et al., using primary human macrophages, 
showed that S1P secreted from dying cells led to an increase in ERK1/2 and phosphoinositide 
3-kinase (PIK3), a known upstream regulator of Akt, in comparison with normal Jurkat cells 
[254]. This re-enforces the idea that S1P may not be constantly secreted from cells but its 
induction can trigger differential cell type specific responses.  
The use of Akt and ERK1/2 siRNA in PC-3 cells indicated that SPHK1 regulation in 
U937 cells is dependent on these pathways (Fig.5.5a); however, their importance appears to 
vary during co-culture. At the very initial phase of co-culture the SPHK1/S1P pathway is the 
main driver for its own activation in U937 cells and is independent of Akt or ERK1/2 
activation in PC-3 cells. However at later stages, Akt and ERK1/2 also play an important role 
in this activation as their absence proved to be crucial for SPHK1-induced expression 
(Fig.5.5a). In order to draw more assertive conclusions from this preliminary data, further 
repetitions need to be performed. Also, the analysis of SPHK1 activity levels in U937 cells 
could be an important indicator as to when SPHK1 is involved in the regulation of these 
signalling transduction pathways.  
To further determine if these effects were cell specific, and to understand a possible 
correlation between SPHK1, Akt and ERK1/2, I have assessed these pathways in other cell 
lines. The analysis of SPHK1 regulation in THP-1 cells during co-culture with PC-3 showed 
biphasic enzymatic activation (Fig.5.6a); however, in this case there was no increase in Akt 
or ERK1/2 phosphorylation, which suggests that SPHK1 is not being mediated by any of these 
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molecules in this system (Fig.5.6b). Furthermore, MDA-231 cells induced a transient increase 
in Akt and ERK1/2 phosphorylation in U937 cells but not in SPHK1 activity or mRNA (Fig.5.7a-
c) suggesting activation of these pathways in MDA-231 does not require SPHK1 activation 
during their interaction with monocytes. 
 Altogether these findings suggest that cancer cell SPHK1 may be important for the 
secretion of molecules that may potentially activate SPHK1 in neighbouring monocytes, 
which in turn mediates its activation in PC-3 cells. Also, Akt and ERK1/2 regulation during 
cancer cell-monocyte interactions are also affected by SPHK1 regulation; however its 
importance as to when its role is essential is not clear and seems to vary according to time 
and cell type. A schematic representation of a possible mechanism for tumour and 
monocyte interactions is shown below (Fig.5.23a). 
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Figure 5.23a: Proposed model for SPHK1 activation and important signal transduction 
pathways in U937 during co-culture with PC-3 cells. 1) The secretion of so far unknown 
molecules by U937 cells leads to the secretion of also unidentified molecules  by PC-3 cells. This 
initial cross-talk results in the activation of SPHK1 at mRNA levels and enzymatic activity, IL-6 and 
MCP-1 expression, as well as AKT, NF-KB and ERK1/2 phosphorylation in U937 cells. The 
involvement of these important signal transduction pathways in SPHK1 regulation remains 
unclear. 2) SPHK1 is likely to produce S1P that can itself lead to the increase of AKT and ERK1/2 
phosphorylation as well as transcriptional activation of several genes, including SPHK1, IL-6 and 
MCP-1. 3) Extracellular IL-6 can induce an increase in SPHK1 and MCP-1 mRNA expression levels 
as well as acting in an autocrine manner to promote its own expression. IL-6 can induce a very 
modest increase in AKT phosphorylation, for ERK1/2 phosphorylation this effect appears to be 
stronger. 4) MCP-1 can induce SPHK1 mRNA levels and enzymatic activity as well as IL-6 
expression. The sequence of events may not reproduce the real dynamics existing between U937 
and PC-3 cells as some of the represented events may occur simultaneously.  

5.12.1 Signalling molecules involved in monocyte/cancer cell interactions 
 
It is known that MCP-1 expression and macrophage infiltration correlates with a poor 
clinical prognosis. Moreover, the increase in MCP-1 expression from monocytes and tumour 
cells during their interaction was also described in a recent in vivo study. Human 
inflammatory monocytes were recruited to the site where pulmonary metastases of human 
breast cancer were formed; it was shown that MCP-1 expression was increased in both cell 
lines. Interestingly the use of an MCP-1 blocking antibody resulted in a decrease in the 
number of metastasis [313]. Together with previous findings in PC-3 cells (chapter 4, Fig.4.7-
9), it was important to evaluate MCP-1 expression in U937 cells and to determine how MCP-
1 can affect SPHK1 regulation in these cells during co-culture with PC-3 cells. The finding that 
MCP-1 expression and secretion levels are increased in U937 cells by the presence of PC-3 
cells (Fig.5.10a-b) indicates the involvement of extracellular signalling molecules capable of 
inducing transcriptional activation of this chemokine in U937 cells. In this context, S1P could 
be a potential candidate; however, SPHK1 knockdown in PC-3 cells showed no effect on 
MCP-1 expression in U937 cells. Also, the over-expression of SPHK1 in PC-3 cells did not 
increase MCP-1 expression in U937 cells (Fig.5.13a) in comparison with control PC-3 cells 
(PC-3/OFP), indicating that S1P is not likely to be the key regulator in MCP-1 expression. It is 
important to note that the results obtained from PC-3 cells transfected with empty vector 
(PC-3/OFP) and PC-3 transfected with vector carrying SPHK1 (PC-3/OFP-SPHK1) may not be 
the best model to analyse the effect of SPHK1 over-expression in U937 cells. This is based on 
the observations that PC-3/OFP cells were not able to increase SPHK1 enzymatic activity or 
expression in U937 cells; an effect that was previously observed with parental PC-3 cells 
(Fig.5.1a-b). Therefore it is not possible to draw firm conclusions of the PC-3/OFP-SPHK1 
effect on U937 cells as the expression profile and normal homeostasis of these cells may be 
affected by the vector used in this study, and therefore masking the effect of SPHK1 
regulated signalling molecules on U937 cells.  
 SKi-II treatment in U937 cells did not alter the induced effect of PC-3 on MCP-1 
expression in the monocytes at early stages of co-culture; in fact, a repressive effect was 
only observed after 24 hours in co-culture (Fig.5.22a), indicating a possible regulation, but 
most likely through secondary activated loops that, in turn, could be mediated by SPHK1 in 
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the first instance. This preliminary data should be analysed with caution; further repetitions 
need to be performed in order to justifiably place greater emphasis on the conclusions 
drawn. 
There is evidence in the literature to support the regulation of MCP-1 by SPHK1/S1P; 
a study by Oskeritzian et al. have shown that S1P induced MCP-1 secretion in mast cells after 
30 minutes [324]. Unfortunately the authors did not show the MCP-1 mRNA expression 
levels and therefore a comparison with my study (Fig.5.20a) cannot be established; 
however, these findings are indicative of the ability of S1P to induce a regulatory effect on 
MCP-1. Furthermore, SPHK1 has been described to regulate the TNF-α-induced increase of 
MCP-1 in endothelial cells [325], whilst DMS, a SPHK1 inhibitor, significantly reduced the 
TNF-α-induced increase in MCP-1 protein levels in Jurkat-U937 cells and PBMCs [292]. 
Despite these literary evidences of SPHK1-mediated regulation of MCP-1 in other cell 
systems, my study suggests that this regulation does not play a significant role in cancer-
cell/monocyte interactions in an early stage of co-culture, but may have an impact at later 
stages. Also, there could be other important factors that have a stronger prevalence in MCP-
1 regulation than SPHK1 during different stages of co-culture.  
  Despite the reduced effect of SPHK1 inhibition on MCP-1 in U937 cells, it is clear 
that MCP-1 plays an important role in our system. In support, rhMCP-1 was shown to have a 
role in SPHK1 regulation by inducing a transient increase in SPHK1 enzymatic activity and a 
later mRNA increase (Fig.5.13a-b). This later increase in SPHK1 mRNA could indicate a 
second activation loop caused by either the MCP-1 signalling cascade itself or by other MCP-
1 activated genes such as IL-6 (Fig.5.19). In fact, recombinant MCP-1 led to an increase in IL-
6 mRNA (Fig.5.19a), which in turn can also act in an autocrine manner by regulating its own 
expression in U937 cells (Fig.5.19b). This direct transcriptional regulation has been described 
previously; for example, a 3D co-culture system showed that IL-6 was important for 
macrophage infiltration in Spheroid tumour derived fibroblasts by regulating MCP-1 levels, 
whilst an anti-IL-6 antibody was shown to decrease MCP-1 levels and subsequent 
macrophage infiltration [425]. In support, an interesting study investigating the cross-talk 
between glioma and microglia cells through the MCP-1/IL-6 axis, showed that, initially, 
glioma cells secrete MCP-1 to microglia cells resulting in an increase in IL-6 secretion from 
microglia cells during co-culture. More interestingly, IL-6 was shown to be essential for the 
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increase in glioma invasiveness, as the neutralising antibody reversed this effect [426]. The 
ability of IL-6 to promote SPHK1 mRNA up-regulation (Fig.5.17a) and possibly Akt and 
ERK1/2 phosphorylation (Fig.5.17b), supports the role of this cytokine as a driver for the 
activation of important genes involved in oncogenic processes. Interestingly IL-6 expression 
levels in U937 cells appear to be independent of SPHK1 levels in PC-3 cells (Fig.5.16a), but 
partially dependent on Akt and ERK1/2 levels in PC-3 cells. Further experimental repeats are 
needed in order to draw more definite conclusions (Fig.5.16b), however it is interesting to 
find that SPHK1 regulated molecules such as Akt and ERK1/2 are able to reduce IL-6 
expression despite no effect of SPHK1 itself. 
A further clarification of IL-6 autocrine signalling in U937 cells during co-culture could 
have come from the analysis of STAT3 phosphorylation levels; however, for as yet 
determined reasons it was not possible to detect any levels of STAT3 phosphorylation.  
   
In summary, this study shows that targeting SPHK1 in tumour cells not only has an 
effect on the tumour cells themselves but also affects the surrounding cells, in this case 
monocytes. The reduction of SPHK1, Akt and ERK1/2 phosphorylation in these cells indicate 
for the first time that targeting SPHK1 in tumour cells also has an indirect effect on SPHK1 
itself and other important signalling molecules in monocytes. As for soluble molecules, IL-6 
and MCP-1 will most certainly play an important role in cancer cell-monocyte interactions, 
however, their dependency on SPHK1 levels still remains unclear, although are likely to be 
time-dependent. To simplify the current findings a suggested model is shown the schematic 
representation below. 
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siSPHK1 siERK1/2 siAKT 
Legend 
SKi-II SKi-II Inhibitory  effect  
siSPHK1 inhibitory  effect  siERK1/2 inhibitory  effect  siAKT inhibitory  effect  
Figure 5.23b: Proposed model for the role of intracellular pathways involved in SPHK1 
regulation in U937 cells during their co-culture with PC-3 cells. 1) SPHK1 knockdown by siRNA in 
PC-3 cells inhibits SPHK1 activity and expression in U937 cells; most likely by reducing the levels 
of a secreted molecule that is able to activate SPHK1 in monocytes, this molecule may well be 
S1P. AKT, NF-kB and ERK1/2 phosphorylation are also reduced by SPHK1 down-regulation. IL-6  
and MCP-1 expression  were not affected by this in PC-3 cells, nonetheless, MCP-1 secreted levels 
were reduced. 2) AKT targeted knockdown in PC-3 cells decrease the PC-3 cells-induced increase 
of SPHK1 expression in U937 cells. In addition, AKT and ERK1/2 phosphorylation levels were also 
reduced when AKT was down-regulated in PC-3 cells. Similarly, IL-6 and MCP-1 expression were 
also reduced in U937 cells during this co-culture. 3) ERK1/2 knockdown by siRNA in PC-3 cells 
markedly reduced the ability of these cells to increase SPHK1 expression in U937 cells; a similar 
effect was also observed for MCP-1 and IL-6 expression. The consequence of AKT and ERK1/2 
knockdown on the secretion of MCP-1 and IL-6 by U937 was not studied; it therefore remains 
unclear as to what extent these knockdowns affect the regulation of these two inflammatory 
mediators. 4) SPHK1 inhibition by SKi-II in U937 cells provoked a reduction in SPHK1 and MCP-1 
expressio,n indicating the importance of SPHK1 activation in monocytes as critical for the 
regulation of molecules capable of  activating SPHK1 in cancer cells.  
  

6. STAT1 involvement in SPHK1 transcriptional regulation in PC-3 
cells during co-culture with U937 cells 
 
6.1 STAT1 transcriptional binding to SPHK1 encoding gene 
 
Some cytokines [325, 326] and growth factors [130, 176] are known to activate 
SPHK1 transcriptional expression; however the transcriptional factors or mediators involved 
in this activation are currently poorly described and remain unclear. So far, activator protein 
2 (AP-2) and specificity protein 1 (SP1) binding to SPHK1 promoter regions have been 
identified as critical for SPHK1 transcriptional activation upon PMA [184], NGF (nerve growth 
factor) [427] and GDNF (glial cell line-derived neurotropic factor) stimulation [428]. In this 
context, signal transducers and activators of transcription (STATs) are known to be regulated 
through the activation of cytokine and hormone receptors. Activation of STATs has been 
correlated with cell survival, apoptosis, proliferation [355, 429] and are known to modulate 
inflammatory responses by maintaining an inflammatory microenvironment with pro- and 
anti-survival benefits for cancer development [362, 430]. STAT3 and STAT1 have similar 
structures, with both having activated tyrosine residues, and despite their binding to very 
specific elements their sets of activated downstream genes can sometimes be overlaid. Both 
can form dimers or heterodimers with each other upon given specific stimuli (e.g. cytokines 
or growth factors). The very low endogenous levels of STAT3 in the PC3 cell line [431, 432] 
prompts the hypothesis that STAT1 is being activated in the “absence” of STAT3 and 
therefore regulating and activating the STAT3 set of target genes. Here, I propose to 
investigate the role of STAT1 as a transcription factor responsible for SPHK1 regulation in PC-
3 cells during co-culture with U937 cells. 
 
 CHIP-Seq data in the public domain (UCSC Genome Bioinformatics, 
genome.ucsc.edu) indicated several SPHK1 genomic regions where STAT1 was shown to bind 
in HeLa-S3 and the leukaemia K562 cell lines after IFN-gamma treatment for 30 minutes and 
six hours (Fig.6.1a). In accordance with these available data, several sets of primers were 
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designed to recognise five different sequences within the vicinity of the SPHK1 encoding 
gene where STAT1 was shown to bind (Fig.6.1b). Each primer pair was tested in PC-3 cell 
lysates after a chromatin immunoprecipitation assay (ChIP), designed to evaluate if U937 
cells were inducing STAT1 binding to SPHK1 genomic DNA. For this purpose PC-3 and U937 
cells were co-cultured for two hours before the PC-3 cell pellet was collected, with lysates 
from PC-3 cells cultured with or without U937 cells compared. Indeed, U937 cells were able 
to induce STAT1 binding within the vicinity of the SPHK1 encoding gene in PC-3 cells when 
compared with cells cultured alone. Of the five tested primer pairs, STAT1 enrichment was 
observed in two different regions, A and D (Fig.6.2a-b). Region A, situated up-stream of the 
SPHK1 coding region, had a 4-fold increase in STAT1 binding upon U937 cell stimulation after 
normalisation with the respective IgG control (Fig.6.2a). Region D, situated inside the coding 
region, showed a 2-fold increase after co-culture (Fig.6.2b).  
 
6.2 SPHK1 modulation of STAT1 phosphorylation 
 
Following on from these initial findings it was important to understand whether 
STAT1 binding to putative SPHK1 regulatory regions was accompanied by an increase in its 
phosphorylation. A co-culture assay was performed where PC-3 cells were cultured in the 
presence or absence of U937 cells for one, three or 24 hours. Western blotting analysis of 
PC-3 cell lysates showed an increase in STAT1 phosphorylation levels when cultured with 
U937 cells for one and three hours (Fig.6.3a), whereas the use of siRNA targeting SPHK1 
abrogated U937 induced-increase in STAT1 phosphorylation in PC-3 cells. Figure 6.3b is a 
representation of figure 4.3e (chapter 4) to show SPHK1 knockdown in PC-3 cells. 
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Region/Primer 
nomenclature 
Position on SPHK1 encoding gene 
(Range) Product Length 
A chr17:74378958-74379370 91bp 
B chr17:74379401-74379628 95 bp 
C chr17:74379671-74379970 107 bp 
D chr17:74381110-74381582  107 bp 
E chr17:74381806-74382343  
115bp 
 
Figure 6.1: Schematic representation of putative STAT1 binding sites to SPHK1 encoding 
gene. a) Representation of CHIP-Seq data on SPHK1 DNA for possible STAT1 binding sites 
(UCSC Genome Bioinformatics; genome.ucsc.edu). Blue peaks indicate STAT1 binding after 
IFN- treatment, with the different lines representative of the different cell lines and time of 
treatment. b) Table shows the regions in SPHK1 genomic DNA where primers were designed 
to detect STAT1 binding (represented by blue arrows in (a)).  
A 
B 
C 
STAT1 binding 
regions 
D 
E 
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Figure 6.2: ChIP assay on PC-3 cells during co-culture. PC-3 cells were seeded in the bottom 
chamber of a transwell for 24 hours in serum-free media prior to the addition of U937 cells to the 
upper chamber for a further two hours. After removal of the top chamber, PC-3 cells were cross-
linked by the addition of 1% formaldehyde for 10 minutes, at which point glycine was added. PC-3 
cells were then lysed and sonicated followed by immunoprecipitation with STAT1 antibody. 
Purified DNA was quantified by real time PCR where two primer pairs were used for a) region A 
and b) region D. The values were normalised for the initial amount of chromatin used in each 
condition (input) and compared with each antibody isotype (IgG) for background signalling. Data 
shown is from one experiment.  
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b) 
Figure 6.3: STAT1 regulation in PC-3 cells during co-culture with U937 cells. PC-3 cells were 
transfected with siRNA targeting SPHK1 (siSPHK1) or non-targeting control siRNA  (siNT) for 24 
hours before cells were washed with PBS and cultured in serum-free media for 24 hours. U937 
cells were then added to the upper chamber and left incubating for the indicated duration. a) 
STAT1 phosphorylation and total levels were determined by western blotting quantified by 
Image J software and normalised to GAPDH. b) SPHK1 expression in PC-3 cell lysates was 
determined by qRT-PCR. Three housekeeping genes, GAPDH, YWHAZ and UBC were used for 
normalisation. a) Data shown is for one experiment, b) Data shown is the mean ± SEM of three 
independent experiments. b) Statistical analysis was performed using student’s t-test relative 
to each individual time point. *p<0.05, **p<0.01, ***p<0.001 for PC-3 siNT  vs.  PC-3 siTN + 
U937 or PC-3 siSPHK1 vs PC-3 siSPHK1 + U937. 
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To further investigate the role of STAT1 in SPHK1 transcriptional regulation, PC-3 cells 
were transfected with a pool of four siRNAs targeting STAT1 for 48 hours prior to collection 
of total RNA (Fig.6.4a). Surprisingly, STAT1 knockdown increased SPHK1 mRNA levels by 2-
fold relative to PC-3 cells transfected with a non-targeting siRNA. To rule out off-target 
effects of individual STAT1 siRNAs, a deconvolution was performed in each of the individual 
siRNAs composing the pool. As seen in figure 6.4b, all four individual siRNA targeting STAT1 
led to an increase in SPHK1 expression in PC-3 cells.  
Next, to assess if the absence of STAT1 in PC-3 cells would affect the interaction with 
U937 cells, a co-culture assay was performed for one, three and 24 hours. As expected, 
STAT1 knockdown in PC-3 cells induced SPHK1 expression, an effect that proved to be 
independent of monocyte presence as there was no further increase or reduction in SPHK1 
mRNA when U937 cells were added to the co-culture (Fig.6.5a). Since I have previously 
shown a level of “cross-talk” between SPHK1 and Akt (chapter 3 and 4), it was important to 
understand whether an inhibition of STAT1, and consequently activation of SPHK1, would 
lead to an increase in Akt phosphorylation in PC-3 cells when in the presence of U937 cells. 
Western blotting analysis showed that Akt phosphorylation was down-regulated by STAT1 
knockdown; indeed, basal levels of Akt phosphorylation were reduced across all time points 
when in comparison with PC-3 cells transfected with a non-targeting siRNA (Fig.6.5d). 
However, the presence of U937 cells had a positive effect as it restored Akt phosphorylation 
levels in STAT1 siRNA transfected PC-3 cells at one and three hours. After 24 hours of co-
culture this increase was not observed as AKT levels were very low (fig.6.5b). It should be 
noted that STAT1 knockdown was not directly assessed during this assay, however, this 
siRNA proved to be efficient, as depicted in figure 6.6. 
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Figure 6.4: Effect of STAT1 knockdown on PC-3 cells. PC-3 cells were transiently transfected 
with a) siRNA smart pool targeting STAT1 or b) four independent siRNA also targeting STAT1, for 
48 hours. A non-targeting siRNA (siNT) was used as a control. SPHK1 expression in PC-3 cell 
lysates was determined by qRT-PCR. Three housekeeping genes, GAPDH, YWHAZ and UBC were 
used for normalisation. a) Data shown is the mean ± SEM of  three independent experiments, b) 
data shows the fold difference of each siSTAT1 relative siNT for one single experiment. 
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a) 
b) 
Figure 6.5: Effect of STAT1 knockdown on PC-3 cells during co-culture with U937 cells. PC-3 cells 
were transfected with siRNA smart pool targeting STAT1 (siSTAT1) or non-targeting control siRNA 
(siNT) for 24 hours before cells were washed with PBS and cultured in serum-free media for 24 
hours. U937 cells were then added to the upper chamber and left incubating for the indicated 
duration. a) SPHK1 expression in PC-3 cell lysates was determined by qRT-PCR. Three 
housekeeping genes, GAPDH, YWHAZ and UBC were used for normalisation. b) AKT 
phosphorylation and total levels were determined by western blotting, quantified by Image J 
software and normalised to GAPDH. Data shown is the mean ± SEM of a) two independent 
experiments, b) data shown represents one experiment. 
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6.3 Phosphorylation of STAT1 and STAT1-regulated genes by IL-6 and MCP-1: the 
role of SPHK1 
 
I have previously shown that IL-6 and MCP-1 were regulated during co-culture of PC-
3 cells with U937 cells. To further assess their effect on STAT1 phosphorylation in PC-3 cells, 
human recombinant IL-6 and MCP-1 were added at a final concentration of 100ng/ml to PC-
3 cells for the indicated time points before collection of lysates for western blotting analysis. 
STAT1 phosphorylation was strongly induced by IL-6 across all of the indicated time points, 
peaking at 30 minutes (Fig.6.6a). This effect was partially inhibited by the use of siRNA 
targeting SPHK1, when the IL-6 induction of STAT1 phosphorylation was reduced by 
approximately 2-fold (Fig.6.6b). The effect of rhMCP-1 on STAT1 phosphorylation (Fig.6.6c) 
was not as accentuated as that observed for IL-6, nonetheless there was still a 1.5-fold 
increase in comparison with non-treated PC-3 cells. SPHK1 knockdown completely blocked 
MCP-1 induced STAT1 activation (Fig.6.6c); this could indicate that MCP-1 and IL-6 (to a 
greater extent) can regulate STAT1 phosphorylation through a SPHK1 dependent 
mechanism. 
To determine whether STAT1 activation regulates SPHK1, PC-3 cells were treated 
with Interferon-gamma (IFN-γ). IFN-γ is a well-known activator of STAT1 [433], and several of 
its downstream genes, such as interferon regulatory factor 1 (IRF-1), are dependent on 
STAT1. IFN-γ was added to PC-3 cells at a final concentration of 500 IU/ml for 24 hours. After 
cell lysates were collected SPHK1 expression was measured by qRT-PCR. A STAT1 activated 
gene, IRF-1, was also measured as a control for STAT1 activation. As expected, IRF-1 
expression showed a 16-fold increase upon IFN-γ stimulation (Fig.6.7a), whilst SPHK1 
expression was decreased by 2-fold after treatment (Fig.6.7b). In terms of IL-6 and MCP-1 
mRNA expression, IFN-γ treatment did not affect IL-6 expression (Fig.6.7c) but markedly 
reduced MCP-1 expression with a 5-fold decrease when compared to untreated PC-3 cells 
(Fig.6.7d).  Furthermore, to assess whether IL-6 or MCP-1 were inducing an IFN-γ/STAT1 
response in PC-3 cells, human recombinant IL-6 and MCP-1 were added to the cells for 24 
hours at a final concentration of 100ng/ml. IRF-1 expression in these cells showed a 1.3-fold 
increase after IL-6 treatment and a 2-fold decrease after addition of MCP-1 (Fig.6.7e).  
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Figure 6.6: IL-6 and MCP-1 effects on STAT1 phosphorylation in PC-3 cells. a) PC-3 cells were 
seeded in a 6-well plate in serum-free medium for 24 hours before the addition of IL-6 
(100ng/ml) for the indicated time points. STAT1 phosphorylation and total levels were 
determined by western blotting, quantified by image J and normalised to GAPDH. b) PC-3 cells 
were transfected with siRNA targeting SPHK1 (siSPHK1), siRNA smart pool targeting STAT1 
(siSTAT1) or a non-targeting control siRNA (siNT) for 24 hours before cells were washed with 
PBS and cultured in serum-free medium for 24 hours. b) IL-6 or c) MCP-1 were added at a final 
concentration of 100ng/ml for 30 minutes. STAT1 phosphorylation and total levels were 
determined by western blotting as described above. Data shown is representative of two 
independent experiments.  
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Figure 6.7: IFN-γ effect on PC-3 cells gene expression. PC-3 cells were seeded in a 6-well plate in 
serum-free media for 24 hours before the addition of IFN-γ (500 IU/ml) for 24 hours. a) IRF-1, b) 
SPHK1, c) IL-6 and d) MCP-1 expression in PC-3 cell lysates was determined by qRT-PCR. Three 
housekeeping genes, GAPDH, YWHAZ and UBC were used to normalise each gene expression. e) 
PC-3 cells were seeded as described above, IL-6 (100ng/ml) and MCP-1 (100ng/ml) were added for 
a further 24 hours. IRF-1 expression was measured as indicated above (a-d). Data shown is the SD 
of two replicates from one experiment normalised to untreated PC-3 cells.  
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To further confirm that IL-6 and MCP-1 were not inducing IFN-γ type responses in PC-
3 cells, HLA-Class I protein levels were measure by flow cytometry. HLA class I molecules are 
cell surface proteins constitutively expressed in most cells, and IFN-γ can further induce their 
expression through a secondary loop involving the activation of IRF-1 and STAT1. For this 
purpose PC-3 cells were treated with IL-6 and MCP-1 for 24 (Fig.6.8a) and 48 hours (Fig.6.8b) 
before HLA-Class I protein levels were determined by flow cytometry. IFN-γ was also added 
as a positive control for the induction of HLA-Class I molecules. As seen in figure 6.8 IFN-γ 
induces a clear increase in HLA-Class I at both time points (panel 3 and 8). MCP-1 treatment 
did not induce any increase in HLA-Class I expression levels when compared with untreated 
PC-3 cells stained with the control fluorescent fluorochrome FITC antibody (panel 4 and 9). 
At 24 hours, IL-6 addition provoked a mild increase in HLA-Class I relative to untreated PC-3 
cells (panel 5), however the increase proved transient as at 48 hours there was a reduction 
of HLA-Class I upon IL-6 treatment (panel 10).   
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Figure 6.8: IL-6 and MCP-1 effect on IFN-ɶ response gene HLA-Class I in PC-3 cells. a) PC-3 cells 
were seeded for 24 hours before the addition of IFN-ɶ (500 IU/ml), IL-6  (100ng/ml) and MCP-1 
(100ng/ml) for 24 hours. At each time point PC-3 cells were fixed with 4% PFA before the addition 
of FITC-HLA-Class I a,b,c antibody. Fluorescence was detected using a BD FACSCanto and results 
were analysed using FlowJo software. Panel 1 and 2 show staining controls for (1) unstained 
background signalling and (2) FITC background signalling of untreated PC-3 cells. Panels 3, 4 and 5 
show staining profiles of IFN-ɶ͕ MCP-1 and IL-6 respectively. Results are presented as the 
geometric mean values of stained samples, and data shown is representative of two independent 
replicates of one independent experiment.  
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Figure 6.8b: IL-6 and MCP-1 effect on IFN-ɶ response gene HLA-Class I in PC-3 cells. a) PC-3 
cells were seeded for 24 hours before the addition of IFN-ɶ (500 IU/ml), IL-6  (100ng/ml) and 
MCP-1 (100ng/ml) for 48 hours. At each time point PC-3 cells were fixed with 4% PFA before the 
addition of FITC-HLA-Class I a,b,c antibody. Fluorescence was detected using a BD FACSCanto 
and results were analysed using FlowJo software. Panels 1 and 2 show staining controls for (1) 
unstained background signalling and (2) FITC background signalling of untreated PC-3 cells. 
Panels 3, 4 and 5 show staining profiles of IFN-ɶ͕ MCP-1 and IL-6 respectively. Results are 
presented as the geometric mean values of stained samples, and data shown is representative 
of two independent replicates of one independent experiment.  
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6.4 Discussion 
 
Signal transducer and activator of transcription 1 (STAT1) is an important mediator of 
the Janus Activated Kinase signalling pathway. STAT1 plays a crucial role in mediating 
immune and pro-inflammatory responses [434, 435] and antitumor responses [433, 436]. 
STAT1 is generally believed to be an antitumor molecule, however some reports describe the 
up-regulation of STAT1 in cancer and therapy resistant cancer cells in comparison with 
normal cells [437, 438]. In support of a tumour-promoting role, STAT1 regulated genes have 
been shown to have anti-apoptotic [439], proliferative [440], and metastatic properties 
[441].  
STAT1 activation is triggered by cytokines, growth factors or hormone binding to cell 
receptors. In this context, interferons (IFN) are the most potent and well known regulators 
of STAT1 activation; upon stimulation STAT1 is phosphorylated forming homo or 
heterodimers that translocate to the nucleus and activate a specific set of genes known 
as IFN-stimulated genes (ISGs). In this regard, SPHK1 has been shown to be regulated by 
STAT1 upon IFN-γ stimulation, with CHIP-Seq data indicating several regions where STAT1 
was binding to SPHK1 DNA either up-stream of the coding region, mostly likely within the 
SPHK1 promoter region, or inside the coding region (Fig.6.1); this could indicate SPHK1 as a 
putative ISG. Our CHIP data analysis on PC-3 cells after co-culture indicated an increase in 
STAT1 binding to SPHK1 promoter after U937 cell stimulation (Fig.6.2). Therefore I 
hypothesise that STAT1 was regulating SPHK1 transcriptional expression during co-culture.  
The U937-induced increase in STAT1 phosphorylation in PC-3 cells after one and 
three hours (Fig.6.3a) came in support of the notion that this phosphorylation may precede 
STAT1 translocation to the nucleus to regulate SPHK1. Interestingly, this effect was 
abrogated by SPHK1 knockdown, indicating that STAT1 could also be regulated by SPHK1 
activated genes. With respect to my previous results it came as a surprise that the absence 
of STAT1 in PC-3 cells, by siRNA targeting, increased SPHK1 expression (Fig.6.4a-b), 
suggesting that STAT1 was having an inhibitory effect on SPHK1 transcription. The effect of 
STAT1 siRNA on SPHK1 expression was not altered by the presence of U937 cells (Fig.6.5a), 
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suggesting that increased SPHK1 expression does not necessarily result in a further increase 
in its expression through the monocyte feedback loop.  
A very recent and interesting work by the Spiegel laboratory, showed that an SPHK1 
increase leads to S1P production and activation of STAT3 through Sphingosine 1-phosphate 
receptor 1 (S1PR1). STAT3 activation then induces a positive feed-back loop involving IL-6, 
resulting in an increase of S1PR1 [299]. Prior to this, Lee et al. indicated that STAT3 is a 
transcription factor for S1PR1 and its activation leads to a persistent activation of STAT3 
resulting in an increase in tumour growth and metastasis [298]. These published works 
indicate that STAT3, and not STAT1, acts as a modulator of this positive feedback loop 
involving S1P, however as STAT3 levels are very low in PC-3 cells, I hypothesised that STAT1 
could be “replacing” STAT3 as an S1P down-stream activator molecule. Indeed, Costa-Pereira 
et al., showed that in STAT3-/- mouse embryo fibroblasts IL-6 induced IFN-γ like responses 
suggesting that IL-6 dependent activation of STAT3 was dependent on STAT1 [442]. In my 
experiments, STAT1 phosphorylation decreases in the absence of SPHK1 (upon U937 cell 
stimulation), suggesting an S1P regulation of STAT1 in a SPHK1 secondary loop-dependent 
mechanism. However without stimulation, STAT1 represses SPHK1 transcription indicating 
that STAT1 can act as an antitumor modulator in the absence of “specific stimuli”.  
Indeed, STAT1 responses appear to be affected by different soluble factors. I have 
shown that IL-6 strongly induces STAT1 phosphorylation in PC-3 cells (Fig.6.6a) and it was 
partially dependent on SPHK1 (Fig.6.6b). To a lesser extent, MCP-1 showed a similar effect 
on STAT1 phosphorylation and its dependency on SPHK1 (Fig.6.6c). Interestingly, the effect 
of these cytokines on IRF-1, an interferon gamma- and STAT1-dependent gene was minimal. 
The finding that both IL-6 and MCP-1 did not result in a great increase in IRF-1 expression, 
indeed MCP-1 induced a clear reduction (Fig.6.7e), indicates that STAT1 activation does not 
necessarily lead to the response of an anti-tumour related gene such as IRF-1 [443]. Whether 
IL-6 induces the activation of a pro-survival set of genes in a STAT1-dependent manner 
remains unclear and should be addressed to clarify the importance of STAT1 in an IL-6 
induced response. The study by Lesinski et al. in melanoma indicated that STAT1 levels were 
not affected by IFN-γ treatment, and in recurrent tumours STAT1 expression proved to be 
higher than in primary tumours [444]. Other groups have reported that STAT1 regulates a 
sub-set of genes involved in radio [438] and chemoresistance [445] upon interferon 
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treatment. It is possible that in the absence or very low levels of STAT3, STAT1 is being 
regulated by cytokines or other soluble molecules that would normally activate STAT3. As a 
consequence, a STAT3 activated set of genes could then be regulated by STAT1, provoking a 
more tumorigenic response in PC-3 cells and consequently a more productive interaction 
with U937 cells. Conversely, IFN-γ strongly induced IRF-1 expression (Fig.6.7a); in 
concomitance HLA class I molecule levels were also increased by IFN-γ (Fig.6.8a-b). HLA class 
I molecules are constitutively expressed in most human cells and can be used as an indicator 
of a secondary phase of IFN-γ transcription activation. Their involvement in antigen 
presenting cell interaction with T lymphocytes leads to an antitumor response [446]. A more 
recent study showed that reduced levels of HLA class I correlate with a poor prognosis in 
patients with non-small cell lung cancer [447]. In my study IL-6 and MCP-1 did not induce 
HLA-Class I molecules despite inducing STAT1 activation (Fig.6.8a-b), and no significant 
increase in IRF-1 expression was observed after either IL-6 or MCP-1 treatment.  
Altogether I have shown that STAT1 is involved in SPHK1 regulation, however the 
repression or activation mechanisms involved still remain unclear. It appears to be 
dependent upon or regulated by different soluble molecules, prompting the notion that the 
tumour microenvironment could dictate a pro or antitumor STAT1 response. Finally I 
propose that the SPHK1/S1P pathway and STAT1 regulation occur through a feedback loop, 
whereby S1P may act as secondary messenger in activating STAT1. A proposed model of this 
possible mechanism is shown below (Fig.6.9).   
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Figure 6.9: Proposed model for STAT1 activation in PC-3 cells. 1) IFN-ɶ receptor binding induces 
STAT1 phosphorylation and translocation to the nucleus where  it is involved in the transcription of  
several genes such as HLA class I and IRF-1. HLA class I is involved in anti-tumoral responses by 
mediating the interaction with APC and T cells. IFN-ɶ represses (red line) SPHK1 and MCP-1 
transcription; the mechanism of  how this repression occurs is not yet understood. 2) PC-3 co-
culture with U937 cells induces STAT1 binding to SPHK1 promoter region increasing its mRNA 
levels. 3) STAT1 knockdown increases SPHK1 mRNA expression levels, suggesting that STAT1 can 
act as a SPHK1 repressor. However, this inhibitory effect appears to be reversed by the interaction 
with U937 cells. The U937-induced increase in AKT phosphorylation is reduced by STAT1 
knockdown, indicating a possible STAT1 regulation on AKT phosphorylation. Interestingly, 4) SPHK1 
knockdown by siRNA reduces STAT1 levels; an effect that could be related with reduced levels of 
S1P. 5) Extracellular MCP-1 induces STAT1 phosphorylation and reduces IRF-1 and HLA Class I, 
supporting the hypothesis that STAT1 can regulate different sets of genes depending on stimulus. 
In support, IL-6 also induces STAT1 but has no effect on IRF-1 or HLA Class I levels. The sequence of 
events may not reproduce the real dynamics existing between U937 and PC-3 cells as some of the 
represented events may occur simultaneously.  
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7. The role of SPHK1 in PC-3 cells resistance to docetaxel during co-
culture 
 
7.1 Introduction 
In patients with locally advanced or metastatic prostate cancer, chemotherapy is 
often given when hormonal therapies have failed. In this context current therapeutics based 
on taxanes, in particular docetaxel, have shown promising results following demonstration 
of beneficial effects on patient survival [448-450]. However, this effect proved to be minor 
as patient survival increase was on average no more than three months; this underlines the 
importance of finding new targets to re-sensitise prostate cancer and subsequently improve 
clinical prognosis. With this objective, Pchejetski et. al firstly reported that SPHK1 over-
expression conferred chemoresistance to docetaxel and camptothecin, whilst the use of a 
pharmacological SPHK inhibitor re-sensitised the cell to these drugs [216]. This report was 
followed with a study by Sauer et. al, whereby a combination of docetaxel and SPHK1 
inhibition led to a 4-fold decrease in the IC50 of docetaxel [78]. Together these findings 
support the use of SPHK1 inhibitors in combination therapy to overcome cancer resistance 
to conventional drugs. 
 Resistance to chemotherapeutic agents can occur due to genetic alterations within 
the cancer cell [451, 452] or by interactions between the cells and their microenvironment 
[453]. In this context the tumour microenvironment has been reported to play an important 
role in chemoresistance, not only in prostate cancer [454] but also in breast [455, 456], 
pancreatic [457] and colorectal cancers [458]. Of particular relevance to the current project 
is the observation that apoptotic tumour cells can secrete S1P to attract and polarise 
macrophages into a tumour-associated phenotype [254, 259]. Considering that the 
SPHK1/S1P pathway has been implicated in chemoresistance [222] and that monocytes can 
up-regulate SPHK1, I hypothesised that monocytes can rescue apoptotic tumour cells via a 
SPHK1/S1P dependent mechanism, and that the signalling pathways involved in this process 
may represent new therapeutic opportunities for limiting tumour progression associated 
with inflammation and chemoresistance. 
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7.2 Effect of U937 monocytic cell line in docetaxel-treated PC-3 cells: the role of 
SPHK1  
To confirm the inhibitory effect of docetaxel (Doc) on prostate cancer cell 
proliferation an SRB assay was performed. PC-3 cells were treated with two different 
docetaxel concentrations, 5nM and 20nM, for up to 72 hours. Docetaxel treatment reduced 
PC-3 cell proliferation at the lower dose of 5nM and completely inhibited proliferation at the 
higher dose of 20nM (Fig.7.1a). As expected from previous work performed in my group, 
20nM docetaxel decreased cell proliferation after only 24 hours of treatment; this effect was 
more evident at 72 hours when a 5-fold difference with respect to non-treated PC-3 cells 
was observed (Fig.7.1a). 
Using a transwell model as described previously, the addition of U937 cells to 
docetaxel treated PC-3 cells proved favourable for cancer cell survival. In a 5nM docetaxel-
treated co-culture, U937 cells promoted an increase in PC-3 proliferation; this effect was 
observed across all three time points, being statistically significant at both 24 and 48 hours 
(Fig.7.1b). Interestingly, the combination of docetaxel treatment and the use of siRNA 
targeting SPHK1 in PC-3 cells abrogated tumour cell proliferation independent of U937s 
(Fig.7.1b). Of note is the observation that siNT PC-3 cells treated with 5nM docetaxel had a 
much lower proliferation than the corresponding untransfected controls (Fig.7.1a); this 
reduction was most likely caused by the extra transfection procedure that these cells were 
subjected to.   
With respect to the 20nM co-culture, the addition of U937 cells also had a positive 
impact on PC-3 cell survival, as characterised by an increased proliferation when compared 
with cells cultured alone (Fig.7.1c). The inhibition of SPHK1 in PC-3 cells by the use of siRNA 
together with docetaxel treatment (20nM) proved to be a potent inhibitor of proliferation 
for these cells as U937 cells could not impact on PC-3 growth upon SPHK1 knockdown 
(Fig.7.1c). 
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Figure 7.1: Effect of docetaxel in PC-3 cell viability during co-culture. a) PC-3 cells were treated 
with or without docetaxel (5 or 20nM) in serum-free media. At each indicated time point SRB 
solution was used to determine PC-3 cell proliferation. b) PC-3 cells were transfected with siRNA 
targeting SPHK1 (siSPHK1) or non-targeting siRNA (siNT) for 24 hours before cells were washed 
with PBS and treated with b) 5nM or c) 20nM of docetaxel for another 24 hours. U937 cells were 
then added to the upper chamber and left incubating for the indicated time points. SRB solution 
was added to the bottom of the transwell after the removal of the upper chamber to measure 
cell proliferation. Data shown is the mean ± SEM of three independent experiments.  Statistical 
analysis was performed using student’s t-test relative to each individual time point. a)***p<0.001 
for PC-3 vs. PC-3 Doc 20nM or §§p<0.01, §§§p<0.001 for PC-3 vs. PC-3 Doc 5nM; b-c) ns p>0.05, 
*p<0.05, **p<0.01, ***p<0.001  for siNT+U937 vs. siSPHK1+U937 or §p<0.05, §§p<0.01, 
§§§p<0.001 for siNT vs. siNT+U937.  
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To understand whether the monocyte-induced increase in docetaxel treated PC-3 cell 
proliferation correlated with a decrease in apoptosis, levels of poly ADP ribose polymerase 
(PARP), an enzyme implicated in DNA repair and programmed cell death, were determined 
by western blotting in PC-3 cells at the indicated time points (Fig.7.2a). As expected, cleaved 
PARP levels were significantly increased by the presence of docetaxel, indicating an 
apoptotic response. The addition of U937 cells decreased cleaved PARP levels in PC-3 cells by 
approximately 2-fold in docetaxel treated cells (20nM) (Fig.7.2a-c). To further investigate 
whether this event was regulated by SPHK1, an apoptotic co-culture assay was performed 
with U937 and PC-3 cells transfected with siRNA targeting SPHK1 (siSPHK1), a non-targeting 
sequence (siNT) and transfection reagent only (Vehicle) control (Fig.7.2b). As demonstrated 
previously, the stimulation of U937 cells led to a decrease in cleaved PARP levels for both 
vehicle control and siNT PC-3 cells; however, in the absence of SPHK1 this effect was not 
observed as the cleaved PARP remained constant upon the addition of U937 cells. These 
findings support the theory that monocytes can confer tumour cell resistance to 
chemotherapeutic agents through SPHK1.   
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a) 
b) 
Figure 7.2: Cleaved PARP levels in docetaxel-treated PC-3 cells following their co-culture with 
U937 cells. a) PC-3 cells were treated with or without docetaxel (20nM) in serum-free media for 
24 hours before the addition of U937 cells to the upper chamber for the indicated duration. 
Cleaved and total PARP levels were determined by western blotting, quantified by Image J 
software and normalised to ɲ-tubulin. b) PC-3 cells were transfected with siRNA targeting SPHK1 
(siSPHK1), non-targeting siRNA (siNT) or transfection reagent (TR) for 24 hours before cells were 
washed with PBS and treated with 20nM of docetaxel for another 24 hours. U937 cells were then 
added to the upper chamber and left incubating for 24 hours more. PC-3 cell lysates were 
collected and Cleaved and total PARP levels were determined by western blotting, quantified by 
Image J software and normalised to ɲ-tubulin. Data shown represents one independent 
experiment performed in duplicate.  
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7.3 SPHK1 regulation in docetaxel-treated PC-3 and U937 cells 
To investigate the involvement of SPHK1 in PC-3 cells during apoptotic co-culture 
with U937 cells, SPHK1 mRNA levels and enzymatic activity were determined at each of the 
indicated time points. The presence of U937 cells triggered a transient increase in SPHK1 
transcriptional levels in PC-3 cells (Fig.7.3a); this effect was observed initially after three 
hours of co-culture when there was an approximate 2-fold increase, whilst a later increase 
was also detected after 24 hours when SPHK1 expression was up-regulated by 3-fold in PC-3 
cultured with U937 cells. At both of these time points the increase proved to be statistically 
significant when compared to corresponding PC-3 cells cultured alone at each time point.  
Similar to SPHK1 mRNA, SPHK1 enzymatic activity in PC-3 cells was clearly increased 
by the presence of U937 cells (Fig.7.3b). Docetaxel treatment of PC-3 cells induced a 
constant response from monocytes that are, in turn, promoting the activation of SPHK1. The 
highest levels of activation were observed following three hours of co-culture whereby an 
approximate 100% increase was observed; indeed this increase in activation proved to be 
statistically significant not only at three hours but also following just one and 24 hours of co-
culture.   
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Figure 7.3: SPHK1 activity and expression in docetaxel-treated PC-3 cells following their co-
culture with U937 cells. a) PC-3 cells were treated with docetaxel (20nM) in serum-free media for 
24 hours before the addition of U973 cells to the upper chamber for the indicated duration. a) 
SPHK1 expression and b) SPHK1 activity were determined in PC-3 cell lysates containing equal 
amounts of mRNA and protein using qRT-PCR and radiolabelling techniques respectively. For qRT-
PCR, SPHK1 mRNA expression levels were normalised using three housekeeping genes, GAPDH, 
YWHAZ and UBC. Data shown is the mean ± SEM of three independent experiments. Statistical 
test was done using student’s t-test relative to each individual time point. ns p>0.05, *p<0.05, 
**p<0.01, for PC-3 Doc vs. PC-3 Doc + U937 cells. 
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Following these initial results, it was important to understand whether the increase 
in SPHK1 levels in PC-3 cells (Fig.7.4) was paralleled in U937 cells. Indeed, there was an up-
regulation of SPHK1 mRNA expression in U937 upon stimulation with apoptotic PC-3 cells for 
all the time points under investigation (Fig.7.4a). Docetaxel alone did not affect SPHK1 
expression in U937 cells over the time-course. It must be noted that docetaxel was not 
added directly to the monocytes, instead, and in order to mimic the co-culture model, 
docetaxel was added for 24 hours to the bottom chamber of the transwell before the 
addition of U937 cells into the top chamber.      
Using the same experimental design as previously described, the enzymatic activity 
of SPHK1 was also measured in U937 cells (Fig.7.4b). Following a similar pattern to that 
observed in PC-3 cells, SPHK1 activity was increased in U937 cells upon the presence of 
apoptotic PC-3 cells. This effect was observed across all the studied time points and proved 
significant up to eight hours of co-culture. Altogether these results indicate an important 
role for SPHK1 during apoptotic co-culture, as its activation in both cell lines appears to be 
important for tumour cell protection against docetaxel. 
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Figure 7.4: SPHK1 activity and expression in U937 cells co-culture with docetaxel treated PC-3 
cells. a) PC-3 cells were treated with docetaxel (20nM) in serum-free media for 24 hours before 
the addition of U973 cells to the upper chamber for the indicated duration. As a control 
docetaxel was added to the bottom chamber for 24 hours before the addition of U937 cells to 
the upper chamber (U937 Doc). a) SPHK1 expression and b) SPHK1 activity were determined in 
U937 cell lysates containing equal amounts of mRNA and protein using qRT-PCR and 
radiolabelling techniques respectively. For qRT-PCR, SPHK1 mRNA expression levels were 
normalised using three housekeeping genes, GAPDH, YWHAZ and UBC. Data shown is the mean 
± SEM of a) two and b) three independent experiments. b) Statistical analysis was performed 
using student’s t-test relative to each individual time point. ns p>0.05, *p<0.05, **p<0.01, for 
U937 doc vs. U937 + PC-3 doc cells. 
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7.4 SPHK1 impact upon cell signalling transduction pathways during co-culture of 
docetaxel-treated PC-3 and U937 cells 
The next step was to understand the molecular mechanisms underpinning SPHK1 
activation. Previous findings indicated that SPHK1 was an important regulator of Akt 
(chapter 4, Fig.4.2) and an increase in Akt phosphorylation was accompanied by an increase 
in SPHK1 levels, therefore it was important to determine Akt phosphorylation levels during 
apoptotic co-culture. For this assay analysis was only performed for the two time points at 
which SPHK1 expression in PC-3 cells was shown to be statistically significant, namely three 
and 24 hours (Fig.7.3a). SPHK1 knockdown efficiency was measured by real time PCR 
(Fig.7.5ai-ii) and showed a 60-70% reduction in SPHK1 mRNA levels; an effect that was 
independent of U937 cell addition at both time points (Fig.7.5ai-ii). Western blotting 
indicated that no increase in Akt phosphorylation levels was apparent in PC-3 cells upon 
stimulation with U937 cells following three hours of co-culture (Fig.7.5bi). SPHK1 knockdown 
had a negative effect on Akt phosphorylation, as demonstrated by a decrease of 50% in 
identified levels, however with the addition of U937 cells these levels were restored to parity 
with non-transfected PC-3 cells (Fig.7.5bi). At a later stage of co-culture, Akt phosphorylation 
levels were increased by the presence of U937 cells; an effect that was abrogated when PC-3 
were transfected with SPHK1 siRNA (Fig.7.5bii). Indeed, the reduced levels of SPHK1 led to a 
reduction in Akt phosphorylation which could not be restored by the presence of U937 cells, 
indicating once more a key role for SPHK1 in Akt regulation.   
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Figure 7.5: SPHK1 expression and AKT phosphorylation levels in docetaxel treated PC-3 cells 
following their co-culture with U937 cells. a) PC-3 cells were transfected with siRNA targeting 
SPHK1 (siSPHK1), non-targeting siRNA (siNT) and b) transfection reagent (TR) for 24 hours before 
cells were washed with PBS and treated with 20nM of docetaxel for another 24 hours. U937 cells 
were then added to the upper chamber and left incubating for further three and 24 hours. a) 
SPHK1 expression in PC-3 cell lysates was determined by qRT-PCR. Three housekeeping genes, 
GAPDH, YWHAZ and UBC were used to normalise. b) AKT phosphorylation levels were 
determined by western blotting, quantified by Image J software and normalised to GAPDH. Data 
shown is the mean ± SEM of a) two independent experiments and b) represents one experiment 
performed in duplicate.   
24 hours Co-culture 
a) 
ii) i) 
 siNT PC-3 siSPHK1 PC-3 
0.0
0.5
1.0
1.5
2.0
2.5
PC-3 Doc PC-3 Doc + U937
S
P
H
K
1
 e
xp
re
ss
io
n
(F
o
ld
 d
iff
e
re
n
ce
)
3 hours Co-culture 
ii) 
b) 
TR siNT siSPHK1 
+ + + + 
+ _ + _ + _ 
+ + 
i) 
1        1.3        1.1      1.2       0.5       1 
pAKT 
GAPDH 
Doc (20nM) 
U937 
3 hours Co-Culture 
pAKT 
GAPDH 
TR siNT siSPHK1 
+ + + + 
+ _ + _ + _ 
+ + Doc (20nM) 
U937 
1       1.3      0.8      1.2        0.5       0.4 
24 hours Co-Culture 
225
Next it was important to understand what molecular regulators were involved in the 
U937 signalling response to PC-3 cells, and if these regulators were dependent on SPHK1 
activation in PC-3 cells. Using the same co-culture model, an analysis of Akt, ERK1/2 and NF-
KB phosphorylation levels in U937 cells was determined by western blotting (Fig.7.6a). The 
levels of Akt phosphorylation in U937 cells were clearly increased by the presence of 
docetaxel-treated PC-3 cells at both time points, with an initial increase observed at three 
hours (Fig.7.6ai- and 7.6bi) increasing further at 24 hours (Fig.7.6aii and 7.6bii). ERK1/2 
phosphorylation was mildly increased by the presence of docetaxel-treated PC-3 cells after 
three hours of co-culture (Fig.7.6ai- and 7.6bi); however, following 24 hours of co-culture a 
larger increase was observed (Fig.7.6aii and 7.6bii). P65, a subunit of the NF-KB complex, 
was also shown to be up-regulated by PC-3 cells at three (Fig.7.6ai- and 7.6bi) and 24 hours 
(Fig.7.6aii and 7.6bii). 
To investigate whether SPHK1 inhibition in docetaxel-treated PC-3 cells would affect 
previously identified U937 signalling pathways such as Akt, ERK1/2 and NF-kB, western 
blotting was performed on protein extracts of U937 cell pellets following their co-culture 
with PC-3 cells transfected with SPHK1 siRNA and treated with docetaxel (Fig.7.7a). 
Interestingly, following three hours of co-culture there was a clear decrease in Akt, ERK1/2 
and NF-KB phosphorylation levels in U937 cells when SPHK1 was knocked down in PC-3 cells 
(Fig.7.7ai and 7.7bi). At 24 hours, there was small increase in Akt and NF-KB phosphorylation 
whereas ERK1/2 was not affected by SPHK1 knockdown in PC-3 cells (Fig.7.7aii and bii). 
These results come in support of the notion that SPHK1 is a major regulator of the tumour 
microenvironment and its activation is vital for other important molecular regulators that 
could ultimately lead to tumour resistance.  
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a) 
b) 
Figure 7.6: Signalling transduction pathways regulation in U937 cells following their co-culture 
with docetaxel-treated PC-3 cells. PC-3 cells were treated with or without docetaxel (20nM) in 
serum-free media for 24 hours before the addition of U973 cells to the upper chamber for the 
indicated duration. As a control docetaxel was added to the bottom chamber for 24 hours 
before the addition of U937 cells to the upper chamber (U937 Doc). a) AKT, NF-kB and ERK1/2 
phosphorylated levels in U937 cell lysates was determined by western blotting, b) quantified by 
Image J software and normalised to α-tubulin. Data shown is the mean ± SEM of two 
independent experiments.  
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Figure 7.7: SPHK1 knockdown in docetaxel-treated PC-3 cells. Effect on AKT, NF-KB and ERK1/2 
phosphorylation levels in U937 cells following their co-culture. PC-3 cells were transfected with 
siRNA targeting SPHK1 (siSPHK1), non-targeting siRNA (siNT) or transfection reagent (TR) for 24 
hours before cells were washed with PBS and treated with 20nM of docetaxel for another 24 
hours. U937 cells were then added to the upper chamber and left incubating for further three and 
24 hours. a) AKT, NF-kB and ERK1/2 phosphorylated levels in U937 cell lysates was determined by 
western blotting, b) quantified by Image J software and normalised to ɲ-tubulin. Data shown is 
the mean r SEM of two independent experiments.  
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7.5 MCP1 secretory levels during co-culture of docetaxel-treated PC-3 and U937 
cells: the role of SPHK1  
Following the observed increases in MCP-1 and IL-6 expression and secretion during 
non-apoptotic co-culture (as discussed in chapters 5 and 6), it was important to understand 
if these two molecules were also playing a role during apoptotic co-culture between PC-3 
and U937 cells. For this purpose the media from previous co-cultures (Fig.7.4 and Fig.7.5) 
was collected and MCP-1 and IL-6 levels were analysed by ELISA. Interestingly MCP-1 
secreted levels and mRNA were increased by the presence of U937 cells; this effect was 
more significant at 24 hours (Fig.7.8ai-ii). The use of siRNA targeting SPHK1 in PC-3 cells did 
not affect the overall levels of MCP-1 present in the media (Fig.7.8b).  
 
A similar effect was observed in U937 cells proximity media, as the extracellular 
levels and mRNA expression of MCP-1 were higher when PC-3 cells were also present 
(Fig.7.9ai-ii), however no difference was noted when SPHK1 was knocked down in PC-3 cells 
(Fig.7.9b). Interestingly, the MCP-1 levels were higher in the media proximal to U937 than in 
the media adjacent to PC-3 cells (Fig.7.8). This comes as a surprise as in the non-apoptotic 
co-cultures the PC-3 cell media was shown to have higher levels than the U937 media 
(discussed previously in chapters 4 and 5). 
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Figure 7.8: MCP-1 levels in docetaxel treated PC-3 cells during co-culture with U937 cells. a) 
PC-3 cells were treated with docetaxel (20nM) in serum-free media for 24 hours before the 
addition of U973 cells to the upper chamber for the indicated duration. b) PC-3 cells were 
transfected with siRNA targeting SPHK1 (siSPHK1) or non-targeting siRNA (siNT) for 24 hours 
before cells were washed with PBS and treated with 20nM of docetaxel for another 24 hours. 
U937 cells were then added to the upper chamber and left incubating for further three and 24 
hours. ai,b) MCP-1 concentration in the bottom chamber media was determined by ELISA. 
Media was incubated with MCP-1 specific antibodies and a standard curve was used to quantify 
the relative amount of MCP-1 in each sample. Protein concentration of each cell lysate was used 
for normalisation. aii) MCP-1 expression in PC-3 cell lysates was determined by qRT-PCR. Three 
housekeeping genes, GAPDH, YWHAZ and UBC were used to normalise. Data shown is the mean 
± SEM of a) three and b) two independent experiments. a) Statistical analysis was performed 
using student’s t-test relative to each individual time point. ns p>0.05, *p<0.05 for PC-3 Doc vs 
PC-3 Doc +U937.  
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Figure 7.9: MCP-1 levels in U937 cells during co-culture of docetaxel treated PC-3 cells. a) PC-3 
cells were treated with docetaxel (20nM) in serum-free media for 24 hours before the addition 
of U973 cells to the upper chamber for the indicated duration. b) PC-3 cells were transfected 
with siRNA targeting SPHK1 (siSPHK1) or non-targeting siRNA (siNT) for 24 hours before cells 
were washed with PBS and treated with 20nM of docetaxel for another 24 hours. U937 cells 
were then added to the upper chamber and left incubating for further three and 24 hours. As a 
control docetaxel was added to the bottom chamber for 24 hours before the addition of U937 
cells to the upper chamber (U937 Doc). ai,b) MCP-1 concentration in the upper chamber media 
was determined by ELISA. Media was incubated with MCP-1 specific antibodies and a standard 
curve was used to quantify the relative amount of MCP-1 in each sample. Protein concentration 
of each cell lysate was used for normalisation. aii) MCP-1 expression in U937 cell lysates was 
determined by qRT-PCR. Three housekeeping genes, GAPDH, YWHAZ and UBC were used to 
normalise. Data shown is the mean ± SEM of ai) two, aii) three and b) one independent 
experiment. aii) Statistical analysis was performed using student’s t-test relative to each 
individual time point. ns p>0.05, *p<0.05 for U937 Doc vs U937 + PC-3 Doc. 
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7.6 IL-6 secretory levels during co-culture of docetaxel-treated PC-3 and U937 cells: 
the role of SPHK1  
The same ELISA procedure was performed to measure IL-6 extracellular levels during 
co-culture. In PC-3 proximity media, IL-6 secretory levels (Fig.7.10ai)  and mRNA expression 
(Fig.7.10aii) were mildly increased by the presence of U937 cells, however the increase did 
not prove to be statistically significant (Fig.7.10aii). Importantly, the use of SPHK1 siRNA did 
not affect IL-6 secretion in PC-3 cells cultured alone, however during co-culture SPHK1 
proved to be necessary as IL-6 secretion was reduced by approximately 2-fold when PC-3 
cells were transfected with SPHK1 siRNA (Fig.7.10b). 
 An approximate 60% increase in IL-6 was detected in U937 cells media upon co-
culture with PC-3 cells for 24 hours (Fig.7.11ai). IL-6 mRNA was also increased in U937 cells 
co-cultured with docetaxel-treated PC-3 cells after one hour (Fig.7.11aii). Interestingly, IL-6 
secretion from U937 cells was slightly reduced by the absence of SPHK1 signalling from PC-3 
cells after 24 hours in co-culture (Fig.7.11b). It must be noted that experiments 7.10b and 
7.11b were performed only once; therefore it is important that these data are analysed and 
considered with caution as further repeats are required to gain confidence in the results and 
allow the drawing of more assertive conclusions. 
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Figure 7.10: IL-6 levels in docetaxel treated PC-3 cells during co-culture with U937 cells. a) PC-3 
cells were treated with docetaxel (20nM) in serum-free media for 24 hours before the addition 
of U973 cells to the upper chamber for the indicated duration. b) PC-3 cells were transfected 
with siRNA targeting SPHK1 (siSPHK1) or non-targeting siRNA (siNT) for 24 hours before cells 
were washed with PBS and treated with 20nM of docetaxel for another 24 hours. U937 cells 
were then added to the upper chamber and left incubating for further three and 24 hours. ai,b) 
IL-6 concentration in the bottom chamber media was determined by ELISA. Media was 
incubated with IL-6 specific antibodies and a standard curve was used to quantify the relative 
amount of IL-6 in each sample. Protein concentration of each cell lysate was used for 
normalisation. aii) IL-6 expression in PC-3 cell lysates was determined by qRT-PCR. Three 
housekeeping genes, GAPDH, YWHAZ and UBC were used to normalise. Data shown is the mean 
± SEM of a) three and b) one independent experiments. aii) Statistical analysis was performed 
using student’s t-test relative to each individual time point. ns p>0.05 for PC-3 Doc vs PC-3 Doc 
+U937.  
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Figure 7.11: IL-6 levels in U937 cells during co-culture of docetaxel treated PC-3 cells. a) PC-3 
cells were treated with docetaxel (20nM) in serum-free media for 24 hours before the addition 
of U973 cells to the upper chamber for the indicated duration. b) PC-3 cells were transfected 
with siRNA targeting SPHK1 (siSPHK1) or non-targeting siRNA (siNT) for 24 hours before cells 
were washed with PBS and treated with 20nM of docetaxel for another 24 hours. U937 cells 
were then added to the upper chamber and left incubating for further three and 24 hours. As a 
control docetaxel was added to the bottom chamber for 24 hours before the addition of U937 
cells to the upper chamber (U937 Doc). ai,b) IL-6 concentration in the upper chamber media was 
determined by ELISA. Media was incubated with IL-6 specific antibodies and a standard curve 
was used to quantify the relative amount of IL-6 in each sample. Protein concentration of each 
cell lysate was used for normalisation. aii) IL-6 expression in U937 cell lysates was determined by 
qRT-PCR. Three housekeeping genes, GAPDH, YWHAZ and UBC were used to normalise. Data 
shown is the mean ± SEM of ai) two, aii) three and b) one independent experiment. aii) 
Statistical analysis was performed using student’s t-test relative to each individual time point. ns 
p>0.05 for U937 Doc vs U937 + PC-3 Doc. 
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7.7 Identification of soluble mediators involved in the co-culture of docetaxel-
treated PC-3 and U937 cells 
In order to understand what other factors may be involved in the apoptotic co-
culture of PC-3 with U937 cells, a proteome profiler assay was performed. Media from PC-3 
cells cultured with docetaxel for 48 hours, PC-3 treated with docetaxel for 24 hours and then 
cultured with U937 for another 24 hours, and media from U937 cells cultured in the 
presence of docetaxel for 24 hours were added separately to individual membranes pre-
coated with 36 different antibodies (Fig.7.12a). The media from PC-3 co-cultured with U937 
cells showed an increase in CD40L, siCAM-1, IL-16 and IL-32α in comparison with either PC-3 
or U937 cells cultured alone (Fi.7.12b). CD40L secretion was mildly increased by the 
presence of U937 cells, whilst as for siCAM-1 secretion there was an increase of 
approximately 4-fold in comparison with PC-3 cells cultured alone and a 2-fold increase in 
comparison with U937 cells cultured alone. IL-16 and IL-32α also showed similar increases 
when compared with PC-3 cells cultured alone, however the secretion of these molecules by 
U937 cells alone could explain this and may suggest that these effects are rather a 
consequence of media diffusion than of the presence of PC-3 cells.  
Based upon the initial findings from the previous assay, a more detailed investigation 
of CD40L and siCAM-1 with respect to their regulation by SPHK1 was proposed. For CD40L it 
was not possible to validate the previous results or explore further its role in SPHK1 
regulation due to technical difficulties with the ELISA for this cytokine, despite several 
attempts to resolve the issue. As for siCAM-1, its secreted levels were increased during co-
culture when compared with PC-3 cells cultured alone (Fig.7.13a). This effect was observed 
at all the studied time points and proved to be independent of SPHK1 as its knockdown did 
not inhibit siCAM-1 secretion (Fig.7.13b). A similar effect was observed in U937 cell media, 
were siCAM-1 secretion was increased by the presence of U937 cells but was not affected 
the absence of SPHK1 in PC-3 cells (Fig.7.13c). The relative values of siCAM-1 suggest PC-3 
cells as the main secretors and most likely responsible for the increase observed in U937 cell 
media, through the natural diffusion that occurs during co-culture. A possible role for siCAM-
1 in chemoresistance could be hypothesised from these findings, however further 
investigation is required to validate this preliminary data.    
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Figure 7.12 Proteome Profiler Assay in apoptotic co-culture. a) PC-3 cells were treated with 
docetaxel (20nM) in serum-free media for 24 hours before the addition of U973 cells to the 
upper chamber for further 24 hours. As a control docetaxel was added to the bottom chamber 
for 24 hours before the addition of U937 cells to the upper chamber (U937 Doc). After collection, 
media was centrifuged in order to remove non-adherent cells. Each media was incubated 
individually with a pre-probed membrane. Signal intensity for each of the 36 molecules on the 
membrane was measured using Image J software and the average intensity from the duplicate 
samples calculated. b) The results obtained for selected molecules are presented graphically and 
were normalised to the protein content; data is representative of a single experiment.  
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Figure 7.13: soluble ICAM-1 levels during co-culture of docetaxel treated PC-3 with U937 cells. a) 
PC-3 cells were treated with or without docetaxel (20nM) in serum-free media for 24 hours. 
sICAM-1 concentration in the upper chamber media was determined by ELISA. Media was 
incubated with siCAM-1 specific antibodies and a standard curve was used to quantify the relative 
amount of sICAM-1 in each sample. Protein concentration of each cell lysate was used for 
normalisation.  b-c) PC-3 cells were transfected with siRNA targeting SPHK1 (siSPHK1) or non-
targeting siRNA (siNT) for 24 hours before cells were washed with PBS and treated with 20nM of 
docetaxel for another 24 hours. U937 cells were then added to the upper chamber and left 
incubating for further three and 24 hours. As a control docetaxel was added to the bottom 
chamber for 24 hours before the addition of U937 cells to the upper chamber (U937 Doc). sICAM-
1 concentration in the b) upper and c) lower chamber was determined was described in (a). Data 
shown is the mean ± SEM of a) three and b-c) two independent experiments. a) Statistical analysis 
was performed using student’s t-test relative to each individual time point. **p>0.01 for PC-3 vs 
PC-3 Doc.  
3h 24h
0
2000
4000
6000
8000
10000
siNT Doc
siNT Doc + U937
siSPHK1 Doc
siSPHK1 Doc + U937
pg
 o
f s
IC
A
M
-1
/m
g 
to
ta
l p
ro
te
in
3h 24h
0
2000
4000
6000
U937 Doc
U937 + siNT Doc
U937 + siSPHK1 Doc
pg
 o
f s
IC
A
M
-1
/m
g 
to
ta
l p
ro
te
in
237
7.8 Discussion 
A dysregulation in the balance of sphingolipid metabolism towards the activation of 
the SPHK1/S1P pathway has been linked with the acquisition of several oncogenic 
characteristics such as cancer cell proliferation, metastasis and chemoresistance [459-461]. 
SPHK1/S1P inhibition was synergistic with camptothecin [216], docetaxel [78] and radiation 
therapy [144] and led to a re-sensitisation of cancer cells to these therapies. In a tumour 
microenvironment context S1P is known to act as a strong chemoattractant for the 
recruitment of immune cells [459, 462]. S1P has been shown to be secreted from apoptotic 
leukemic cells; consequently monocytes and macrophages were attracted to these dying 
cells via S1P [259]. In this context I investigated the involvement of SPHK1/S1P in monocyte-
induced resistance to chemotherapy in apoptotic tumour cells. I found that U937 cells 
increased proliferation in docetaxel-treated PC-3 cells; this effect was significant either with 
a lower (Fig.7.1b) or higher (Fig.7.1c) docetaxel concentration. In support, cleaved PARP 
levels were also reduced in docetaxel-treated PC-3 cells after co-culture with U937 cells 
(Fig.7.2a) indicating a protective effect of this co-culture. Interestingly SPHK1 levels in PC-3 
cells were crucial for monocytes to rescue apoptotic cells, as the use of siRNA targeting 
SPHK1 in these cells abrogated U937-induced proliferation (Fig.7.1b and Fig.7.1c) and 
inhibited the decrease in cleaved PARP levels in PC-3 cells (Fig.7.2b). Supporting the 
importance of SPHK1, PC-3 (Fig.7.3) and U937 cells (Fig.7.4) both showed an increase in 
SPHK1 transcription and enzymatic activity following their co-culture; in fact SPHK1 activity 
in both cells was consistently increased when in co-culture (Fig.7.3b and Fig.7.4b). These 
results are clear indicators that monocytes are responding to apoptotic PC-3 cells and vice 
versa, with SPHK1 being one of the main regulated molecules.  
Due to its autocrine and paracrine action, S1P emerges as a possible regulator and 
activator of SPHK1 in both cell types. I previously showed that S1P can induce SPHK1 
transcriptional activation in both PC-3 and U937 cells (chapter 4 and 5). Other groups have 
also suggested that S1P is involved in cancer cell resistance via a “cross-talk” interaction with 
macrophages, for instance Weigert et al. showed that apoptotic breast cancer cells (MCF-7) 
induced macrophage polarisation towards an alternative phenotype, leading to an increase 
in their viability. More interestingly the use of the apoptosis resistant MCF-7-Bcl2 cell line 
failed to induce an alternative activation of macrophages leading to a loss of cell viability in 
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MCF-7; a similar effect was also seen when S1P production was inhibited, suggesting a role 
for apoptosis-released S1P in induction of macrophage polarisation [463]. In support, Gude 
et al. showed that S1P was released from U937 cells upon doxorubicin treatment; 
interestingly this increase was accompanied by an increase in SPHK1 expression and led to 
an attraction of other monocytes and macrophages [259].  
The use of siRNA against SPHK1 in PC-3 cells not only affected Akt regulation in these 
cells (Fig.7.5) but also affected important signalling molecules such as ERK1/2, NF-KB and Akt 
in U937 cells (Fig.7.7). In fact, for the first time it is shown that SPHK1 levels in cancer cells 
can regulate the activation of ERK1/2, NF-KB and Akt in monocytes. Indeed, these pathways 
were activated in U937 cells upon the presence of apoptotic PC-3 cells (Fig.7.6), but to a 
lesser extent when SPHK1 was repressed in PC-3 cells. This comes in support of the concept 
that SPHK1 is involved in the secretion of soluble molecules from apoptotic tumour cells that 
in turn lead to the activation of pro-survival pathways in monocytes. Reports in the literature 
indicate Akt and ERK1/2 as important regulators of myeloid survival. Marfe et al. showed 
that Akt inhibition in resistant chronic myeloid leukaemia cells (Ki562) led to an increase in 
cell sensitivity to imatinib (tyrosine kinase inhibitor). With particular relevance to this work, a 
decrease in SPHK1 expression and activity was observed when Akt was inhibited [187]. In 
accordance, another study showed human primary monocyte-derived macrophages 
increased their resistance to TNF-α and Cycloheximide (CHX) induced-apoptosis when 
cultured in the presence of apoptotic cell media or S1P. This protection was found to be 
dependent on Akt, and to a less extent ERK1/2, activation as the use of pharmacological 
inhibitors for Akt and ERK1/2 increased their sensitivity to TNF-α and CHX [254]. These 
findings suggest an important role of Akt and ERK1/2 in macrophage resistance to apoptosis 
and modulation of their response to cancer cells. Importantly, my work shows that Akt and 
ERK1/2 can be indirectly inhibited in monocytes by SPHK1 inhibition in apoptotic cancer 
cells, supporting the concept of SPHK1/S1P involvement in apoptotic cross-talk between 
cancer cells and their surroundings.  
As for other possible mediators in the apoptotic tumour-monocyte interaction, MCP-
1 and IL-6 were considered as their levels were previously found to be high during co-culture 
of untreated PC-3 (chapter 4, Fig.4.7 and Fig.4.10) with U937 cells (chapter 5, Fig.5.10 and 
Fig.5.15). Despite their increase during co-culture in the presence of docetaxel, secreted 
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levels of both MCP-1 (Fig.7.8 and Fig.7.9) and IL-6 (Fig.7.10 and Fig.7.11) did not prove to be 
affected by SPHK1 knockdown in PC-3 cells, with the exception of IL-6 at 24 hours 
(Fig.8.10b). It should be noted that the experiments shown in figures 7.8b, 7.9b, 7.10b and 
7.11b, were performed only once; it is therefore important that analysis of these data is 
considered with caution as further repeats are required to gain confidence in the results. 
However, and together with the previous chapters, these results suggest a SPHK1-
independent regulation of these cytokines during apoptotic co-culture and indicate the 
activation of other pathways during this interactive process. Nonetheless in previous 
chapters IL-6 was shown to regulate SPHK1 expression and activity in PC-3 (chapter 4, 
Fig.4.12a-b) and U937 cells (chapter5, Fig.5.17), as well as MCP-1 expression in U937 
(chapter 5, Fig.5.19). It is certainly possible that the same phenomenon is occurring during 
apoptotic co-cultures and it is therefore important to study their role in greater detail. An 
interesting study showed that MCP-1 mRNA levels were increased upon docetaxel treatment 
in two different prostate cancer cell lines (LNCaP and LAPC4), whilst the inhibition of MCP-1 
re-sensitised cells to docetaxel inhibitory effect upon cell proliferation. In addition, it was 
shown that in patients that underwent chemotherapy a significant increase in gene 
expression of MCP-1 and IL-6 was observed in tumours. [464].  
Supporting the role of IL-6 in tumour chemoresistance, Castells et al. proposed that 
IL-6 secreted by macrophages led to an increase in chemoresistance in ovarian cancer cells, 
however the factor triggering IL-6 secretion was not identified [465]. Furthermore, Wang et 
al. showed that IL-6 treatment of multiple myeloma cells led to an activation of SPHK1, 
resulting in protection from apoptosis, and SPHK1 siRNA inhibited the IL-6 effect on cell 
protection, leading to an increase in apoptosis [294].  
The proteome profiler assay indicated other potential targets such as siCAM-1, CD40L 
and IL-32α (Fig.7.12). siCAM-1 is a soluble form of Intracellular Adhesion Membrane-1 
(ICAM-1) that is shed from cells, and high levels have been found in serum of patients with 
inflammation, infection and cancer [319]. In vivo it has been reported to promote tumour 
growth [466] and in patients with colorectal cancer siCAM-1 levels were significantly higher 
than in control patients, with high levels correlating with formation of metastasis. A more 
recent study showed the involvement of S1P/S1PR2 in ICAM-1 expression through an NF-KB 
dependent mechanism [467]. In this study I show for the first time that siCAM-1 is secreted 
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from PC-3 cells upon docetaxel treatment (Fig.7.13a) and this effect is even more 
accentuated in the presence of U937 cells (Fig.7.13b), but does not appear to be mediated 
by SPHK1 (Fig.8.13c). Altogether, siCAM-1 appears to play a role in cancer development and 
could be an important mediator in the acquisition of drug-resistance by cancer cells. The 
exact effect on monocyte activation and recruitment as well as its involvement in SPHK1 
regulation is not known yet and should be studied in further detail.   
CD40L and IL-32α levels during apoptotic co-culture were not possible to measure, 
however reports in the literature suggest a possible role in cancer-immune cell interactions 
for these two molecules. Futagami et al. showed that CD40L and MCP-1 stimulated 
macrophages and induced the expression of COX-2 correlating with an increase in PGE2 and 
VEGF production [468]. On the contrary, CD40L has been reported to have anti-tumour 
activity; however its soluble form sCD40L contributes to systemic inflammatory diseases 
[469]. Another interesting molecule that was up-regulated in the apoptotic PC-3 co-culture 
was IL-32α, a pro-inflammatory cytokine that has been shown to be activated by other 
cytokines such as TNF-α and IL-1β through PI3K and NF-ĸB activation in myofibroblasts [470]. 
Nishida et al. showed an increase in IL-32α expression in pancreatic cancer cells when 
compared with normal pancreatic cells; moreover, the use of IL-32α-specific siRNA 
suppressed the expression of Bcl-2 and Mcl-1, known anti-apoptotic proteins, leading to an 
increase in apoptosis [471]. Together with siCAM-1 these two molecules are likely to play a 
role in tumorigenesis and inflammation, so their role in SPHK1 regulation and prostate 
cancer progression should be assessed.   
Taken together these data re-enforce the idea that SPHK1 should be considered as a 
possible target as part of a combined therapy with chemotherapeutic agents, in particular 
when monocytes/macrophages are highly present as part of the stromal microenvironment. 
The ability of SPHK1 to influence other important signalling pathways via autocrine or 
paracrine actions of its regulatory molecules should be considered as an important 
therapeutic target against cancer and its stromal microenvironment cross-talk.  
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8. General Discussion 
 
8.1 SPHK1 and cancer development 
 
Sphingosine Kinase-1 (SPHK1) is a highly conserved lipid kinase that is ubiquitously expressed 
and catalyses the formation of sphingosine-1-phosphate (S1P), an important mediator with 
intra and extracellular functions.  S1P and SPHK1 can regulate a wide range of cellular 
processes, including cell proliferation, survival, migration and immune cell trafficking. A 
deregulation in SPHK1 levels has been described in many cancers such as prostate, breast, 
lung and pancreatic, with increased levels associated with poor clinical prognosis. 
Conversely, SPHK1 down-regulation by siRNA or pharmacological inhibition markedly 
reduced cell proliferation in both an in vitro and in vivo setting [144, 203, 222]. Of particular 
relevance to this study, the SPHK1 inhibitor SKi-II was previously described to have in vivo 
anti-tumoral activity; French et al showed an approximate 60% reduction in JC mammary 
adenocarcinoma mouse model after 10 days with dose of 100mg/kg [472]. In this study, my 
data upholds these findings and shows that in vivo SKi-II significantly impairs tumour growth 
in a xenografted prostate cancer model. This effect was accompanied by a decrease in 
SPHK1 mRNA, supporting SPHK1 as a valid target for cancer therapeutics. It is important to 
note that future therapies using SPHK1 inhibitors should consider each type of cancer as 
individual cases as supported by recent reports indicating that some tumours appear to 
respond better to different sphingosine kinsase inhibitors. This is demonstrated in a recent 
study that shows only SKi-I, and not SKi-II, can act as a tumour growth inhibitor in melanoma 
tumours [351].  
In a cancer related event, it is thought that tumour cells are able to recruit 
inflammatory cells to the tumour site and orchestrate their response towards a pro-
tumorigenic effect [389, 473]. Previous studies have demonstrated the capabilities of 
monocytes in promoting tumour development in both in vitro and in vivo models [246, 248, 
250]. In this study, and using a co-culture system, my data supports the positive effect of 
monocytes on cancer cell proliferation, more specifically in prostate (PC-3) and breast cancer 
cells (MDA-231 and BT549). This effect extends to PC-3 cells treated with docetaxel, as 
monocytes are capable of reducing the inhibitory effect of this drug on cancer cell 
242
proliferation. This is of particular relevance as the microenvironment has been suggested to 
play an active role in supporting cancer against such drugs, as exemplified by the tendency 
of CRPC tumours to become unresponsive to chemotherapeutic agents, resulting in a poor 
clinical prognosis for the patient. My group have previously shown that targeting SPHK1 
sensitises prostate cancer cells to docetaxel, whilst SPHK1 overexpression induces an 
opposite effect [216]. My data upholds these findings and shows that SPHK1 targeted 
inhibition not only reduces tumour cell growth but can also reduce the positive impact of 
monocytes on resistance to current chemotherapeutic drugs such as docetaxel. 
  In addition, I show for the first time that SPHK1 enzymatic activity and transcriptional 
regulation is up-regulated in both cancer cells and monocytes during co-culture indicating 
the involvement of SPHK1 in the signalling mechanisms driving this interaction. In support, I 
showed that SPHK1 inhibition in PC-3 cells not only abrogates the monocyte-induced effect 
on PC-3 cell proliferation but also decreases SPHK1 levels in monocytes. Furthermore, SKi-II 
pre-treatment of monocytes reduces SPHK1 activation in PC-3 cells, re-enforcing the 
existence of a bidirectional signalling loop mediated by SPHK1. Indeed the existence of a 
positive signalling loop mediated by SPHK1 has been proposed, with two recent papers 
indicating the SPHK1/S1P/S1PR1 loop as being persistently activated in tumours and acting 
as a main driver for tumour development and persistent inflammatory conditions [299, 474]. 
According to my results, S1P can indeed lead to the activation of SPHK1 in both cancer cells 
and monocytes and therefore be considered a possible mediator in this interaction. The role 
of S1P in tumour development has been demonstrated in several xenograft models where 
the use of an S1P targeting antibody leads to a significant reduction in tumour growth [214]. 
Further investigation is required to assess S1P levels as well as the importance of S1P 
receptors during this interaction between different cell types. In an inflammatory context, 
the secretion of S1P from apoptotic cells was shown to induce macrophage polarization 
[463] and secretion by macrophages of prostaglandin E(2) (PGE2), a known inducer of cancer 
migration and proliferation [475], to support cancer progression . Interestingly, my data 
shows a higher SPHK1 activation in monocytes when PC-3 cells were treated with docetaxel, 
which in part could be mediated by the S1P released from apoptotic cancer cells.  
Altogether these data reveals the importance of SPHK1 during cancer-monocyte 
interaction and reveals the existence of a paracrine signalling loop between these two cell 
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types. This loop is mediated by soluble molecules that appear to be under SPHK1 regulation 
being S1P a very plausible and natural candidate. More importantly I show that SPHK1 target 
therapy could not only affect targeted cells but also its surrounding and therefore impact on 
the cancer microenvironment which is a known promoter of cancer progression.   
 
8.2 Mechanism of SPHK1 regulation during co-culture 
 
SPHK1 occupies a powerful position in sphingolipid metabolism and consequently in 
many biological processes with implications in several malignancies such as cancer. A better 
understanding of SPHK1 regulatory pathways is of great interest as it could explain the 
mechanism through which SPHK1 exerts its pro-survival actions in cancers. In this context, 
accumulating evidence suggests AKT, an oncogenic protein often activated in prostate 
cancer, to be under SPHK1 regulation [340, 342, 476]. In my study AKT activation follows a 
similar pattern as observed for SPHK1; the increase in phosphorylation levels in both PC-3 
and U937 cells during co-culture suggests a cross-regulation between these two oncogenic 
proteins. A further evidence of this regulation arises from the findings in which AKT 
phosphorylation is reduced upon siRNA targeting of SPHK1 in cancer cells; this effect was 
monocyte independent as the addition of monocytes did not affect SPHK1-induced AKT 
inhibition. Interestingly, SPHK1 inhibition in PC-3 cells reduced AKT phosphorylation in 
monocytes supporting once more the existence of a SPHK1 regulatory loop during co-
culture. Indeed, in other studies it has been shown that AKT activation was mediated by a 
SPHK1/S1P signalling loop [187, 406, 477], however these studies were focused on the 
autocrine loop and did not investigate the involvement of a paracrine loop within a 
stimulatory microenvironment. Here I propose a bidirectional model whereby SPHK1 
activation leads to the production and secretion of S1P that in turn can induce AKT and 
SPHK1 activation in neighbouring cells, creating favourable conditions for tumour 
development. The ability of S1P to increase AKT phosphorylation in either PC-3 or U937 cells 
supports of this model and accords with other studies showing a similar effect on AKT 
phosphorylation by S1P [477-479].  
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ERK1/2 is another important signalling molecule that also appears to play a role in 
this interaction; interestingly the increase in ERK1/2 phosphorylation levels in U937 follows a 
similar trend to that observed for AKT and SPHK1. The capability of ERK1/2 to phosphorylate 
and activate SPHK1 is well described in the literature [166, 182], and I propose that ERK1/2 
activation could be an early event in the SPHK1/S1P/AKT signalling loop between cancer cells 
and monocytes. Evidence in this work support this model, with particular reference to the 
decrease of SPHK1 expression and AKT phosphorylation in monocytes when ERK1/2 was 
silenced by siRNA in PC-3 cells. This indicates the ability of ERK1/2 to impact upon molecules 
that are able to activate SPHK1 and AKT in U937 cells, and suggests a more detailed analysis 
of S1P levels in ERK1/2 knockdown co-culture would be informative. The increased levels 
and/or phosphorylation of these important signalling molecules (AKT, ERK1/2 and SPHK1) in 
both cancer cells and monocytes indicates an activation of pathways involved in essential 
cellular functions that underpin the biology of cancer and supports the important role of 
monocytes in its development.                                                                                                                                                                 
 The transcriptional regulation of SPHK1 appears to be directly mediated by STAT1 
when PC-3 cells are in co-culture with U937 cells. STAT1 binding to the up-stream genomic 
region of SPHK1 suggests a possible binding to the promoter, leading to increased 
transcription of SPHK1. However, this activation appears to be modulated by monocytes, 
more specifically by their secreted molecules. Most studies attribute a pro-apoptotic and 
tumour-repressive role to STAT1 activation [354, 367], however a few reports indicate that 
STAT1 activation is associated with oncogenic events [374, 438]. Here I propose that the 
repressive role of STAT1 in SPHK1 transcription is overcome by U937 cell stimulation; the 
mechanisms by which this switch may occur remain unclear. 
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8.3 Signalling molecules 
 
MCP-1 is a known inflammatory mediator involved in cancer development [309]. In 
this study, my data shows an increase in MCP-1 mRNA and secreted protein levels in both 
prostate cancer cells (PC-3) and U937 cells when in co-culture, reinforcing the importance of 
this chemokine in prostate cancer growth and proliferation [323] and of the inflammatory 
state in prostate cancer development [304, 309, 322]. The ability of SPHK1 to regulate 
inflammatory mediators such as MCP-1 has been previously reported in lung carcinoma cells 
[326], mast cells [324] and epithelial cells [293]; here I show that SPHK1 knockdown can 
partially abrogate U937-induced increase of MCP-1 levels in PC-3 cells. This is significant as it 
has been shown that MCP-1 secreted from prostate cancer cells acts as a driver for 
macrophage infiltration that in turn benefits tumour cell growth and survival [322]. These 
data deem it reasonable to propose that SPHK1 modulation could provide a novel approach 
in treating prostate cancer associated with a highly inflammatory state.  
 
Another important inflammatory mediator with a proven effect on prostate cancer 
development is IL-6 [290]. In this study, SPHK1 inhibition in PC-3 cells did not result in a 
decrease in IL-6 mRNA or secreted levels suggesting that IL-6 is not under SPHK1 regulatory 
control in PC-3 cells as has been previously demonstrated in other cell types [294, 480, 481]. 
However, the ability of S1P and MCP-1, which are under SPHK1 regulation, to increase IL-6 
mRNA expression levels in monocytes could explain the increase observed in the U937 
proximity media. Interestingly ERK1/2 and AKT levels in PC-3 cells appear to be important for 
the increase in IL-6 mRNA in U937 cells, indicating that in PC-3 cells ERK1/2 and AKT 
activation can also mediate the secretion of soluble factors in a SPHK1-independent manner. 
Alterations of these pathways during co-culture appears to dictate the secretory profile of 
each cell type, with the dynamic balance between these factors varying with time as well as 
the requirements of the cells. The bidirectional activation of these strong pro-tumorigenic 
mediators [327, 401] supports the model in which cancer cells benefit from the interaction 
with monocytes, with SPHK1 having an important role in their activation. A recent study 
deemed the role of SPHK1 in macrophages as negligible for the formation of inflammatory 
responses [482]; in the study murine macrophages lacking SPHK1 and SPHK2 did not 
decrease cytokine expression after treatment with inflammatory mediators such as LPS and 
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TNF-α. This contradicts previous studies, which have shown that SPHK1 inhibition in 
macrophages leads to reduction of pro-inflammatory cytokines such as IL-6 and MCP-1 [297, 
483, 484]. It is possible that macrophages without SPHK1 from an early stage of 
development could acquire other mechanisms that compensate for SPHK1 absence. Despite 
the observation that an absence of SPHK1 results in a reduction of intracellular S1P [482] it 
would be interesting to look at other SPHK1 intracellular regulated molecules in the murine 
knockout cells, such as AKT or ERK1/2, to understand if the basal levels remain the same as 
those of the control macrophages.  
 
 Other soluble factors were detected in this study that could play an important role in 
cancer-monocyte signalling interactions. In the case of GM-CSF, my study reveals for the first 
time a possible regulation by SPHK1 of secreted GM-CSF protein levels. This is particularly 
relevant as GM-CSF is a known inducer of prostate cancer proliferation [415] and has been 
described to have a role in monocyte and macrophage proliferation [410]. The targeted 
inhibition of SPHK1 in cancer cells could reduce GM-CSF release from such cells, resulting in 
possible disruption of one of the signalling molecules that cancer cells use to recruit immune 
cells. The ability of GM-CSF to activate AKT and ERK1/2 through the RAS pathway [485] 
reinforces its potential as one of the mediators involved in ERK1/2 and AKT phosphorylation 
in monocytes in my co-culture model.   
 
Similarly, GROα association with the SPHK1/S1P pathway has not been described in 
literature. Evidence exists that GROα inhibition leads to a reduction in both tumour growth 
and formation of metastases in breast cancer [486], and in prostate cancer its inhibition 
leads to a reduction of NF-KB and COX-2, two important inflammatory mediators [487], 
suggesting its involvement in maintaining a favourable inflammatory environment. In my 
study neither of these mediators were focused upon in depth and therefore no firm 
conclusions can be inferred from this preliminary data; however, taken together, my data 
and evidence in literature suggest that a more detailed analysis of the factors in a cancer-
inflammation event could prove beneficial for future cancer therapies.   
  
Intercellular Adhesion Molecule 1 (ICAM-1) is a known effector of inflammation, 
ensuring coordinated interactions that allow leukocytes to home in on sites of injury. Since 
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both endothelial and myeloid cells express this transmembrane protein it is of no surprise 
that ICAM-1 has been shown to be highly present in the serum of cancer patients [488] and 
at inflammatory sites [489]. A direct correlation between ICAM-1 expression levels in cancer 
and immune cell infiltration has not yet been described, however my initial findings indicate 
that ICAM-1 may play a role in cancer-monocyte interactions during chemotherapy. Here I 
show that docetaxel treatment of PC-3 cells significantly increases secreted ICAM-1 levels, 
with the effect further increased when U937 cells are present, suggesting ICAM-1 as an 
active mediator of these interactions. The fact that ICAM-1 levels are not affected by siRNA-
target inhibition of SPHK1 in cancer cells indicates an SPHK1-independent regulatory 
mechanism. Nonetheless, the role of ICAM-1 in chemoresistance should be taken into 
consideration in further studies. The secreted molecules and intracellular mechanisms which 
I have deduced from my studies are involved in monocyte-tumour cell interaction are 
summarised in Figure 8.1.    
 
Future directions of this work comprise the clarification of S1P levels and characterisation of 
S1P receptors in both cancer cells and monocytes, this could be achieved through the 
analysis of mRNA and protein levels for these receptors as well as measuring S1P levels by 
HPLC. In order to understand how monocyte recruitment is affected by SPHK1, an in vivo 
assay could be performed whereby U937 cells are stably transfected with GFP and injected 
into PC-3 xenograft mice in the presence or absence of SKi-II inhibitor. U937 infiltration and 
migration to the tumour site could then be detected by live imaging and 
immunohistochemistry analysis of the tumour and other organs. Understanding the role of 
SPHK1 in the recruitment of monocytes to the tumour site could provide new insights as to 
why tumours may benefit from this interaction and further support the development of 
SPHK1/S1P inhibitors that in conjugation with current drugs could ultimately benefit PCa 
patients with tumours containing high levels of inflammatory cells. 
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9. Conclusion 
 
The tumour microenvironment encompasses a myriad of molecules, cell types and 
interactions that could open the door to many potential therapeutic agents, offering the 
opportunity to augment or halt the progression of cancer to a metastatic state. The work in 
this study has identified SPHK1 as a key regulator of monocyte-cancer cell interactions and 
indeed supports the key role that the proximity of these cells within the microenvironment 
plays in the activation of this key regulator. The true extent to which SPHK1 orchestrates 
important signalling pathways remains to be seen, although its importance is demonstrated 
by the manifestation of cancer cell proliferation and resistance to chemotherapeutics upon 
its activation. Indeed a highly inflammatory environment, as characterised by immune cell 
infiltration, is associated with elevated levels of SPHK1; consequently, targeting of this 
molecule offers new therapeutic approaches to reducing this inflammatory state and 
subsequent disease progression.  
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